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A B S T R A C T
Background
Pharmacotherapies for smoking cessation increase the likelihood of achieving abstinence in a quit attempt. It is plausible that providing
support, or, if support is offered, offering more intensive support or support including particular components may increase abstinence
further.
Objectives
To evaluate the effect of adding or increasing the intensity of behavioural support for people using smoking cessation medications, and
to assess whether there are different effects depending on the type of pharmacotherapy, or the amount of support in each condition. We
also looked at studies which directly compare behavioural interventions matched for contact time, where pharmacotherapy is provided
to both groups (e.g. tests of different components or approaches to behavioural support as an adjunct to pharmacotherapy).
Search methods
We searched theCochraneTobaccoAddictionGroupSpecialisedRegister, clinicaltrials.gov, and the ICTRP in June 2018 for records with
any mention of pharmacotherapy, including any type of nicotine replacement therapy (NRT), bupropion, nortriptyline or varenicline,
that evaluated the addition of personal support or compared two or more intensities of behavioural support.
Selection criteria
Randomised or quasi-randomised controlled trials in which all participants received pharmacotherapy for smoking cessation and
conditions differed by the amount or type of behavioural support. The intervention condition had to involve person-to-person contact
(defined as face-to-face or telephone). The control condition could receive less intensive personal contact, a different type of personal
contact, written information, or no behavioural support at all. We excluded trials recruiting only pregnant women and trials which did
not set out to assess smoking cessation at six months or longer.
Data collection and analysis
For this update, screening and data extraction followed standard Cochrane methods. The main outcome measure was abstinence from
smoking after at least six months of follow-up. We used the most rigorous definition of abstinence for each trial, and biochemically-
validated rates, if available. We calculated the risk ratio (RR) and 95% confidence interval (CI) for each study. Where appropriate, we
performed meta-analysis using a random-effects model.
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Main results
Eighty-three studies, 36 of which were new to this update, met the inclusion criteria, representing 29,536 participants. Overall, we
judged 16 studies to be at low risk of bias and 21 studies to be at high risk of bias. All other studies were judged to be at unclear risk of
bias. Results were not sensitive to the exclusion of studies at high risk of bias. We pooled all studies comparing more versus less support
in the main analysis. Findings demonstrated a benefit of behavioural support in addition to pharmacotherapy. When all studies of
additional behavioural therapy were pooled, there was evidence of a statistically significant benefit from additional support (RR 1.15,
95% CI 1.08 to 1.22, I² = 8%, 65 studies, n = 23,331) for abstinence at longest follow-up, and this effect was not different when we
compared subgroups by type of pharmacotherapy or intensity of contact. This effect was similar in the subgroup of eight studies in
which the control group received no behavioural support (RR 1.20, 95% CI 1.02 to 1.43, I² = 20%, n = 4,018). Seventeen studies
compared interventions matched for contact time but that differed in terms of the behavioural components or approaches employed.
Of the 15 comparisons, all had small numbers of participants and events. Only one detected a statistically significant effect, favouring a
health education approach (which the authors described as standard counselling containing information and advice) over motivational
interviewing approach (RR 0.56, 95% CI 0.33 to 0.94, n = 378).
Authors’ conclusions
There is high-certainty evidence that providing behavioural support in person or via telephone for people using pharmacotherapy to
stop smoking increases quit rates. Increasing the amount of behavioural support is likely to increase the chance of success by about
10% to 20%, based on a pooled estimate from 65 trials. Subgroup analysis suggests that the incremental benefit from more support is
similar over a range of levels of baseline support. More research is needed to assess the effectiveness of specific components that comprise
behavioural support.
P L A I N L A N G U A G E S U M M A R Y
Does more support increase success amongst people using medications to quit smoking?
Background
Medications (including all types of nicotine replacement therapy, bupropion and varenicline) have been shown to help people quit
smoking, and people who want help to quit will often be offered medication (pharmacotherapy). Behavioural support also helps people
to quit. Behavioural support may include brief advice or more intensive counselling, and may be provided face-to-face on a one-to-
one basis or in groups, or by telephone, including ’quitlines’. It has been unclear how much additional benefit is gained from adding
support, or providing more intensive support for people who are using medication to help them quit.
Study characteristics
We looked for studies that included smokers and provided or offered medication to everyone. People in the studies were then randomly
split into groups which received different amounts or kinds of behavioural support. To assess whether the support given helped people
to quit, the studies had to count the number of people not smoking after six months or more. We did not look at studies that only
included pregnant women.
Key results
We searched for studies in June 2018. We included 83 studies, with almost 30,000 people. Most studies included people who wanted
to quit smoking, but a small number of studies offered support to people who were not trying to quit. Combining results from 65
trials suggested that increasing the amount of behavioural support for people using a stop-smoking medication increases the chances
of quitting smoking. About 17% of people in the groups receiving less or no support quit smoking, compared to about 20% in the
groups receiving more support. Providing some support via personal contact, face-to-face or telephone, is helpful. Few studies compared
different types of support. More research is needed to find out if some types of behavioural support help more people using medication
to quit smoking.
Quality of the evidence
We judged the overall quality of evidence to be high, meaning further research is very unlikely to change our results. This review has
been updated twice and both times the findings remained very similar, even though many new studies were added.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation
Patient or population: People using smoking cessat ion pharmacotherapy
Settings: Healthcare and community sett ings
Intervention: Behavioural intervent ions as adjuncts to pharmacotherapy
Outcomes Illustrative absolute effects* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed successful
quitters without inter-
vention
Estimated quitters with
intervention
Pharmacotherapy
(with variable level of
behavioural support)
Additional behavioural
support
(in addition to pharma-
cotherapy)
Smoking cessation at
longest follow-up
Follow-up: 6 - 24
months
Study population1 RR 1.15
(1.08 to 1.22)
23,331
(65 studies)
⊕⊕⊕⊕
high2,3
Ef fect very stable over
t ime: updates of this
analysis (15 new stud-
ies added 2015; 18 new
studies added 2019)
have had minimal im-
pact on the ef fect es-
t imate. Lit t le evidence
of dif f erences in ef fect
based on amount of
support or type of phar-
macotherapy provided
171 per 1000 197 per 1000
(185 to 209)
The est imated rate of quit t ing with behavioural intervent ion (and its 95% conf idence interval) is based on the assumed quit rate in the control group and the relative effect of
the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Based on the control group crude average
2Sensit ivity analysis removing studies at high risk of bias yielded results consistent with those f rom the overall analysis. A
funnel plot was inconclusive but suggested there may have been slight ly more small studies with large ef fect sizes than with
small ef fect sizes. However, asymmetry was not clear and we did not downgrade on this basis; given the large number of
included studies and the degree of homogeneity between them, it is unlikely that smaller unpublished studies showing no
ef fect, if they existed, would signif icant ly alter our results.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Giving up smoking is themost effectiveway for people who smoke
to reduce their risk of premature death and disability. People who
smoke need to quit as soon as possible using evidence-based aids
to increase their chances of success. These aids include behavioural
support and pharmacotherapies.
Description of the intervention
Behavioural support interventions range from written materials
containing advice on quitting to multisession group therapy pro-
grammes or repeated individual counselling in person or by tele-
phone. Providing standard self-help materials alone seems to have
a small effect on success, but there is good evidence of a benefit of
individually tailored self-help materials or more intensive advice
or counselling (Lancaster 2017; Livingstone-Banks 2019). There
is also good evidence that nicotine replacement therapy prod-
ucts (NRT), varenicline, and bupropion all increase the long-term
success of quit attempts (Cahill 2016; Hartmann-Boyce 2018;
Hughes 2014).
How the intervention might work
Clinical practice guidelines recommend that healthcare providers
offer people who are prepared to make a quit attempt both phar-
macotherapy and behavioural support. The two types of treatment
are believed to have complementary modes of action, and to in-
dependently improve the chances of maintaining long-term absti-
nence (Cofta-Woerpel 2007; Hughes 1995). Although guidelines
recommend intensive support to improve abstinence rates, it is
also recognised that many people will not attendmultiple sessions.
NRT products are available over the counter without a prescrip-
tion in many countries, and people who purchase them may not
access any specific behavioural support. People who obtain pre-
scriptions for pharmacotherapies may receive some support, but
this may be focused on explaining the proper use of the drug and
not on counselling. It therefore may be that offering additional
behavioural support increases quit rates above those seen in people
given pharmacotherapy alone.
Why it is important to do this review
Other Cochrane Tobacco Addiction reviews have evaluated the
evidence on behavioural and pharmaceutical interventions in-
dividually (Cahill 2016; Hartmann-Boyce 2018; Hughes 2014;
Lancaster 2017; Livingstone-Banks 2019; Matkin 2019; Stead
2017). These reviews restrict inclusion to trials where interven-
tions are unconfounded. Trials of pharmacotherapies must pro-
vide the same amount of behavioural support (materials, advice,
counselling contacts) to all participants, whether they receive ac-
tive treatment, or a placebo or no medication. Likewise, when be-
havioural interventions are evaluated there should be no system-
atic difference in the offer of medications between the active and
control arms of the trial. Only reviews that evaluate interventions
by specific providers (e.g. nurses, Rice 2017), or in specific settings
(e.g. hospitals, Rigotti 2012), may include trials of interventions
that combine behavioural therapies and various medications (e.g.
NRT, bupropion, varenicline).
This review is one of two that systematically identify trials of inter-
ventions that combine effective pharmacotherapies (NRT, vareni-
cline, bupropion, nortriptyline)with behavioural support (tailored
materials, brief advice, in-person or telephone counselling). This
review evaluates trials that compare different levels of behavioural
intervention for people receiving any pharmacotherapy for smok-
ing cessation, to provide an estimate of the effectiveness of in-
tensifying behavioural support as an adjunct to pharmacotherapy,
and, as such, overlaps with some separate reviews evaluating in-
tervention types included here (e.g. Matkin 2019), which include
studies of relevant behavioural therapies both on their own and
as adjuncts to pharmacotherapy. The companion review (Stead
2016) includes trials in which an intervention combining pharma-
cotherapy and behavioural support is compared to standard care
or a brief behavioural intervention without pharmacotherapy.
O B J E C T I V E S
To evaluate the effect of adding or increasing the intensity of be-
havioural support for people using smoking cessationmedications,
and to assess whether there are different effects depending on the
type of pharmacotherapy, or the amount of support in each condi-
tion. We also look at studies which directly compare behavioural
interventions matched for contact time, and where pharmacother-
apy is provided to both groups (e.g. tests of different components
or approaches to behavioural support as an adjunct to pharma-
cotherapy).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials.
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Types of participants
We included trials that recruited people who smoke, recruited
in any setting. We excluded trials that only recruited pregnant
women; this population is considered in Coleman 2015. Trial
participants did not need to be selected according to their interest
in quitting, or their suitability for pharmacotherapy. However,
since pharmacotherapy was offered or provided, participants were
expected to be relativelymotivated and prepared to usemedication
as part of their quit attempt.
Types of interventions
We included trials of smoking cessation interventions where all
participants had access to a smoking cessation pharmacotherapy
(including NRT, varenicline, bupropion and nortriptyline, or a
combination or choice of these) and in which one or more inter-
vention conditions received more intensive behavioural support
than the control condition. Control group participants could be
offered any level of support from minimal (e.g. written informa-
tion provided as part of the medication prescription) to multi-
session counselling. The intervention could use different or addi-
tional types of therapy content (e.g. cognitive behaviour therapy,
motivational interviewing). The additional support had to involve
person-to-person contact which could be face-to-face or by tele-
phone. In this update, we also included trials testing specific be-
havioural components that used a control matched for contract
frequency and duration.
Types of outcome measures
Following the standard methodology of the Cochrane Tobacco
Addiction Group, the primary outcome was smoking cessation at
the longest follow-up using the strictest definition of abstinence,
i.e. preferring sustained over point prevalence abstinence and us-
ing biochemically-validated rates, where available. In addition we
noted any other abstinence outcomes reported, and conducted
sensitivity analyses if the choice of outcome in a study might have
altered the results of a meta-analysis. We excluded studies which
did not set out to assess smoking cessation at six months or longer.
Search methods for identification of studies
We identified trials from theCochrane TobaccoAddictionGroup’s
Specialised Register (the Register), and the clinical trials registries:
clinicaltrials.gov, and the ICTRP. The Register is generated from
regular searches of the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, Embase, and PsycINFO, for tri-
als of smoking cessation or prevention interventions. We ran our
most recent searches in June 2018. At the time of the search, the
Register included the results of searches of the Cochrane Central
Register of Controlled trials (CENTRAL), issue 1, 2018; MED-
LINE (via OVID) to update 20180531; EMBASE (via OVID) to
week 201824; PsycINFO (via OVID) to update 201800528. See
the Cochrane Tobacco Addiction Group website for full search
strategies and list of other resources searched.
We searched the Register for records with any mention of pharma-
cotherapy, including any type ofNRT, bupropion, nortriptyline or
varenicline in title, abstract or indexing terms (see Appendix 1 for
the final search strategy). We checked titles and abstracts to iden-
tify trials of interventions for smoking cessation that combined
pharmacotherapy with behavioural support. We also considered
for inclusion trials with a factorial design that varied both phar-
macotherapy and behavioural conditions. For the first version of
this review, we also tested an additional MEDLINE search using
the smoking-related terms and design limits used in the standard
Register search and the MeSH terms ‘combined modality therapy’
or (Drug Therapy and (exp Behavior therapy or exp Counseling)).
This search retrieved a subset of records already screened for in-
clusion in the Register, and was used to assess whether it might
retrieve studies where there was no mention of a specific cessation
pharmacotherapy in the title, abstract or indexing. We did not
find any additional studies from this approach, and so did not use
it for subsequent updates.
Data collection and analysis
Selection of studies
For this version of the review, two reviewers (BH, HW, JHB) in-
dependently screened all studies for inclusion, with disagreements
resolved by discussion or referral to a third reviewer.
Data extraction and management
For this version of the review, two reviewers (BH, HW, JHB, CM,
JLB) independently extracted data and assessed risk of bias for
each included study, with disagreements resolved by discussion or
referral to a third reviewer.We extracted the following information:
• Country and setting of trial
• Study design
• Method of recruitment, including any selection by
motivation to quit
• Characteristics of participants including gender, age,
smoking rate
• Characteristics of intervention deliverer
• Common components: type, dose and duration of
pharmacotherapy
• Intervention components: type and duration of behavioural
support
• Control group components: type and duration of
behavioural support
• Outcomes: primary outcome length of follow-up and
definition of abstinence, other follow-up and abstinence
definitions, use of biochemical validation, adverse events
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• Sources of funding & potential conflicts of interest
• Information used to assess risk of bias (see below)
Assessment of risk of bias in included studies
We evaluated studies on the basis of the randomisation procedure,
allocation concealment, incomplete outcome data assessment and
any other bias using the standard Cochrane methods (Cochrane
Handbook 2011).We also judged studies on the basis of detection
bias, according to standard methods of the Cochrane Tobacco
Addiction Group. For trials of behavioural interventions (such as
those included here), it is not relevant to assess performance bias
as blinding of participants and personnel is not feasible due to the
nature of the intervention. In these trials, we assessed detection bias
based on the outcome measure; e.g. if the outcome was objective
(biochemically-validated) or if contact wasmatched between arms,
or both, we judged the studies as having low risk of bias, but if the
outcome was self-reported and the intervention arm receivedmore
support than the control arm, we judged differential misreport to
be possible and rated these studies as having high risk of bias.
Measures of treatment effect
We expressed trial effects as a risk ratio (RR) (calculated as: quitters
in treatment group/total randomised to treatment group)/(quitters
in control group/total randomised to control group), alongside
95%confidence intervals (CIs). A risk ratio greater than1 indicates
a better outcome in the intervention group than in the control
condition.
Unit of analysis issues
We included both individually and cluster-randomised trials. In
extracting data from cluster-randomised trials, we considered
whether study authors had made allowance for clustering in the
data analysis reported, and planned to use data adjusted for clus-
tering effects, where available.
Dealing with missing data
We reported numbers lost to follow-up by group in the ’Risk
of bias’ table. Following standard Cochrane Tobacco Addiction
Group methods, we assumed people lost to follow-up to be smok-
ing and included them in the denominators for calculating the risk
ratio. We have reported any exceptions to this assumption in the
’Risk of bias’ table. We noted separately any deaths during follow-
up and excluded them from denominators.
Assessment of heterogeneity
We assessed statistical heterogeneity using the I² statistic (Higgins
2003). As guided by Higgins 2003, we considered a value greater
than 50% as evidence of substantial heterogeneity.
Assessment of reporting biases
We used funnel plots to assess small-study effects and investigate
the possibility of publication bias.
Data synthesis
For groups of trials where we judged meta-analysis appropriate,
we pooled RRs using a Mantel-Haenszel random-effects model,
and reported a pooled estimate with a 95% CI.
If trials had more than one intervention condition, we compared
the most intensive combination of behavioural support and phar-
macotherapy to the control in the main analysis.
We categorised the intensity of behavioural support in both in-
tervention and control conditions based on two of the categories
used in the US Guidelines (Fiore 2008): ‘Total amount of contact
time’ (Categories: 0, 1 to 30*, 31 to 90, 91 to 300, > 300 min-
utes (*guideline categories ’1 to 3’ and ’4 - 30’ combined for this
review)) and ‘Number of person-to-person sessions’ (Categories:
0*, 1 to 3*, 4 to 8, > 8 (*guideline categories ’0 to 1’, and ’2 to 3’
combined for this review)). Additionally we used the number and
duration of contacts as continuous predictors in meta-regression,
described below.
Subgroup analysis and investigation of heterogeneity
We used the difference in average intensity of support (number
or duration of contacts) between intervention and control condi-
tions as the main potential feature to explain any heterogeneity.
In an exploratory analysis new to this version of the review, we
planned to use a non-linear meta-regression model in R version
3.5.2 (R program) to explore the effect of difference in number
and duration of contacts on intervention effect, anticipating that
differences in the intensity of support would have the largest im-
pact when the amount of contact in the control group was small-
est. However, graphs of intervention effect against these factors
did not provide evidence of this non-linear trend, and so instead
results were presented graphically and summarised using a stan-
dard meta-regression model with each of the factors as a linear
predictor. Studies where the intensity of support could not be de-
termined for one or more treatment groups were excluded from
the meta-regression.
Sensitivity analysis
We considered whether the main results were sensitive to the ex-
clusion of studies at high risk of bias in any domain. We also con-
sidered whether the definition and duration of follow-up or the
inclusion of intermediate-intensity arms in trials with more than
two relevant arms had any impact on treatment effect.
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Summary of findings table
Following standard Cochrane methodology, we created a ’Sum-
mary of findings’ table for our primary outcome using the five
GRADE considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the cer-
tainty of the body of evidence for each outcome, and to draw
conclusions about the certainty of evidence within the text of the
review.
R E S U L T S
Description of studies
Results of the search
Our combined searches for all versions of this review retrieved ap-
proximately 3837 records. We excluded most of them as not rele-
vant based on title and abstract.Of the records that did relate to tri-
als of interventions for smoking cessation, most were not relevant
because they were placebo-controlled trials of pharmacotherapies,
in which the behavioural support was the same for intervention
and control conditions. We identified 83 studies for inclusion and
listed 63 as excluded. We identified 36 ongoing studies. Further
studies of combined pharmacotherapy and behavioural support
that did not offer pharmacotherapy to the control group are in-
cluded in Stead 2016. Some studies had multiple study arms and
contributed to both Stead 2016 and to this review. The flow of
studies is reported in Figure 1.
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Figure 1. Study flow diagram for 2019 update
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Included studies
We identified 83 studies as relevant for inclusion, of which 36were
new for the 2019 update. 29,536 participants are now included
in relevant arms of these studies. Details of each study are given
in the Characteristics of included studies table, and a summary of
intervention and control group characteristics in Table 1.
Study setting, participant recruitment and motivation
Twenty-nine studies were conducted in a healthcare setting (ex-
cluding smoking cessation clinics); this included ten studies in pri-
mary care (Aveyard 2007; Bock 2014; Cook 2016; Ellerbeck2009;
Fiore 2004; Ockene 1991; Schlam 2016; Smith 2014; Stanton
2015; Van Rossem 2017; Wagner 2016), one in a chest clinic
(Tonnesen 2006), one in a cardiovascular disease outpatient clinic
(Wiggers 2006), one in a rheumatology clinic (Aimer 2017), one
in an immunology clinic (Stanton 2015), three in HIV clinics
(Lloyd-Richardson 2009; Humfleet 2013; O’Cleirigh 2018), one
in a lesbian, gay, bisexual, and transgender health centre (Matthews
2018), one in mental health clinics (Williams 2010), one in a
mental health research centre (Baker 2015), three in substance
abuse clinics (Lifrak 1997; Rohsenow 2014; Stein 2006), two in a
Veterans Administration hospital (Brody 2017; Simon 2003), and
three in cardiac wards (Berndt 2014; Busch 2017; Hasan 2014)
or any ward (Warner 2016).
Since the intervention included the provision of pharmacotherapy,
many of the studies recruiting in a healthcare setting recruited vol-
unteers who were interested inmaking a quit attempt, but motiva-
tion to quit was not always an explicit eligibility criterion. Wiggers
2006 used a motivational interviewing approach and participants
did not all make quit attempts. Ockene 1991 offered nicotine re-
placement therapy (NRT) and participants were not initially se-
lected by motivation, and Ellerbeck 2009 included a small pro-
portion of people in the ’precontemplation stage’ of the transthe-
oretical model.
A further four studies recruited members of health maintenance
organisations (HMOs) (Boyle 2007; Lando 1997; Swan 2003;
Swan 2010). Boyle 2007 proactively recruited HMO members
who had filled a prescription for smoking cessation medication,
while the others sought volunteers by advertising to HMO mem-
bers. Universities or research facilities were the study sites for
five studies (Baker 2015; Bloom 2017; Prapavessis 2016; Schmitz
2007a; Webb Hooper 2017).
Forty studies recruited community volunteers interested in quit-
ting, including three which recruited people who were attending
cessation clinics (Alterman 2001; Rovina 2009; Yalcin 2014). The
study setting was not explicitly stated in four studies (LaChance
2015; Macpherson 2010a; Strong 2009; Vidrine 2016).
One study recruited adolescents (Bailey 2013); all other studies
were conducted in adults.
Characteristics of intervention and control conditions
Pharmacotherapy
NRT was offered in the majority of studies, with 41 providing
nicotine patch only.Whilemost of these provided a supply ofNRT
for between eight and 12 weeks, three studies offered only a two-
week supply (Bricker 2014; MacLeod 2003; Warner 2016). Eight
studies used nicotine gum only (Ahluwalia 2006; Ginsberg 1992;
Hall 1985; Hall 1987; Hall 1994; Huber 2003; Ockene 1991;
Wewers 2017), one used sublingual tablets (Tonnesen 2006), and
three did not specify the type (Aimer2017; Bushnell 1997;Wagner
2016). Five studies offered patch and/or gum (Bricker 2014;
Cook 2016; Humfleet 2013; Schlam 2016; Smith 2013a). Seven
studies provided bupropion alone (Cropsey 2015; Gifford 2011;
McCarthy 2008; Rovina 2009; Schmitz 2007a; Strong 2009;
Swan 2003), one provided nortriptyline alone (Hall 1998) and
four provided varenicline alone (NCT00879177; Smith 2014;
Swan 2010; Van Rossem 2017). Three studies offered a choice
of pharmacotherapy; NRT or bupropion (Boyle 2007; Ellerbeck
2009), or NRT, bupropion, or varenicline (Yalcin 2014). Gariti
2009 randomised participants to NRT or bupropion using a dou-
ble-dummy design. Hall 2002 randomised participants to either
bupropion or nortriptyline (placebo arms not used in this review).
Three studies provided combination therapy of both NRT and
bupropion (Hall 2009; Killen 2008; Vander Weg 2016).
Behavioural support
The intensity of the behavioural support, in both the number of
sessions and their duration, was very varied for both intervention
and control conditions.
In seven trials, there was no counselling contact for the controls: in
six, participants received pharmacotherapy by mail (Boyle 2007;
Ellerbeck 2009; MacLeod 2003; Solomon 2000; Solomon 2005;
Vander Weg 2016), and in Fiore 2004 there was no counselling
or advice for the control group although there was face-to-face
contact with study staff. In 30 studies, the control arms had be-
tween one and three contacts (which could be face-to-face or by
telephone) and most of these had a total contact duration of be-
tween four and 30 minutes, although three had between 31 and
90 minutes contact scheduled (Gifford 2011; Lando 1997; Reid
1999). In 34 studies, the control groupwas scheduled to receive be-
tween four and eight contacts, with all except eight (Aveyard 2007;
Bricker 2014; Cook 2016; Gariti 2009; Kim 2015; Smith 2013a;
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Vidrine 2016;Wu 2009) involving a total contact duration of over
90 minutes. Twelve studies offered over eight contacts for the con-
trols (Bailey 2013; Baker 2015; Begh 2015; Bloom 2017; Brody
2017; McCarthy 2008; Patten 2017; Prapavessis 2016; Strong
2009; Webb Hooper 2017; Williams 2010; Yalcin 2014).
Typically, the intervention involved only a little more contact than
the control, so that the most intensive interventions were com-
pared with more intensive control conditions. In five trials, the
intervention consisted of between one and three sessions, with
a total duration of 31 to 90 minutes in most of them (Calabro
2012; Rohsenow 2014; Stein 2006; Wiggers 2006), although
Calabro 2012 also provided access to a tailored internet pro-
gramme. Warner 2016 offered a brief (under 5 minutes) quitline
facilitation intervention. Forty-five studies tested interventions of
between four and eight sessions, about half of which were in the
91 to 300 minute-duration category. The remaining 32 studies of-
fered more than eight sessions, typically providing over 300 min-
utes of counselling in total. The number of contacts planned was
not always delivered, but generally using the average number de-
livered would not have changed the coding category. In a few cases
where the number of contacts was either not specified or open-
ended, we coded the average number delivered and noted this in
the Characteristics of included studies table.
In Analysis 1.2, we grouped trials by the number of interven-
tion and control contacts. In 12 trials, the intervention and con-
trol condition fell into the same coding category for number of
contacts (one to three contacts: Calabro 2012; Rohsenow 2014;
Stein 2006; Wiggers 2006; four to eight contacts: Aveyard 2007;
Bushnell 1997;Huber 2003;Tonnesen 2006;Wu2009;more than
eight contacts: McCarthy 2008; Williams 2010; Yalcin 2014). A
summary of the number of sessions and duration for intervention
and control conditions for each trial is provided in Table 1.
Length of follow-up and definitions of abstinence
The majority of the included studies followed participants for a
duration of six to 12months from the target quit date, or entry into
the study. Exceptions were Hall 2009 and Ellerbeck 2009 which
each had a two-year follow-up, and Baker 2015 with a three-year
follow-up. The design of the Ellerbeck study, in which participants
were repeatedly offered support to quit, means that participants
who had quit at the end of follow-up would not necessarily have
been quit for as long as two years. Thirty-five studies only followed
participants for six months.
The majority of studies reported abstinence as a prevalence mea-
sure, rather than requiring reported sustained abstinence, or absti-
nence atmultiple follow-up points. Fifteen studies did not attempt
any biochemical verification of self-reported abstinence; this is dis-
cussed further in Risk of bias in included studies.
Excluded studies
We listed 63 studies as excluded, along with reasons for their ex-
clusion, in the Characteristics of excluded studies table. The ma-
jority were excluded because they provided less than six months
follow-up. Studies in which the intervention group received both
pharmacotherapy and behavioural support and the control group
received neither (or just brief behavioural support) were eligible for
the companion review and are included or excluded there (Stead
2016).
Risk of bias in included studies
Overall, we judged 16 studies to be at low risk of bias (low risk of
bias across all domains) and 21 studies to be at high risk of bias
(high risk of bias in at least one domain). All other studies were
judged to be at unclear risk of bias. A summary of ’risk of bias’
judgements can be found in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged24 studies to be at low risk of selectionbias, based on the
reported method of random sequence generation and allocation
concealment.We judged three studies to be at high risk of selection
bias, due to the method of sequence generation (Yalcin 2014), or
allocation concealment (Berndt 2014; Brown 2013; Yalcin 2014).
The remaining studies did not given enough detail on one or both
of these aspects so we rated the risk of bias as unclear.
Blinding (detection bias)
Following standard Cochrane Tobacco Addiction Group guid-
ance, we did not formally assign a risk of performance bias for each
trial as, due to the nature of the intervention, people providing
the behavioural support could not be blinded.
We judged detection bias on the basis of biochemical validation of
abstinence and, where biochemical validation was not provided,
on the basis of differential levels of contact. Twelve studies were
judged to be at high risk of detection bias as outcomes were via
self-report only and the intervention and control arms received
different levels of support, making differential misreport possible
(Aimer 2017; Berndt 2014; Boyle 2007; Cook 2016; Hollis 2007;
MacLeod 2003; Ockene 1991; Otero 2006; Solomon 2005; Swan
2003; Swan 2010; Vander Weg 2016). The remainder of studies
were judged to be at low risk for this domain.
Incomplete outcome data
Loss to follow-up is often relatively high in smoking cessation
trials. If trials lost fewer than 20% of participants at longest follow-
up, we judged the risk of bias to be low in this domain. In most
of the included trials, the proportion lost to follow-up was more
than 20% but losses were balanced across groups and less than
40%; for these, we also classified the risk of bias as low. We rated
eight studies as having unclear risk of bias, either because attrition
was not reported or because overall losses to follow-up of greater
than 20% were reported and a breakdown by treatment arm was
not provided (Bushnell 1997; Hall 1994; NCT00879177; Otero
2006; Schlam 2016; Smith 2001; Strong 2009; Tonnesen 2006).
We judged seven studies to be at high risk of bias due to high
(> 50%) attrition overall or differential rates of attrition between
arms (> 20% difference between arms), as per Cochrane Tobacco
Addiction Group guidance (Bock 2014; Calabro 2012; Gifford
2011;Macpherson 2010a; O’Cleirigh 2018; Smith 2014;Wagner
2016).
Other potential sources of bias
We found no studies to be at risk of other potential sources of bias.
Effects of interventions
See: Summary of findings for themain comparisonBehavioural
interventions as adjuncts to pharmacotherapy for smoking
cessation
Intensive versus less intensive or no support
When comparing more intensive versus less intensive behavioural
support or to no support, we pooled 65 studies contributing data
to this comparison, including a total of over 23,331 participants
(note: in subgroups by intervention intensity, a slightly smaller
number of studies was included as, in some cases, intensity of
intervention or control group contact was not clear). There was
little evidence of statistical heterogeneity (I² = 8%). Hall 2002
contributed separate data to two subgroups in the primary meta-
analysis. Seventeen of the studies had point estimates below 1, that
is, with higher quit rates in the less intensive condition, but all
these had wide confidence intervals (CIs) which crossed the line of
no effect. Seven studies detected benefits of the intervention with
confidence intervals that excluded 1. The estimated risk ratio (RR)
was 1.15, with 95% CI 1.08 to 1.22. This suggests that increasing
the intensity of behavioural support for people making a cessation
attempt with the aid of pharmacotherapy increases the proportion
who are quit at six to 12 months (Figure 3; Analysis 1.1; Summary
of findings for the main comparison).
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Figure 3. Effect of increasing behavioural support. Abstinence at longest follow-up. Subgroups by type of
pharmacotherapy
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Difference in pharmacotherapy
The effect size was similar across subgroups (test for subgroup
differences, P = 0.45, I² = 0%). Though in some subgroups the
confidence interval included no effect, this was likely to reflect the
smaller number of studies and lower precision rather than a true
difference in effect.
Subgroups by difference in intensity
Analysis 1.2 categorised trials based on the relative difference in
the number of contacts between groups, with the subgroups with
the largest contrast in intensities listed first and studies where the
intensity of intervention and control fell into the same category
shown last. There was little evidence of subgroup differences (P
= 0.21, I² = 32%) nor was there evidence of any dose-response.
We did not repeat this approach for duration of intervention cat-
egories, as inspection suggested that the number of studies falling
into different categories was small and that further subgroup anal-
ysis could be misleading.
At the suggestion of a peer reviewer, we conducted two additional
subgroup analyses. In Analysis 1.3, we categorised by the level of
control group contact to investigate whether there might be a dif-
ference between trials where the control could be categorised as a
brief intervention (up to 30 minutes) and trials which might be
characterised as testing a dose-response for behavioural support,
which we defined as being where the controls received more than
30 minutes of behavioural support. The eight trials where controls
had no advice or contact formed a third subgroup. Twenty-two
trials and just over half the participants were in the ’brief interven-
tion’ subgroup, and 32 trials and a third of participants were in the
’dose-response’ category. Again, there was no significant difference
between the subgroups (P = 0.41, I² = 0%).
In this version of the review, we also conducted an exploratory
meta-regression to explore associations between effect sizes and
number and duration of contacts. A comparison of the interven-
tion effect (log risk ratio) by the difference between the treatment
groups in the duration and number of contacts is shown in Figure
4. There was no clear effect of either increasing duration of contact
(RR 1.00 per 100 minutes additional contact time, 95% CI 0.99
to 1.01) or increasing number of contacts (RR 1.00 per additional
contact, 95% CI 0.99 to 1.02).
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Figure 4. Meta-regression results (the fitted meta-regression trend is shown as the solid line)
Differences in modality of intervention contact
In the second non-prespecified analysis, we categorised studies ac-
cording to whether there was some face-to-face contact as part of
the intervention, or whether all support was given by telephone
(Analysis 1.4). Here, the test for subgroup differences was signif-
icant (P = 0.03, I² = 78%), with telephone counselling showing
greater relative benefit than face-to-face support. In the subgroup
of eight studies using telephone counselling (which had some over-
lap with studies where there was no personal contact for the con-
trol), the point estimate was 1.25 (95% CI 1.15 to 1.37, I² = 0%,
6670 participants) in favour of additional behavioural support. In
the remaining 57 studies where all intervention and most control
conditions had face-to-face support, there was also evidence of
benefit of additional behavioural support in this update, although
the estimate was slightly smaller (RR 1.11, 95% CI 1.03 to 1.19,
I² = 9%; 16,661 participants).
Inclusion of medium-intensity intervention from studies
with multiple intervention conditions
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Eight studies (Alterman 2001; Ellerbeck 2009; Fiore 2004; Hollis
2007; Humfleet 2013; Jorenby 1995; Prapavessis 2016; Smith
2001; Swan 2010) included an intervention condition interme-
diate in intensity between the highest intensity and the control.
We have not included these arms in the primary analysis in case
they reduced the contrast between intervention and control. In a
sensitivity analysis, we added in these arms. This had almost no
impact on the estimated effect (RR 1.13, 95% CI 1.07 to 1.20, I²
= 8%; 65 studies, n = 27,425; Analysis 2.1), tending to support
the finding that there was not a clear dose-response relationship
with the amount of support.
Definition of abstinence
We considered whether the way in which abstinence was defined
was related to the effect size, and also to absolute quit rates. Here
again, there were no significant subgroup differences (P = 0.22,
I² = 30%, Analysis 2.2). Some studies that reported sustained
outcomes also reported point prevalence rates, but substituting
the less stringent definition did not change the overall findings.
However, studies with point prevalence outcomes had, on average,
higher quit rates in both intervention and control arms. A study
comparing outcomes based on different abstinence definitions re-
ported within studies found that, for pharmacotherapy studies,
point prevalence and sustained abstinence outcomes were strongly
related, with sustained abstinence averaging around 74% of point
prevalence rates (Hughes 2010).
Unit of analysis issues
Two included studies were cluster-randomised trials (Berndt 2014;
Lando 1997). One of these (Berndt 2014) performed an analysis
adjusting for clustering effects and found them to be not signifi-
cantly different from zero, and so we used the original data values.
The other (Lando 1997) also allowed for clustering but did not
report adjusted results, and so the magnitude of clustering effects
was unknown. As the number of included studies in the review
was large, this was not likely to have any noticeable effect on our
overall conclusions.
Risk of bias
In a sensitivity analysis, removing studies judged to be at high risk
of bias in at least one domain, the effect observed was consistent
with that of the main analysis (RR 1.09, 95% CI 1.01 to 1.17, I²
= 0%; 47 studies, n = 13355).
Studies not included in meta-analysis
Two studies comparing more versus less intensive support were
not included in the meta-analysis due to a lack of usable data.
NCT00879177 is a completed study that was not yet published at
the time of searching, and while numerical data were not available,
the author indicated that results were broadly comparable between
groups.Wagner 2016 compared individual counsellingwith group
counselling, and although follow-up was conducted at later time
points, the only data available at time of searching was for 12-
week quit rates, where there was no evidence of difference in quit
rates (RR 0.96, 95% CI 0.51 to 1.81; n = 400).
Studies matched for contact time
Seventeen studies compared interventions matched for contact
time. Fifteen of these provided usable data, which is available in
Analysis 3.1. Of the 12 comparisons, all had small numbers of
participants and events. Only one, comparing motivational inter-
viewing to health education (which the authors described as stan-
dard counselling containing information and advice), detected a
statistically significant effect, in this case in favour of health ed-
ucation (RR 0.56, 95% CI 0.33 to 0.94, n = 378). Only one
comparison included more than one study; this group of studies
compared culturally-tailored support with non-tailored support.
Four studies (n = 929) contributed to this comparison (RR 1.14,
95% CI 0.68 to 1.92). Statistical heterogeneity was substantial (I²
= 78%) and was driven by one small study (Wu 2009; n = 139)
in Chinese smokers which found a significant benefit in favour
of the culturally-tailored intervention (RR 2.26, 95% CI 1.47 to
3.49). For comparisons in which only one study contributed, see
Analysis 3.1 for data and effect estimates.
A further two studies compared interventions matched for contact
time but had insufficient data to be recorded in Analysis 3.1:
• Schmitz 2007a compared cognitive behavioural therapy to
standard therapy but quit rates in the control group could not be
accessed.
• Strong 2009 also compared cognitive behavioural therapy
(CBT) to standard therapy (ST) but we could not access quit
rates beyond 12 weeks. At 12 weeks, there was “no significant
difference in the risk of lapse or relapse across CBT and ST
psychosocial treatments” (abstinence data not reported).
D I S C U S S I O N
Summary of main results
A meta-analysis pooling 65 studies with a total of over 23,000
participants found high-certainty evidence that providing more
intensive behavioural support for people making a cessation at-
tempt with the aid of pharmacotherapy will typically increase the
success rates by about 10% to 20% (Summary of findings for the
main comparison). This held true when comparing more versus
less support and when comparing behavioural support to no be-
havioural support. This effect estimate has remained stable over
time: with the addition of nine trials in 2015, the number of par-
ticipants increased by 20% and yet the risk ratio remained almost
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the same, changing from 1.16 to 1.17; and with the addition of a
further 18 trials in 2019, the number of participants increased by a
further 25% and the risk ratio was 1.15. This increases confidence
that there is a benefit. There continues to be little evidence of sta-
tistical heterogeneity overall, despite the variability in the amount
and nature of the behavioural support tested. Direct comparisons
indicate a benefit of providing more support regardless of the base-
line level of support provided. Sensitivity analyses suggest that this
estimate is quite robust. Although the relative effect is generally
smaller than when testing behavioural support in the absence of
pharmacotherapy, it is important to put the effect in the context of
control conditions that were offering effective pharmacotherapy
and, typically, some behavioural support, i.e. a level of support
consistent with guideline best practice. Quit rates in the control
groups reflected this, with amedian quit rate across trials of around
17%, meaning the estimated relative increase translates into an
absolute increase of around two to three percentage points. Given
the importance of smoking cessation for future health outcomes,
this is a clinically relevant difference (West 2007).
Overall completeness and applicability of
evidence
The studies identified for this review have largely been conducted
in the USA or Europe. It is possible that we have failed to find
relevant studies conducted in other places. Participants were typ-
ically moderate to heavy smokers and were interested in quitting.
Most studies recruited participants who had already tried to quit a
number of times. Most of the evidence came from studies testing
additional face-to-face support. The eight trials which tested the
addition of telephone counselling found a stronger effect in favour
of additional contact, but we are unable to determine if this was
based on true differences in effects or other differences between
the studies.
A potential limitation of the review is that the between-trial anal-
ysis focussed on the amount of behavioural support rather than
the specific components, or the quality of delivery. However, in
this update, we included studies directly comparing interventions
matched for contact time (e.g. testing different behavioural ap-
proaches or types of support). Only one of the 15 comparisons
detected a significant effect, but most comparisons only included
one study, and all comparisons had small numbers of participants.
The question of specific components of behavioural support and
associations with effectiveness is being investigated further in a
separate Cochrane review (Hartmann-Boyce 2018a).
Certainty of the evidence
We judged the evidence regarding additional behavioural support
to be of high certainty, meaning further research is judged very
unlikely to change our confidence in the effect. This judgement
is supported by the consistency of the effect estimate over time,
and this is likely to be the last update of this review. However,
despite high certainty in results, some areas relating to the five
GRADE considerations (risk of bias, imprecision, indirectness,
inconsistency, and publication bias) warrant discussion, namely
risk of bias, inconsistency, and publication bias.
Risk of bias
While we judged most of the trials to be at low or unclear risk
of bias, we rated 21 studies as having high risk of bias. Reassur-
ingly, sensitivity analysis excluding studies at high risk of bias did
not change the overall effect. The quality of the trials was typi-
cal of smoking cessation research in general. We did not formally
evaluate whether there was a risk of performance bias due to a
lack of blinding of providers or participants. Blinding of providers
would not have been possible, and it was difficult to determine
whether participants knew how their treatment compared to the
other options offered. All participants were getting an active phar-
macotherapy andwould have been aware of this (apart froma small
proportion in placebo-controlled factorial studies). Expectancy ef-
fects for the behavioural components would probably have been
small, and we do not think the small effect of the interventions
could be attributed entirely to higher expectancies in intervention
conditions.
Inconsistency
There were potentially important differences between trials in the
relative difference in the support given to the intervention and
control groups. Despite the lack of statistical heterogeneity, we un-
dertook a number of subgroup analyses, including some that were
not prespecified. In response to a concern that we were combining
tests of behavioural support versus no support with tests of a dose-
response to intensity of support, we divided trials into those where
the control did not involve personal contact; where the control
group provided a brief intervention, operationalised as under 30
minutes contact; and those where the control condition was more
intensive (Analysis 1.3). There was no evidence of a difference in
the relative effect between these three subgroups. In this update,
we also conducted an exploratory meta-regression, in which re-
sults continue to suggest that the dose-response curve is shallow
for behavioural support. We drew similar conclusions in a com-
panion review to this, which compared combined pharmacother-
apy and behavioural support to minimal support; indirect com-
parisons between trials using more and less intensive behavioural
interventions also failed to detect large differences (Stead 2016).
The present review also detected a clearer benefit of more support
in studies where all contact was delivered by telephone, but this
too was not prespecified and may reflect the larger size of trials
done in quitline settings, or possibly that most of these studies did
not use biochemical validation of abstinence.
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Publication bias
A funnel plot was inconclusive, suggesting there may have been
slightlymore small studies with large effect sizes thanwith small ef-
fect sizes (Figure 5). However, asymmetry was not clear and when
we investigated further by conducting sensitivity analyses exclud-
ing outliers this did not substantially alter the effect. Given the
large number of included studies and the degree of homogene-
ity between them, it is unlikely that smaller unpublished studies
showing no effect, if they existed, would significantly alter our
results.
Figure 5. Funnel plot of comparison: 1 Effect of increasing behavioural support. Abstinence at longest
follow-up, outcome: 1.1 Subgroups by type of pharmacotherapy.
Potential biases in the review process
We used the Cochrane Tobacco Addiction Group’s Specialised
Register and searched trial registries to identify studies. The Reg-
ister includes reports of trials identified from the major biblio-
graphic databases. There is no straightforward term for the type
of intervention we were interested in but we screened any trial
report that mentioned a pharmacotherapy. It is possible that the
Register does not include all relevant trial reports or that we failed
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to identify some. Our methods for data extraction and analysis are
those used for other Cochrane reviews. The practice of imputing
missing data as smoking has been traditionally used for primary
and secondary research in smoking cessation and has the advan-
tage that absolute cessation rates are not inflated by ignoring loss
to follow-up. Bias in the relative effect will only be introduced if
misclassification differs for people who are lost from the interven-
tion condition compared to the control. If proportionately more
of those who are lost in the control group are assumed to be smok-
ers but have in fact quit, then the treatment effect would be over-
estimated.
Agreements and disagreements with other
studies or reviews
The major source of systematic data about the dose-response to
behavioural support is the US Public Heath Service Clinical Prac-
tice Guideline, last updated in 2008 (Fiore 2008). This includes
meta-analyses (last updated in 2000) for different levels of support
and contact time. The analyses included trials of different levels
of support versus control. These showed trends towards increas-
ing effects in trials that had more sessions and more contact time,
compared to minimal conditions. For example, estimated effects
compared to minimal contact differed between trials with four to
30 minutes of contact time (OR 1.9, 95% CI 1.5 to 2.3) and trials
with 91 to 300 minutes (OR 3.2, 95% CI 2.3 to 4.6) (Fiore 2008
Table 6.9) and between two to three treatment sessions (OR 1.4,
95% CI 1.1 to 1.7) and over eight sessions (OR 2.3, 95% CI 2.1
to 3.0) compared to 0 to 1 sessions (Fiore 2008 Table 6.10). These
analyses were not limited to direct (within trial) comparisons of
treatment intensity. They also did not distinguish between studies
with and without pharmacotherapy, and the majority of studies
in our analysis were published after 2000 so would not have been
included. Our review is likely to give a more precise estimate of the
effect of additional support alongside pharmacotherapy, based on
the analysis of trials directly comparing different levels of support.
There is observational evidence that access to more behavioural
support is associated with greater success in quitting. For exam-
ple, a study of English Stop Smoking Services, in which there was
a high use of pharmacotherapy, found a positive association be-
tween the number of scheduled sessions and short-term quit rates
(West 2010). A study of NRT users calling the California quitline
found that people who received multiple sessions of counselling
had higher quit rates after one year (Zhu 2000).
Increasingly, studies which test the effects of behavioural support
provide pharmacotherapy to both arms. That means that many of
the studies included here are covered (as subsets only) in other re-
views of behavioural interventions. These include telephone coun-
selling and face-to-face counselling, both in person and in groups
(Lancaster 2017; Matkin 2019; Stead 2017). Our results from the
subgroup of trials in which additional support was delivered via
telephone are remarkably consistent with those from theCochrane
review of telephone counselling (Matkin 2019). Matkin 2019 also
included studies without pharmacotherapy and thus had substan-
tially more studies than our eight, but the point estimate was the
same as ours in studies that recruited smokers who did not call a
helpline (RR 1.25, 95% CI 1.15 to 1.35; 65 trials; 41,233 partici-
pants, I² = 52%). In theCochrane review of individual behavioural
counselling (Lancaster 2017), effects were again consistent with
our findings: there was moderate-quality evidence (downgraded
due to imprecision) of a modest benefit of counselling when all
participants received pharmacotherapy (RR 1.24, 95% CI 1.01
to 1.51; 6 studies, 2662 participants; I2 = 0%). The effect was
stronger in studies in which participants did not receive pharma-
cotherapy. Similarly, in the Cochrane review of group behaviour
therapy programmes (Stead 2017), the effect was stronger in stud-
ies in which participants did not receive pharmacotherapy; only
five trials included pharmacotherapy, with a point estimate indi-
cating a modest benefit but with wide confidence intervals incor-
porating no effect (RR 1.11, 95% CI 0.93 to 1.33, I2 = 0%; n =
1523).
Finally, one explanation for the relatively small impact of pro-
viding more behavioural support is that it is not provided at the
time when it could be most effective. Relapse after initial suc-
cess is the norm for quit attempts, and by the time people are
getting additional calls they may already have relapsed. Various
study authors commented on this (e.g. Reid 1999; Smith 2001).
Although these studies are not typically characterised as being
about ’relapse prevention’, there is a small overlap between this re-
view and the Cochrane review of relapse prevention interventions
(Livingstone-Banks 2019a), which concluded that there was no
evidence of a benefit of additional behavioural support to prevent
relapse. On the other hand, in some cases, an initial benefit of the
intervention disappeared once treatment ended, and authors sug-
gested that further extended support might havemade a difference
(e.g. Killen 2008; Solomon 2000), although replication of one of
these studies with more extended support (Solomon 2005) still
showed the same pattern of late relapse. Another possible expla-
nation is that uptake of extended treatment may be poor, so the
actual number of contacts received may not vary substantially by
group. Few studies reported uptake measures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Providing behavioural support for smokers using establishedmed-
ication in an attempt to stop smoking will increase the proportion
of successful attempts. This is true when comparing more versus
less support and when comparing behavioural support to no be-
havioural support.
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Implications for research
Identifying the optimal amount of behavioural support to use
alongside pharmacotherapy remains a challenge. Studies need to
be appropriately powered for small treatment effects, and test in-
terventions that are acceptable and accessible to smokers, and af-
fordable to deliver. More studies are needed outside of the USA
and Europe. Further research is needed to test associations be-
tween effectiveness and different behavioural components of in-
terventions (which will be covered by a separate review moving
forward).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahluwalia 2006
Methods Setting: community health centre, USA
Recruitment: African-American light smokers recruited from the clinic and using various
routes of advertisement
Participants 755 smokers of ≤ 10 cigarettes per day; the characteristics of 378 participants in the
relevant arm were as follows: 66.1% to 68.3% female; average age 43.5 to 45.2; average
cigarettes per day 7.5 to 7.8
Therapists: trained counsellors who followed semi-structured scripts
Interventions Pharmacotherapy: NRT; 2mg nicotine gum for 8 weeks including weaning period. Dose
depended on the number of cigarettes smoked per day
1. Motivational interviewing: 3 sessions in person and 3 sessions by telephone, each
lasting 20 minutes
2. Health education: 3 sessions in person and 3 sessions by telephone, each lasting 20
minutes
Outcomes 7-day point prevalence abstinence at weeks 1, 3, 6, 8, 16 and 6 months
Validation: cotinine-verification (≤ 20 ng/mL), expired carbone monoxide ≤ 10 ppm
Source of Funding/CoI National Cancer Institute at the National Institutes of Health (R01CA091912) Glaxo-
SmithKline provided study medication. No declarations of interest
Notes New for 2019 update. Previously excluded.
Reason: Conselling conditions had same number of contacts and duration. Compared
Motivational Interviewing and Health Education (HE) in a factorial trial with nicotine
gum or placebo (results favoured HE (control) condition). Included in Lindson-Hawley
2015 Cochrane review of motivational interviewing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Low risk Sealed envelope with pre-assigned ran-
domisation numbers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11.1% to 16.9% lost to follow-up at 6
months
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Aimer 2017
Methods Setting: rheumatology clinic (single centre), Christchurch, New Zealand
Recruitment: smokers with rheumatoid arthritis. No mention of intended selection for
motivation but the authors mentioned that the study population was likely to have been
highly motivated
Participants 39 smokers; 55% female; average age 56.5; average cigarettes per day 16.5
Therapists: community-based arthritis educators trained in smoking cessation
Interventions Pharmacotherapy: NRT for 8 weeks
1. usual care (brief advice and subsidised NRT) for 3 months
2. usual care + rheumatoid arthritis-specific programme for 3 months via face-to-face,
telephone and email; 4 sessions at week 0, 1, 4, 8
Outcomes Continuous abstinence at 3 and 6 months
Validation: none
Source of Funding/CoI New Zealand Health Research Council, Arthritis New Zealand and University of Otago
Research Fund. Authors declared receipt of consultant fees, speaking fees, and/or hono-
raria from AbbVie and Janssen (less than $10,000 each)
Notes New for 2019 update
One participant was excluded from analysis after intervention and follow-up when found
not to have rheumatoid arthritis. Did not contribute to analysis 1.2 or analysis 1.3 as
duration of control group contact not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by a biostatis-
ticianusing anExcel spreadsheet in 6blocks
x 8 allocations
Allocation concealment (selection bias) Unclear risk Insufficient details given
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0-15.8% lost to follow-up at 6 months
37Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Alterman 2001
Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Participants 240 smokers of > 1 pack/day; 45% to 54% female, average age 40, average cpd 27
Therapists: Nurse practitioners (NP) and trained counsellors
Interventions Pharmacotherapy: NRT; 21 mg patch for 8 weeks (including weaning period)
1. Low intensity. Single 30-minute session with nurse practitioners
2. Moderate intensity. as 1 plus additional 3 x 15 to 20-minute sessions at weeks 3, 6, 9
with nurse practitioners
3. High intensity. As 2 plus 12 45 to 50-minute sessions cognitive behavioural therapy
with trained therapist within 15 weeks
Outcomes Abstinence at 1 year
Validation: urine cotinine < 50 ng/mL, CO ≤ 9 ppm
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes 3 versus 1 in main analysis. Quit rates significantly lower in 2 than 1 or 3. 35/160 quit
when 2 & 3 combined
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Urn technique”
Allocation concealment (selection bias) Unclear risk Nodetails given. Allocation tookplace after
baseline session common to all conditions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Small and similar rate lost to follow-up in
each group (approx 7%). “Intent to treat”
analyses reported in the paper excluded 2
deaths and 2 who did not provide cotinine
samples
Aveyard 2007
Methods Setting: 26 general practices (primary care clinics), UK
Recruitment: 92% volunteers in response to mailings
Participants 925 smokers; 51% F, av. age 43, 50% smoked 11 to 20 cpd
Therapists: practice nurses trained to provide cessation support & manage NRT
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Aveyard 2007 (Continued)
Interventions Pharmacotherapy: NRT; 16 mg patch for 8 weeks
1. Basic support; 1 visit (20 to 40 mins) before quit attempt, phone call on TQD, visits/
phone calls at 7 to 14 days & at 21 to 28 days (10 to 20 mins); 4 contacts, ~80 mins
2. Weekly support; as 1. plus additional call at 10 days & visits at 14 & 21 days; 7
contacts, ~140 mins
Outcomes Abstinence at 12 months (sustained at 1, 4, 12, 26 weeks)
Validation: CO < 10 ppm at treatment visits, saliva cotinine < 15 ng/mL at follow-up
Source of Funding/CoI Cancer Research UK. Authors declared interests.
Notes Therapists were not full-time specialist counsellors. Difference between support condi-
tions relatively small
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number generator
Allocation concealment (selection bias) Low risk Numbered sealed envelopes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 30% lost to follow-up but similar per-
centage followed up in both groups (69%
intervention vs 68% control, no evidence
of differential attrition)
Bailey 2013
Methods Setting: high schools in San Francisco, USA
Recruitment: adolescent smokers were recruited over a period of 3 years on a non-rolling
basis, with a new cohort participating each academic school year. Selected for motivation
to quit
Participants 143 smokers; 37.6% female; average age 16.9; average cigarettes smoked per week 97.1
Therapists: research intervention staff with Bachelor’s degree or higher. Supervised by
the project director (clinical psychologist)
Interventions Pharmacotherapy: NRT (nicotine patch); 9 weeks (dosage and titration schedule deter-
mined by number of cigarettes smoked per day)
1. Group based cognitive behavioural therapy and skills training (10 weeks)
2. Group based cognitive behavioural therapy and skills training (10 weeks) + extended
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Bailey 2013 (Continued)
face-to-face group sessions (9 sessions over 14 weeks)
Outcomes 7-day point prevalence abstinence at 6 months
Validation: expired carbon monoxide using Bedfont Smokerlyzers
Source of Funding/CoI National Cancer Institute at the National Institutes of Health (R01 CA 118035 to JDK)
. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Insufficient details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rate: extended group 16.
7%; other 16.9%
Baker 2015
Methods Setting: Centre for Brain and Mental health Research, University of Newcastle, New
SouthWales; School of Public Health, University of New SouthWales, Sydney; Monash
Alfred Psychiatry Research Centre, Monash University and the Alfred, Melbourne, Aus-
tralia
Recruitment: smokers recruited from three sites in Newcastle, Sydney and Melbourne,
Australia. Referral sources included health services, media advertisement and other re-
search programmes or registers
Participants 235 smokers; 41.3% female; average age 41.6; average cigarettes smoked per day 28.6
Therapists: psychologists guided by intervention manuals
Interventions Pharmacotherapy: NRT; 24 weeks’ supply of NRT delivered at weeks 1, 4 and 8 and
thereafter by arrangement. Participants smoking ≥ 30 cigarettes per day were eligible
to receive double patching in addition to up to 12 x 2 mg lozenges per day, with NRT
tapering occurring in the last month of delivery
1. Predominantly telephone-based (17 sessions; 290 minutes in total)
2. Face-to-face healthy lifestyle therapy (17 sessions; 1050 minutes in total)
Outcomes 7-day point prevalence abstinence at week 15 and months 12, 18, 24, 30, 36
Validation; carbon monoxide ≤ 10 ppm
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Baker 2015 (Continued)
Source of Funding/CoI Australian National Health and Medical Research Council and the Commonwealth
Department ofHealth andAging.NRTwas provided free of charge byGlaxoSmithKline.
No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Permuted block randomisation approach
mentioned but no further detail
Allocation concealment (selection bias) Low risk Sealed randomisation envelope by an in-
dependent person displaying a participant
identification code. Participants opened
the envelope at the end of the initial inter-
vention session
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 39.8 to 45.9% lost to follow-up at 3 years
Bastian 2012
Methods Setting: USA
Recruitment: participants identified from electronic medical records. Eligibility assess-
ment in person and selected for motivation to quit
Participants 471 smoker; 8.5% female, average age 59; heaviness of smoking index mean 2.8
Therapists: masters-level counsellors with training
Interventions Pharmacotherapy: NRT; inhaler, patch, spray and/or bupropion (regimen and dosage
dependent on the number of cigarettes smoked per day and tobacco cessation anxiety)
1. Usual care: 5 telephone sessions every 3-4 weeks; each session lasting 20 minutes
2. Family-supported 5 telephone sessions every 3-4weeks; each session lasting 20minutes
Outcomes 7-day point prevalence abstinence at 5 and 12 months
Validation: attempted verification by mailing saliva-sampling kits to test for cotinine
level but the return rates were low (50.5%)
Source of Funding/CoI Department of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, and Health Services Research and Development. Authors declared a
consultancy to Gilead Sciences and Watermark Research Partners
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Bastian 2012 (Continued)
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low rates of return when biochemical
validation was attempted, but contact-
matched so differential misreport judged
unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk 21.7 to 28.4% lost to follow-up rate
Begh 2015
Methods Setting: NHS Stop Smoking clinic, UK
Recruitment: smokers recruited from the participating general practices and Stop Smok-
ing services. Selected for motivation to quit
Participants 119 smokers; 69% female; average age 44.8; average cigarettes smoked per day 20.8
Therapists: trained research nurses and Stop Smoking advisors
Interventions Pharmacotherapy: NRT; 21 mg per 24 hour nicotine patches for 8 to 12 weeks
1. 7 weekly sessions of withdrawal support, of which 5 sessions included placebo training
(16 minutes each) starting one week prior to quit date
2. 7 weekly sessions of withdrawal support, of which 5 sessions included attentional
retraining (16 minutes each) starting one week prior to quit date
Outcomes Prolonged abstinence at weeks 4, 8, and at 6 months
Validation: exhaled carbon monoxide < 10 ppm
Source of Funding/CoI National Institute for Health Research. Authors declared research and consultancy
for manufacturers of smoking cessation medication, including consultancy for Glax-
oSmithKline Consumer Healthcare and research-initiated project grant funding from
Pfizer
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
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Begh 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated simple randomisa-
tion scheme
Allocation concealment (selection bias) Low risk An independent programmer entered the
sequence onto a dedicated online database
which was accessed by study staff in clinics
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 30.0% to 40.7% lost to follow-up at 6
months
Berndt 2014
Methods Setting: cardiac wards, Netherlands
Recruitment: inpatients by ward nurses, at the bedside
Participants 372 in relevant arms, excl 7 deaths (5 TC, 2 FC)
73% M, av age 56, av cpd 21
Therapists: face-to-face counselling (FC) provided by recently trained cardiac nurses,
telephone counselling (TC) provided by experienced telephone counsellors
Interventions Pharmacotherapy: NRT; patches (21 mg/day or 14 mg/day (10 to 20 cpd) for 8 weeks
incl weaning)
1. UC (control): brief quit advice from ward nurses + brochure; no NRT (historical
control, before wards assigned to interventions, not used in review)
2. TC: usual care + 7 x 15-min telephone sessions, weekly for 5 weeks, week 7, week 12
3. FC: usual care + 6 x 45-min + 1 x 15 min face-to-face sessions, same schedule as TC
Outcomes Abstinence at 6 months (90 day PP since last counselling session)
Validation: none
Source of Funding/CoI ZonMw, the Dutch Organization for Health Research and Development. Authors de-
clared no conflicts of interest
Notes 3 vs 2 in analyses, patch use was similar across TC & FC groups
Intraclass correlation coefficient assessed; “intraclass correlations were small and not
statistically different from zero”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Cluster randomisation with sequential
cross-over design. Method of randomising
wards to begin with FC or TC not de-
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Berndt 2014 (Continued)
scribed
Allocation concealment (selection bias) High risk Nurses knew assignment when recruiting
patients. “Although not reported by the
nurses, theymay have been selective in their
recruitment because patients in the inter-
vention groups appeared more motivated
in their drive to quit smoking”. However,
this probably had greater impact on com-
parison with usual care, not used in this re-
view
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Approximately 20% lost to follow up in
each group (TC = 22%, FC = 21%)
Bloom 2017
Methods Setting: research fitness facility, USA
Recruitment: smokers recruited from newspaper and radio advertisements
Participants 61 smokers; 63.3% to 67.7% female; average age 47; average cigarettes smoked per day
19.4 to 20.3
Therapists: aerobic exercise sessions were supervised by exercise physiologist. Unclear
who provided health education sessions
Interventions Pharmacotherapy: NRT; 8 weeks of transdermal nicotine patch (21 mg for weeks 5 to
8, 14 mg for weeks 9 to 10, 7 mg for weeks 11 to 12)
1. 8 sessions of telephone counselling (20 minutes each) + 12 weekly group health
education sessions (60 minutes each)
2. 8 sessions of telephone counselling (20 minutes each) + 12 weekly sessions of group
aerobic exercise (20 to 40 minutes) + 12 weekly cognitive behavioural sessions just before
the exercise sessions (20 minutes each)
Outcomes Continuous abstinence at months 3, 6, 12
Validation: expired carbon monoxide < 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes New for 2019 update
Authors confirmed a typographical error in the abstinence rate in Bloom 2017 paper
and stated the figures in Abrantes 2014 are correct.
Risk of bias
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Bloom 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Urn randomisation
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10.0-12.9% lost to follow-up at 12months
Bock 2014
Methods Setting: 3 primary care clinics, New England, USA
Recruitment: smokers identified by clinic personnel during registration. Research assis-
tants screened interested individuals
Participants 846 smokers
69% F, av age: 40, av cpd not described
Therapists: smoking cessation specialists
Interventions Pharmacotherapy: NRT; patch for 8 weeks
1. Standard care: brief physician advice, patch education
2. Motivational enhancement treatment: standard care + 45-min individual counselling
session & 2 counselling calls either on quit day & 2 weeks later or at 2 & 4 weeks after
1st session
Outcomes Abstinence at 12 months (7-day PP)
Validation: carbon monoxide < 5 ppm
Source of Funding/CoI National Institute on Drug Abuse. Authors declared no conflicts of interest
Notes Data previously confirmed with authors for another review; 48/406 vs 58/440
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomised
Allocation concealment (selection bias) Low risk Research assistants enrolled prior to com-
puter randomisation
45Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bock 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout over 50%; 58.6% in SC238/440)
and 52.7% in ME (232/406)
Boyle 2007
Methods Setting: Health Maintenance Organization, USA
Recruitment: proactive recruitment of members filling a prescription for cessation med-
ications; selected if motivated to quit
Participants 1329 HMO members; 58% F, av age 47, 66% smoked > pack/day
Interventions Pharmacotherapy: all participants had filled a prescription. Almost 95% used; ~51%
only bupropion, 26% only NRT, remainder both
1. No further intervention
2. Proactive call to offer counselling, up to 9 calls, given choice of structured course or
unstructured format
Outcomes Abstinence at 12 months (repeated 7-day PP at 3 months & 12 months)
Validation: none
Source of Funding/CoI Robert Wood Johnson Foundation Addressing Tobacco in Managed Care Program. No
declarations of interest
Notes 49% of intervention group reached, 36% of those declined, 31% of total accepted
counselling. Average N of calls 5. There was no evidence of a greater relative effect in
those reached or those accepting counselling
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, stratified by presence of
chronic disease. Method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 30% lost to follow-up but similar per-
centage followed up in both groups (66%
intervention vs 65% control, no evidence
of differential attrition)
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Bricker 2014
Methods Setting: Quitline in South Carolina, USA
Recruitment: recruited uninsured callers to the South Carolina State Quitline
Participants 121 smokers; 69% female; average age 39.1; 65% smoked more than half pack per day
Therapists: counsellors were Bachelors or Masters level providers with at least 3 years of
general counselling experience
Interventions Pharmacotherapy: NRT; 2-week course of nicotine patch or gum (participant’s choice)
1. 5 sessions of cognitive behavioural therapy telephone intervention (1st call 30 minutes
and each subsequent call 15 minutes)
2. 5 sessions of acceptance and commitment therapy telephone intervention (1st call 30
minutes and each subsequent call 15 minutes)
Outcomes 30-day point prevalence abstinence at 6 months
Validation: none
Source of Funding/CoI National Institute on Drug Abuse, National Cancer Institute. Authors declared consul-
tancy for Pfizer
Notes New for 2019 update. Previously excluded. Reason: both the control and the intervention
received equal amounts behavioural counselling; telephone-delivered acceptance and
commitment therapy (ACT) versus cognitive behavioral therapy (CBT) for smoking
cessation was being assessed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Insufficient details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Self-report only but contact matched
in both groups so differential misreport
judged unlikely
Incomplete outcome data (attrition bias)
All outcomes
Low risk 27.1-38.7% lost to follow-up at 6 months
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Brody 2017
Methods Setting: Veterans Affairs Los Angeles Healthcare System, USA
Recruitment: smokers recruited via flyer advertisement from the smoking and
schizophrenia treatment programmes. Selected for motivation
Participants 42 smokers; 100% male; average age 56.3 to 57.5 years; average cigarettes smoked per
day 18.5 to 19.6
Therapists: cognitive behavioural therapy by a psychologist; home visits by the study
investigators
Interventions Pharmacotherapy: NRT;
- combination extended treatment groups (with or without home visit): combination of
three medications (bupropion, nicotine patch, nicotine lozenge) for 6 months
- usual care: single smoking cessation medication (patch, bupropion or varenicline)
typically for at least 2 to 4 weeks
1. combination extended treatment without home visit: 12 weekly sessions of cognitive
behavioural therapy (60 minutes each)
2. combination extended treatment plus home visit: 12 weekly sessions of cognitive
behavioural therapy (60 minutes each) + biweekly home visits (20 to 30 minutes each)
3. usual care (excluded from our meta-analyses due to different pharmacotherapy to the
other groups)
Outcomes 7-day point prevalence abstinence at week 12 and at 6 months
Validation: exhaled carbon monoxide ≤ 3 ppm
Source of Funding/CoI National Institute on Drug Abuse, Department of Veterans Affairs Office of Research
and Development and Tobacco-Related Disease Research Program. No declarations of
interest
Notes New for 2019 update
Lost to follow-up numbers were obtained from the authors via email correspondence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rates were 21.4% to 28.
6% in combination extended treatment
groups and 7.1% in usual care group at 6
months
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Brown 2013
Methods Setting: community, USA
Recruited: community volunteers who had “previous difficulty quitting for even short
periods of time.” Selected if motivated to quit
Participants N = 49; dropouts: 7
49% F, av age: standard = 48.30; distress tolerance = 47.19, av. cpd standard = 22; distress
= 21
Therapists: doctoral-level psychologists or trainees (psychology interns/postdoctoral fel-
lows) delivered the treatment
Interventions Pharmacotherapy: “8 weeks of nicotine replacement therapy in the form of the nicotine
patch (Nicoderm CQ) beginning on quit day, including 4 weeks of the 21 mg patch, 2
weeks of 14 mg, and 2 weeks of 7 mg.”
1. standard smoking cessation treatment
2. distress tolerance treatment = incorporated elements of exposure-based therapies and
Acceptance and Commitment Therapy
Outcomes Abstinence at 26 weeks (7-day PP)
Validation: expired carbon monoxide (CO, 5 ppm or less) + cotinine verification (coti-
nine, 10 ng/mL or less)
Source of Funding/CoI National Institute on Drug Abuse. Authors declared no conflicts of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants treated in groups, 3 groups
for each condition; “each treatment assign-
ment was randomly selected from the fixed
pool of possible assignments”
Allocation concealment (selection bias) High risk Type of treatment allocated for next group
likely to have been known before partici-
pant recruitment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall 14% lost; standard 9% (2/22), dis-
tress 19% (5/27)
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Busch 2017
Methods Setting: Miriam and Rhode Island Hospitals in Providence, USA
Recruitment: inpatient cardiac units at the Miriam and Rhode Island Hospitals in Prov-
idence
Participants 64 smokers; 27.1% female; average age 55.6; average cigarettes smoked per day 16.4
Therapists: research teammembers (licenced clinical psychologist and clinical psychology
post-doctoral fellow)
Interventions Pharmacotherapy: NRT; 8 weeks of nicotine patches starting on 21 mg patch for those
smoking > 10 cigarettes per day and on 14 mg for those starting ≤ 10 cigarettes per day
1. Usual care: one in-hospital counselling session (50 minutes) + 5 mailings of print
materials + 5 brief “check-in” calls from a health educator following each mailing (5 to
10 minutes each)
2. One in-hospital counselling session + > 5 post-discharge contacts at 1, 3, 6, 9 and
12 weeks. Sessions 1 & 2 (50 minutes each) in-person at a research clinic or in the
participant’s home; Sessions 3 to 6 (30 minutes each) by phone
Outcomes 7-day point prevalence abstinence at weeks 12 and 24 post-discharge from the hospital
Validation: carbon monoxide < 10 ppm
Source of Funding/CoI National Heart, Lung, and Blood Institute of the National Institutes of Health. No
declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk The study statistician provided sequenced
randomisation envelopes. The randomisa-
tion envelopes were opened by counsellors
following the completion of each in-hospi-
tal smoking cessation session. Counsellors
then immediately informed the participant
of their treatment condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 21.2 to 22.6% lost to follow-up at 24weeks
post-discharge
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Bushnell 1997
Methods Setting: community with large military population, USA
Recruitment: community volunteers
Group size:max 50 AmericanCancer Society (ACS) or 15 Vanderbilt UniversityMedical
Center (VUMC)
Participants 314 military and civilian smokers, excluded 198 people, assignment NS, who did not
attend any sessions after randomisation. 44% F, age and smoking not described
Therapists: ACS-trained volunteers, VUMC-healthcare professionals
Interventions All participants offered free NRT (in group 2 conditional on attending 75% classes)
1. ACS: 4 x 1 hour large group sessions (max 50), no TQD
2. VUMC: 8 x 1 hour group sessions (max 15), relapse prevention model including stress
management, diet, exercise
Outcomes Abstinence at 6 months (PP)
Validation: CO < 8 ppm, salivary cotinine ≤ 10 mg/mL
Source of Funding/CoI
Notes Early benefit of VUMC lost at 6 months. No observed effect in active duty participants
at any time
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”, method not stated,
stratified by military or civilian
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 198 (out of 512 randomised) did not par-
ticipate, group not stated, not clear if par-
ticipants knew what group they were as-
signed to before attending first session
Calabro 2012
Methods Setting: university student body, USA
Recruitment: advertised through flyers in campus halls, newsletters, email, and during
presentations in classes
Smoking cessation counsellors enrolled participants
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Calabro 2012 (Continued)
Participants 509 smokers (≥ 1 cpd)
53% F, av age 24.5, 39% smoked 11-20 cpd
Therapists: counsellors trained specifically in behaviour change/cigarette counselling
Interventions Pharmacotherapy: NRT; patch offered to participants smoking ≥ 5 cpd
1. Self-help written material,≤ 5 mins minimal counselling, and no persuasive commu-
nication or assistance to participants
2. In-person motivational counselling with health feedback, 2 x 60 to 120 mins over 3
months, and access to 5 web-based booster sessions
Outcomes Abstinence at 12 m (30-day PP)
Validation: 46 of 79 who reported abstinence provided a salivary cotinine value ≤ 5 ng/
mL
Source of Funding/CoI National Cancer Institute. Authors declared no conflicts of interest
Notes Coded as validated, however not all self-reported quitters were validated due to problems
with sample collection
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistical software package generated ran-
domisation.
Allocation concealment (selection bias) Low risk Randomisation by computer occurred after
enrolment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout high and differential; interven-
tion 43% (120/278), control 66% (153/
231)
Cook 2016
Methods Setting: primary care clinics, USA
Recruitment: adult smokers recruited during primary care visits who were willing to
reduce their smoking but not quit
Participants 517 smokers; 63.4% female, average age 47.0; average number of cigarettes smoked per
day 17.5
Therapists: no details given
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Cook 2016 (Continued)
Interventions Pharmacotherapy: NRT; 14 mg patches daily for 6 weeks and/or 2 mg gum for 6 weeks
(≥ 9 per day, 1 piece for 1 to 2 hours)
1. behavioural reduction: an initial 20 minute in-person counselling session followed by
6 weekly 10-minute counselling calls; 7 sessions in total
2. motivational interviewing: an initial 20-minute in-person counselling session followed
by three biweekly, 10-minute counselling calls over 6 weeks; 4 sessions in total
Outcomes 7-day point prevalence abstinence at week 12 and at 6 months
Validation: none
Source of Funding/CoI National Cancer Institute, the Wisconsin Partnership Program. Authors supported by
National Research Service Award from the Health Resources and Services Administra-
tion, NSF grant, NIH grants, Merit Review Award from theUS Department of Veterans
Affairs. No declarations of interest
Notes New for 2019 update
Abstinence data received from authors via email correspondence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk “staff were blinded to randomisation until
eligibility was confirmed but not beyond
that point; participants were blinded until
consent was provided”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow up n = 66; withdrawn n = 17
Cropsey 2015
Methods Setting: community corrections offices, USA
Recruitment: smokers under community corrections supervision were recruited via flyers
posted at the community corrections offices
Participants 500 smokers; 33.0% female, average age 37.4; average number of cigarettes smoked per
day 17.9
Therapists: counsellors were doctoral or masters level clinical psychologists who had been
trained in smoking cessation counselling
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Cropsey 2015 (Continued)
Interventions Pharmacotherapy: NRT; 12 weeks’ supply of bupropion
1. one session of face-to-face brief advice
2. four weekly sessions of face-to-face brief advice and intensive counselling, each lasting
20 to 30 minutes
Outcomes Abstinence (carbon monoxide level≤ 3 ppm) at all study visits (weeks 8, 12 and months
6, 9, 12)
Validation: carbon monoxide level (≤ 3 ppm) measured using the Vitalograph Breath
Carbone Monoxide monitor
Source of Funding/CoI The National Cancer Institute and the National Institute of Heatlh. No declarations of
interest
Notes New for 2019 update
Data on the number of abstinent participants received from the authors via email corre-
spondence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomisation scheme was blocked on
race…”. No further details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rates at 12 months:
no counselling arm 25.8%; counselling
arm 23.4%
Ellerbeck 2009
Methods Settng: primary care patients, 50 rural practices, Kansas, USA
Recruitment: smoking patients not selected for motivation, but 67% of those eligible
enrolled, only 8.7% in pre-contemplation stage of change
Participants 750 smokers of > 10 cpd, 59% F, av age 47, av cpd 24, 61% contemplation, 30%
preparation
Interventions All participants mailed an offer of free pharmacotherapy every 6months, 4 times in total.
Nicotine patch 21 mg for 6 weeks or bupropion SR (150 mg twice daily) for 7 weeks
1. Control. No other contact
2. Moderate intensity disease management: up to 2 calls from counsellor in each cycle
encouraging uptake of pharmacotherapy, newsletter mailings & periodic progress reports
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Ellerbeck 2009 (Continued)
with counselling suggestions faxed to physician
3. High-intensity disease management, up to 6 calls at approx 1, 3, 6, 9, 12 weeks from
start of each cycle
Outcomes Abstinence at 24 months (PP). Study also reported analysis based on combination of
effects at all follow-up points. Sustained abstinence not a suitable outcome since no quit
date and repeated intervention
Validation: attempted saliva cotinine (< 15 ng/mL) by mail at 12 and 24 months. Proxy
report used at 24 months for non-returners. Rate of validation similar across groups
Source of Funding/CoI National Cancer Institute. Medication provided by GlaxoSmithKline, “The funding
sources were not involved in the design, conduct or analysis of this study or the decision
to submit the study for publication”. No declarations of interest
Notes Participants could have multiple courses of pharmacotherapy; 23%, 33%, 23%, 12%,
and 9% of participants requested 0, 1, 2, 3, or 4 courses, Disease management conditions
increased use in first cycle and reduced it later. 41% of cycles used bupropion & 59%
patch. Over 24 months, average number of calls 3.6 in 2. and 8.2 in 3. Fewer calls in
later cycles
No evidence of effect based on PP, but some evidence of benefit when all follow-ups
taken into account
High intensity vs control in main comparison. Moderate intensity quit almost identical
(35/238 14.7%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated randomnum-
bers tablewas utilized to generate allocation
cards in blocks of 24with allocation equally
distributed across treatment groups”
Allocation concealment (selection bias) Low risk Quote: “cards were placed in sequentially
numbered, opaque, sealed envelopes”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated and proxy report
used for non-returners; rate of non-return
similar across groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 20% lost to follow-up, similar
distribution amongst groups (11% control,
16% in both moderate- and high-intensity
intervention arms)
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Ferguson 2012
Methods Setting: National quitline, Engalnd
Recruitment: non-pregnant smokers aged ≥ 16 years, residing in England who called
the quitline and agreed to set a quit date
Participants 2591 smokers in total (1295 in the relevant arms); 52.3% female, average age 38; average
number of cigarettes smoked per day: 497 in ≤ 10 cpd category; 1226 in 11 to 20 cpd
category; 547 in 21 to 30 cpd category; 230 in ≥ 31 cpd category
Therapists: trained advisors from two helpline centres
Interventions Pharmacotherapy: NRT; no cost vouchers for 21 days’ supply of 15 mg per 16 hour
transdermal nicotine patches which were redeemed by a telephone call. A second 21
days’ supply could be redeemed in the same way three weeks after the initial batch
1. usual care (support materials by email, letter or text message before, on and after quit
date + proactive telephone contact + brief motivational messages)
2. 6 sessions of more intensive, proactive support by telephone
Outcomes Prolonged abstinence at months 1 and 6
Validation: a minority of participants (255 out of 2591 had face-to-face follow-up for
validation of abstinence by carbon monoxide (cut-off of < 10 ppm))
Source of Funding/CoI The English Department of Health, the UK Centre for Tobacco Control Studies. No
declarations of interest
Notes New for 2019 update
Previously excluded. Contact amount not known so excluded from analyses 1.2 and 1.3
Use of pharmacotherapy was low; only 42.9% of those offered NRT reported receiving
any and of those only 51.3% used every day. There was also little difference between
number of calls completed between proactive and standard telephone counselling con-
ditions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rate:
NRT + usual care arm 44.7%; NRT +
proactive support arm 45.5%
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Fiore 2004
Methods Setting: primary care patients, 16 clinics, USA
Recruitment: clinic attenders willing to accept treatment
Participants 961 smokers of ≥ 10 cpd. (a further 908 were allowed to select treatment, not included
in review. Demographic details based on 1869); 58% F, av age 40, av cpd 22
Therapists: trained cessation counsellors
Interventions Pharmacotherapy: NRT (patch, 22 mg, 8 weeks including tapering)
1. NRT alone
2. As 1 plus Committed Quitters programme, single telephone session and tailored self-
help
3. As 2 plus face-to-face individual counselling, 4 x 15 to 25-min sessions, pre-quit,
~TQD, next 2 weeks
Outcomes Continuous abstinence at 1 year (no relapse lasting 7 days), also PP
Validation: CO, cut-off not specified. 2 discordant
Source of Funding/CoI National Cancer Institute. SmithKline Beecham provided nicotine patches and access to
the CQ program, but did not participate in any aspect of study design or data analysis
Notes 3 versus 1 used in primary analysis. 3 & 2 versus 1 was more conservative since 2 had
lower quit rates than 1. Use of PP outcome did not alter findings
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk People who did not pick up patches were
excluded from analyses, similar distribu-
tion amongst groups (17% control, 16%
in intervention arm 1, 14% intervention
arm 2). No reported loss to follow-up for
remaining participants
57Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gariti 2009
Methods Setting: academic research centre, USA
Recruitment: community volunteers, interested in quitting
Participants 260 light smokers (6 - 15 cpd), 57% F, av age ~43, av cpd 11, approx 1/3 smoked < 10
cpd, approx 50% had history of smoking 20 cpd
Therapists: cessation counsellors
Interventions 2 x 2 double-blind double-dummy. Participants randomised to either nicotine patch (21
mg/day or 14 mg/day (< 10 cpd) for 8 wks incl weaning) or bupropion (9 wks)
1. Pharmacotherapy & medication management, 4 x 5-10 min visits over 6 wks
2. Pharmacotherapy & counselling, 10 weekly individual 10-15 min sessions
Outcomes Abstinence at 1 yr, sustained with no relapse of over 7 days smoking (study primary
outcome was PP abstinence)
Validation: CO ≤ 9 ppm & cotinine (NicAlert) ≤ 200 ng/mL or cotinine < 50 ng/mL
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes NRT & bupropion conditions not reported separately by counselling condition, so 2 vs
1 entered in NRT or bupropion section. Favoured NRT but no significant difference at
any follow-up.More evidence of effect on sustained than PP rates at 1 yr, but substituting
PP in MA did not affect findings
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated “urn” randomisation
by independent data analyst
Allocation concealment (selection bias) Low risk Randomisation after enrolment, not pre-
dictable
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 108 (84%) intervention and 108 (82%)
control reached at 1 yr
Gifford 2011
Methods Setting: academic research centre, USA
Recruitment: community volunteers
Participants 303 smokers with at least 1 quit attempt in past 2 years
58.7% F, av age: 45.99, av cpd 24
Therapists: abuse therapist + clinical psychology doctoral students
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Gifford 2011 (Continued)
Interventions Pharmacotherapy: bupropion for 10 weeks.
1. Control; 1 hr of “medication instruction group presenting the rationale for bupropion”
2. Bupropion plus functional analytic psychotherapy (FAP) and acceptance and com-
mitment therapy (ACT), 20 sessions, 1 group & 1 individual session per wk for 10 wks
Outcomes Abstinence at 1 yr (7-day PP). Continuous abstinence also reported but denominators
not clear
Validation: CO ≤ 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes Numbers quit calculated from percentages. Included in brief intervention subgroup 1.
1.1, sensitivity analysis in dose-response did not alter estimates
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using generator www.ran-
domizer.org
Allocation concealment (selection bias) Low risk Randomisationdidnot occur until after en-
rolment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk 38% intervention & 67% control lost to
follow-up, including 10 intervention & 2
control dropouts before treatment
Ginsberg 1992
Methods Setting: academic research centre, USA
Recruitment: community volunteers
Participants 99 smokers with an acquaintance willing to participate as a support partner; 54% F, av
age 38, av cpd 26
Interventions Pharmacotherapy: nicotine gum, 2 mg, duration not specified
1. Instruction for gum use & educational materials, 2 brief sessions over 2 weeks
2. Instructions as 1. included with a group-based behavioural programme including skill
training, 5 sessions over 4 weeks. Duration not specified, assumed to be 91 to 300 min
3. As 1. plus behavioural programme and partner-support programme, 8 sessions over
5 weeks. Not included in this review
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Ginsberg 1992 (Continued)
Outcomes Abstinence at 52 weeks (not clear if abstinence required at prior assessment at wks 4, 12,
26)
Validation: CO < 10 ppm, urine cotinine < 50 ng/mL. Paper stated that cotinine levels
failed to confirm self-report in 7 people, 3 of whom were still coded as abstinent on the
balance of evidence
Source of Funding/CoI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly assigned to 3-6 member
groups in order of entrance into treatment
within time constraints. Treatment for each
group was randomly selected ...”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9 participants lost to follow-up counted as
smokers. 1 participant who died excluded
from analyses
Hall 1985
Methods Setting: clinic, USA
Recruitment: referred by physicians, friends or self
Participants 84 smokers in relevant arms; 53% M, av age 38, av cpd 30.5
Therapists: 2 psychologists
Interventions Pharmacotherapy: NRT; gum (2 mg, available for 6 months)
1. Intensive behavioural treatment (incl relapse prevention skill training, relaxation, 30
seconds aversive smoking of 3 cigs). 14 x 75 min sessions over 8 weeks
2. Low-contact . Met x 4 in 3 weeks, educational materials, written exercises, group
discussion
3. Intensive behavioural, no gum. Not included in this review
Outcomes Abstinence at 52 weeks (assume PP)
Validation: CO < 10 ppm, thiocyanate < 85 mg/mL, reports of significant others (bio-
chemical measures failed to confirm self-report in 3 instances)
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Hall 1985 (Continued)
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomly assigned within time con-
straints.” Author clarification: “There were
two or more treatment conditions avail-
able within any time block, and partici-
pants were randomly assigned to condi-
tions within that time block”
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 dropouts from group 2 and 3 from group
3. Assumed to be included in denomina-
tor for reported % abstinent used to derive
numbers quit
Hall 1987
Methods Setting: clinic, USA
Recruitment: community volunteers or referrals
Participants 139 smokers; 53% M, av age 39, av cpd 30 (71 in relevant arms)
Therapists: advanced graduates in clinical psychology or health psychology
Interventions Pharmacotherapy: NRT (gum). Placebo arms of factorial trial not used in review
1. Intensive behavioural treatment, 14 x 75 min sessions (period not stated) (incl 6
seconds aversive smoking, RP skills training, written exercises)
2. ’Low contact’ 5 x 60 min sessions (incl written exercises, educational materials, group
discussions, quitting techniques)
Outcomes Abstinence at 52 wks (assume PP)
Validation: thiocyanate < 95 mm/L (unless marijuana use reported), CO < 8 ppm,
significant other
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes
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Hall 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; method not described
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 dropouts in 1 & 2 in 2 included in ITT
analyses. “Differences between conditions
were not statistically significant.”
Hall 1994
Methods Country: USA
Recruitment: community volunteers or referrals
Participants 149 smokers (> 10 cpd)
52% F, av age 41, av cpd 25, 31% had history of MDD
Therapists: physician, psychologist. Both received training.
Interventions Pharmacotherapy: NRT (gum, 2 mg for up to 12 wks, tapering from wk 4)
1. Mood Management. 10 x 2 hr sessions over 8 wks. Similar to control, plus specific
cognitive-behavioural components for developing skills for copingwith situations leading
to poor mood. Thought stopping, rational-emotive techniques, relaxation etc
2. Standard group therapy. 5 x 90 min sessions over 8 wks. Information and group
support for planning and implementing individual strategies
Outcomes Continuous abstinence at 52wks (confirmed quit at all prior assessments and no smoking
in previous wk)
Validation: CO ≤ 10 ppm and urine cotinine ≤ 60 ng/mL
Source of Funding/CoI National Institute on Drug Abuse. Merrell Dow Pharmaceuticals Inc. provided drugs.
No declarations of interest
Notes Both behavioural interventions were relatively intensive. Positive effect reported for sub-
group with history of major depression
Risk of bias
Bias Authors’ judgement Support for judgement
62Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hall 1994 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts included as smokers, but num-
bers not specified
Hall 1998
Methods Setting: cessation clinic, USA
Recruitment: community volunteers. Exclusion criteria included MDD within 3 m of
baseline
Participants 199 smokers of ≥ 10 cpd; 55% F, av age 40, av cpd 21-25; 33% had history of MDD
Therapists: 3 doctoral-level clinical psychologists
Interventions Pharmacotherapy: nortriptyline (titrated to therapeutic levels - usually 75-100 mg/day
for 12 wks). Placebo arms of factorial trial not used in review
1. Mood management. 10 x 2 hr sessions over 8 wks
2. Standard group therapy control. 5 x 90 min sessions over 8 wks (see Hall 1994 for
description of each intervention)
Outcomes Abstinence at 64 wks (1 yr post-treatment). Continuous abstinence rates not reported
by psychological treatment group
Validation: CO < 10 ppm and cotinine < 341 nmol/L
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes Both behavioural interventions were relatively intensive.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer, after stratifica-
tion on history of MDD and number of
cigs smoked
Allocation concealment (selection bias) Low risk Computer randomisation after data collec-
tion
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Hall 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 16% lost to follow-up at 1 yr, no differ-
ence by group, included in denominators
for MA
Hall 2002
Methods Country: USA
Recruitment: community volunteers. Exclusion criteria included current MDD
Participants 220 smokers (146 in relevant arms); ≥ 10 cpd; 40%-47% F, av age 37-43, av cpd 20-
23; 33% had history of MDD
Interventions Pharmacotherapy: bupropion (300 mg for 12 wks) or nortriptyline (titrated to thera-
peutic levels, typically 75 or 100 mg/d). Factorial 3 x 2 design, placebo arms not used
in this review
1. Medical Management (MM) control: physician advice, S-H, 10-20 min 1st visit, 5
min at 2, 6, 11 wks
2. Psychological Intervention (PI) as MM plus 5 x 90 min group sessions in wks 4, 5, 7
& 11
Outcomes PP abstinence at 1 yr (47 wks post-quit date). Continuous abstinence not reported by
subgroup
Validation: CO ≤ 10 ppm, urine cotinine ≤ 60 ng/mL
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes Bupropion PI vs MM & nortriptyline PI vs MM used in relevant subgroups. Trial also
contributed to review of combined interventions Stead 2016, using different combina-
tion of arms.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not specified, “dou-
ble blind”
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
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Hall 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19% lost to follow-up at 12 m, similar
numbers across groups
Hall 2009
Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Participants 402 smokers (≥ 10 cpd) aged ≥ 50; 40% F, av age 57, av cpd 21
Interventions Pharmacotherapy: NRT (gum, 10 weeks, 2 or 4 mg) & bupropion (12 weeks). 2 arms
had extended access to gum
1. “Standard treatment”; 5 group sessions over 8 weeks, ’Clear Horizons’ manual
2. ExtendedCBT; 11 individual 20 to 40min sessions fromweek 10 to week 52, schedule
front-loaded. Inclmotivation,moodmanagement, weight control, social support, coping
with withdrawal
3. Extended NRT. nicotine gum available until week 52, no additional behavioural
support
4. Extended combined, CBT & NRT; 3 & 4
Outcomes Abstinence at 104 weeks (one year after end of all treatment) (PP)
Validation: CO ≤ 10 ppm and urine anatabine/anabasine ≤ 2 mg/mL
Source of Funding/CoI National Institute on Drug Abuse. No declarations of interest
Notes Meta-analysis comparison was 2 & 4 vs 1 & 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised at end of initial treatment,
computerised allocation list by statistician
who had no contact with participants.
Stratified on gender, history of MDD, cur-
rent cigarette abstinence status
Allocation concealment (selection bias) Low risk “The assignment of individual participants
by subject number was then transmitted
electronically to clinical staff.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 20% lost to follow-up in each
group, denominator excluded participants
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Hall 2009 (Continued)
who died during the study but counted all
others lost to follow-up as smokers
Hasan 2014
Methods Setting: North Shore Medical Center in Salem, USA
Recruitment: smokers admitted with a cardiac or pulmonary illness were electronically
identified
Participants 122 smokers in total (81 in the relevant arms); 39.5% female, average age 54.4 to 55.3;
average number of cigarettes smoked per day 20.5 to 21.2
Therapists: no details given
Interventions Pharmacotherapy: NRT; free one-month supply of nicotine patches with the initial
dose based on the number of cigarettes they smoked prior to hospitalisation. Also given
nicotine gum or lozenges to administer as needed
1. one intensive in-hospital counselling (30minutes) + five telephone callswith additional
counselling at 1, 2, 4, 8 and 12 weeks post-discharge (15 minutes each)
2. one intensive in-hospital counselling (30minutes) + five telephone callswith additional
counselling at 1, 2, 4, 8 and 12 weeks post-discharge (15 minutes each) + one in-person
hypnotherapy session within 1 to 2 weeks of hospital discharge (90 minutes)
Outcomes 7-day point prevalence abstinence at week 12 and at 6 months
Validation: urinary cotinine levels (< 15 mg/mL). In case of no urine sample returned,
abstinence was confirmed by contacting a household proxy
Source of Funding/CoI The Norman H. Read CharitableTrust Foundation. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “permuted blocks of three (1:1:1)”. No fur-
ther details given
Allocation concealment (selection bias) Low risk “Assignments sequentially numbered and
schedule was maintained independent of
the study by the project coordinator. Ran-
domised assignments were concealed from
both patients and research staff until pa-
tients had signed the informed consent
document and were enrolled in the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
66Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hasan 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rates:
Counselling arm 29.3%; counselling +
hypnotherapy arm 32.5%
Hollis 2007
Methods Setting: community-based telephone quitline programme, Oregon, USA
Recruitment: callers invited to participate; assumed to be fully or partly motivated to
quit
Participants 4614 smokers randomised to: brief counselling (872, no NRT; 868, with NRT); mod-
erate counselling (718, no NRT; 715, with NRT); intensive counselling (720, no NRT;
721, with NRT)
40% M, av age 41, 90% white, av cpd 21
Interventions Factorial design; arms that were offered free NRT (patches, initial 5-wk supply, 3 more
wks available) contributed to this review
Intervention 1. Brief counselling (usual care), 15-min call + referral material + tailored
S-H materials
Intervention 2. Moderate counselling: 40 mins counselling based on MI + 1 brief call
to encourage use of community services, tailored S-H materials
Intervention 3. Intensive counselling: As 2, plus offer of up to 4 additional telephone
calls. Each call incorporated MI techniques, stage assessment, RP as needed
Outcomes 30-day PPA at 6 and 12 months
Validation: none
Source of Funding/CoI National Cancer Institute. GlaxoSmithKline supplied nicotine patches. Two authors
employed by Free & Clear, Inc, a for-profit company providing telephone counselling
services
Notes 3 vs 1 in main comparison. Actual contact in 3; mean 2.9 sessions, 60.6-min contact
Also contributed to review of combined interventions Stead 2016
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “a computer algorithm randomly assigned
participants”.
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and different amounts of
contact between arms
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Hollis 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate level of attrition but balanced be-
tween groups, and participants lost to fol-
low-up counted as smokers (72% followed
up in groups 1 and 2, 68% followed up in
group 3)
Huber 2003
Methods Setting: academic research centre, Germany
Recruitment: community volunteers
Participants 225 smokers (102 in relevant arms); 55% F, av age 38, av cpd 28
Interventions Pharmacotherapy: nicotine gum, 2 or 4 mg
1. 5 x 90-min weekly meetings. Included contracting, reinforcement, relaxation, skills
training
2. Same schedule of meetings, 45-min only, focus on sharing experiences
3. As 1, no nicotine gum. Not included in this review
4. Wait-list control for 6 m. Not included in this review
Outcomes PP abstinence at 12 m
Validation: CO ≤ 4 ppm
Source of Funding/CoI Not specified. No declarations of interest
Notes Control and intervention fell into same categories for number and duration of sessions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 31 people attending 2 or fewer meetings
not included in analysis. Said to be evenly
distributed. Later dropouts included as
smokers; 90% of those receiving therapy
(excluded wait-list group 4, who were also
excluded from this review) followed up at
12 m
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Humfleet 2013
Methods Setting: HIV clinics, USA Health Care
Recruitment: HIV clinic patients, volunteering for study
Participants 209 smokers
82% M, av age 45, av cpd 20
Therapists: clinicians specialising in smoking cessation/social work/psychology
Interventions Pharmacotherapy: NRT; patch or gum for 10 weeks, available to those who smoked ≥
5 cpd, number not eligible, not specified
1. Self help: “How to Quit Smoking”; brief meeting with study staff who reviewed guide
and recommended establishing a quit date
2. Individual counselling: 6 x 40 to 60-min sessions of CBT targeted towards needs of
HIV positive smokers, weeks 1, 2, 3, 4, 8 & 12
3. Computer-based: each component structured into a “step” roughly corresponding to
the first 5 sessions of the counselling intervention. Individuals were directed to complete
self-assessment exercises and homework assignments
Outcomes Abstinence at 52 weeks (7-day PP)
Validation: CO ≤ 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. California Tobacco-Related Disease Research Pro-
gram. Authors declared no conflicts of interest
Notes Individual counselling compared to self-help in main MA, added computer-based arm
in sensitivity analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Smokers stratified based on N cpd, gen-
der, history of depression and then within
each stratum randomised via computer al-
gorithm to 1 of 3 conditions in 1:1:1 fash-
ion into a parallel-group design
Allocation concealment (selection bias) Low risk Randomisation occurred after enrolment
& stratification.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19% overall loss to follow-up
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Jorenby 1995
Methods Country: 2 academic research sites, USA
Recruitment: community volunteers
Participants 504 smokers (≥ 15 cpd); ~53% F, av age 44, av cpd 26-29
Therapists: trained smoking cessation counsellors
Interventions Compared 22 mg vs 44 mg nicotine patch and 3 types of adjuvant treatment. Patch
groups collapsed. All participants had 8 weekly assessments by research staff
1. Minimal: Given S-H pamphlet by physician during screening visit for trial entry, and
instructed not to smoke whilst wearing patch. No further contact with counsellors
2. Individual: Given S-H pamphlet at screening visit along with motivational message.
Alsomet nurse counsellor x 3 following quit date.Nurse helped generate problem-solving
strategies and provided praise and encouragement.
3. Group: Given S-H pamphlet at screening visit along with motivational message.
Received 8 x 1-hour weekly group sessions. Skills training, problem-solving skills
Outcomes 7-day PP abstinence at 26 wks
Validation: CO < 10 ppm
Source of Funding/CoI Elan Pharmaceutical Research Corporation. Authors declared potential conflicts of in-
terest
Notes No significant difference in dose-related outcome and no dose-counselling interaction at
26 weeks reported. Patch arms collapsed in analysis. 3 vs 1 used in primary comparison,
RR 0.99 (95% CI 0.69 to 1.42). RRs for other comparisons: 2 & 3 vs 1 = 1.10 (95%
CI 0.81 to 1.49), 2 vs 1 = 1.21 (95% CI 0.86 to 1.70), 3 vs 2 = 0.82 (95% CI 0.58 to
1.15)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, method not stated
Allocation concealment (selection bias) Unclear risk “In a double blind manner” for NRT, but
not specified for counselling
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses not specified by group, relatively
low rate lost to follow-up overall (16.3%),
Counted as smokers in report & MA
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Kahler 2015
Methods Setting: community, USA
Recruitment: smokers recruited through advertisements on multiple media
Participants 77 smokers; 50% female, average age 47.4 to 44.5; average number of cigarettes smoked
per day 18.7 to 18.8
Therapists: six female doctoral level counsellors with prior experience in behavioural
health counselling
Interventions Pharmacotherapy: NRT; 8 weeks of nicotine patches beginning on their scheduled quit
date, which coincided with the third session (2 weeks after the initiation of treatment).
Dosage dependent on the number of cigarettes smoked per day
1. Usual care: six sessions (five weekly and a final session that occurred 2 weeks later);
session 1 lasted 60 minutes and the later sessions 30 minutes; 30 minutes of the session 1
and 20 minutes of the subsequent sessions were dedicated to teaching progressive muscle
relaxation
2. Positive psychotherapy: same as the usual care in terms of the number and duration of
the sessions but 30 minutes of the session 1 and 20 minutes of the subsequent sessions
were dedicated to positive psychotherapy-specific content
Outcomes Continous abstinence at weeks 8, 16, 26
Validation: alveolar carbon monoxide (≤ 8 ppm) using a Bedfont Scientific Smokelyzer
breath carbon monoxide monitor; saliva cotinine (≤15 ng/mL) radioimmune assay anal-
ysis
Source of Funding/CoI The National Cancer Institute. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk “data for the randomisation were sent by
research assistant to the project coordina-
torwho conducted the computer-based urn
randomisation and informed the treatment
provider of treatment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rates:
Usual care arm31.6%; positive psychother-
apy arm 25.6%
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Killen 2008
Methods Setting: community cessation clinic, USA
Recruitment: community volunteers
Participants 301 smokers (≥ 10 cpd or 3.5 packs/wk) (excluded 3 participants who received wrong
treatment); 40% F, av age ~46, av cpd ~20
Interventions Pharmacotherapy: bupropion (300mg, 9wks)&NRT(21mgpatch, 8wks incl tapering)
Common behavioural therapy: 6 x 30-min individual CBT sessions at baseline, TQD,
1, 2, 4, 6 wks
1. Extended therapy: 4 x 30-min sessions at 8, 12, 16, 20 wk, & weekly check-in calls
to automated system; report of relapse or craving prompted proactive calls
2. Control: 5-min general support calls at 8, 12, 16, 20 wks
Outcomes Abstinence at 52 wks (7-day abstinence at both 20 & 52 wks) (continuous abstinence
also reported but not used in MA as could underestimate any effect on recycling)
Validation:CO<10ppm (11 self-reported quitters no longer living in study area accepted
as quitters without validation)
Source of Funding/CoI National Institute on Drug Abuse. Authors declared no conflicts of interest
Notes Tested extended duration therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a permuted block
method (block size = 4), stratified on gen-
der
Allocation concealment (selection bias) Low risk Participants assigned to next available ID
number in corresponding gender. Re-
searchers & participants were blinded to
extended treatment assignment to the end
of the open-label phase
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% followed up in standard-care group,
90% followed up intervention group
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Kim 2015
Methods Setting: community centre or office, USA
Recruitment: smokers recruited via advertisements in Korean newspapers. Selected for
motivation to quit
Participants 30 smokers; 23.3% female, average age 46.5; average number of cigarettes smoked per
day 19.0
Therapists: two Korean bilingual clinicians
Interventions Pharmacotherapy: NRT; 8 weeks’ supply of nicotine patches
1. Eight weekly sessions of face-to-face individualised counselling focusing onmedication
management, each lasting 10 minutes
2. Eight weekly sessions of face-to-face individualised and culturally tailored cognitive
behavioural therapy, each lasting 40 minutes
Outcomes Continuous abstinence at weeks 1, 4 and months 3, 6
Validation: carbon monoxide (< 6 ppm) measured by a Micro+ Smokerlyzer Carbone
Monoxide monitor; saliva cotinine (≤ 1 ng/mL) assessed by the NicAlert test
Source of Funding/CoI National Institute of Drug Abuse. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up rates:
Control 25.0%; intervention 21.4%
LaChance 2015
Methods Setting: USA (no further detail reported)
Recruitment: from the community via newspaper and television advertisement
Participants 49 participants, 32.7% female, average age: 42.8 ± 11.2, average cigs/day: 18.2 ± 5.2
Therapists: five therapists; a licensed psychologist, a master’s level clinician, an intern,
and two bachelor’s level therapists
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LaChance 2015 (Continued)
Interventions Pharmacotherapy: 8 weeks of transdermal nicotine replacement therapy
Intervention: behavioural couples treatment. Total contact time: 60 minutes each x 7 =
420 minutes
Control: individual standard treatment. Total contact time: 60 minutes each x 7 = 420
minutes
Outcomes 7-day point prevalence abstinence at 3 and 6 months
Validation: CO ≤ 8 ppm, or urinary cotinine
Source of Funding/CoI Funding:National Institute onDurgAbuse andNationalHeart Lung andBlood Institute
at the National Institutes of Health, and the Department of Veterans Affairs
No declaration of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Urn randomisation
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar drop-out rates (BCT-S: 23.0%; ST:
21.7%)
Lando 1997
Methods Setting: Health Maintenance Organization, USA
Recruitment: physician referral and HMO clinic newsletters
Participants 509 smokers of > 20 cpd, motivated to quit; 56% F, av age 42, av cpd 28
Interventions All participants received prescriptions for free nicotine patch (Prostep), 22 mg for a
maximum of 6 weeks plus 11 mg for 2 wks. All attended 90-min group orientation
session describing study, use of patch, behavioural information, set quit date. Standard
written materials with patch included description of a toll-free telephone help line.
1. No further support
2.Orientation session included encouragement to call toll-free number and a registration
card.
3. Additional proactive telephone counselling, 4 x 10 to 15-min calls (approx 1, 4, 7, 9,
12 weeks from quit date). Reinforced success or negotiated a new quit date
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Lando 1997 (Continued)
Outcomes Abstinence at 12 months (from quit date)
Validation: CO at 6 months. 96% of quitters were confirmed.
Source of Funding/CoI Lederle Laboratories. No declarations of interest
Notes Also contributed to Cochrane review of telephone counselling (Matkin 2019)
Effect of counselling compared to contact & quitline alone (1 & 2 combined since fewer
than 1% called quitline and no difference between quit rates). Participants who did not
return questionnaires at 2, 5, 8, 12 weeks were called by telephone.
Average number of calls completed 3.76
Cluster-randomised trial: analysis reported stated that it was adjusted for clustering effects
via a mixed model, but these results were not reported except that group comparisons
did not “approach statistical significance”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Cluster-randomised,methodnot described
Allocation concealment (selection bias) Unclear risk Allocation by orientation session attended;
participants did not know condition in ad-
vance so risk of selection bias probably low
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82% response rate at 12 m, no difference
between groups, missing treated as smok-
ing
Lifrak 1997
Methods Setting: substance abuse outpatient facility, USA
Recruitment: community volunteers
Participants 69 smokers; 61% F, av age 39, av cpd 25
Interventions Pharmacotherapy: nicotine patch (24-hr, 10-wk tapered dose)
1. Moderate intensity - 4 meetings with nurse practitioner who reviewed S-H materials
and instructed in patch use
2. High intensity. As 1 plus 16 weekly 45-min cognitive behavioural relapse prevention
therapy from clinical social worker or psychiatrist experienced in addiction treatment
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Lifrak 1997 (Continued)
Outcomes Abstinence at 12 months, 1-week PP
Validation: urine cotinine for some participants, but no corrections made for misreport-
ing
Source of Funding/CoI None stated
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (block size 10)
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low rate of attrition (though breakdown
by group not provided): 12 administrative
dropouts/exclusions not included in analy-
ses
Lloyd-Richardson 2009
Methods Setting: 6 outpatient HIV clinics & 2 primary care clinics, USA
Recruitment: eligible patients identified by physicians, motivation to quit not required
Participants 444 HIV+ smokers; 37% F, av age 42, av cpd 18
Interventions Pharmacotherapy: nicotine patch for up to 8 weeks if willing to set quit date
1. 2 brief counselling sessions, biweekly patch collection without counselling contact
2. 4 x 30-min sessions plus quit day call, using motivational interviewing approach
Outcomes 7-day point prevalence abstinence at 12 months
Validation: carbon monoxide < 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. Authors declared no conflicts of interest
Notes 72% used patch at some point during study.
Risk of bias
Bias Authors’ judgement Support for judgement
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Lloyd-Richardson 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomised, stratified by gender and
motivation to quit
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 75% intervention, 71% control followed
up at 6 m. ITT and available-case analyses
reported
MacLeod 2003
Methods Setting: community, Australia
Recruitment: community volunteers
Participants 854 smokers interested in quitting; 51% F, av age 42, av cpd 24
Interventions All participants received a free 2-wk supply of nicotine patch by mail, instructed to
purchase further supply; 14 or 21 mg depending on body weight
1. No further intervention
2. As 1. + 5 proactive telephone counselling calls at 1, 2, 3, 6 & 10 wks. 20-min session
1 wk, 10-min others. Toll-free hotline, S-H materials
Outcomes Abstinence at 6 m (90-day continuous)
Validation: none, warning of CO test only
Source of Funding/CoI GlaxoSmithKline funded study and all authors were employed by GSK. “The conduct
of the study was independently monitored and the data verified by Datapharm Australia.
GlaxoSmithKline took part in discussions about study design, but had no direct role in
the analysis or interpretation of the results or preparation of the report for publication.”
Notes Also contributed to Cochrane review of telephone counselling (Matkin 2019). No face-
to-face contact
Average number of calls 4.7. 9% of participants called hotline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized” by shuffling folders each
day after participants to be included were
listed. Since there was no personal contact
with participants, risk of bias judged to be
low
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MacLeod 2003 (Continued)
Allocation concealment (selection bias) Low risk Potential for bias since allocation sequence
not fixed in advance; however, baseline
characteristics similar across groups so no
evidence of selection bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential levels of
support
Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant difference in loss to follow-
up, 17% in NRT only, 15% in NRT+ at 6
m
Macpherson 2010a
Methods Setting: USA (no further detail reported)
Recruitment: using radio, web-based, and newspaper advertisements
Participants 68 participants, 48.6% female, average age: intervention: 45 ± 12.2, control: 42.6 ± 11.
5, average cigs/day: intervention: 18.8 ± 7.1, control: 17.3 ± 8.1
Therapists: two therapists with clinical psychology doctoral degrees and three therapists
who were clinical psychology doctoral students
Interventions Pharmacotherapy: NRT; nicotine patches from quit date with an initial dose of 21 mg
for 4 weeks, followed by 2 weeks of 14 mg, and 2 weeks of 7 mg. Participants who
smoked on average 10 to 12 cigarettes per day started with 14 mg for the first 6 weeks
Intervention: 8 weekly sessions of behavioural activation treatment. Total contact time:
60 minutes each x 8 = 480 minutes
Control: 8 weekly sessions of standard treatment. Total contact time: 60 minutes each x
8 = 480 minutes
Outcomes Abstinence: continuous abstinence at 1, 4, 16 weeks, and 6 months
Validation: carbon monoxide ≤ 10 ppm, cotinine ≤ 5 ng/mL
Source of Funding/CoI Funding: National Institute on Drug Abuse
No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
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Macpherson 2010a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk High losses to follow-up in both arms: con-
trol: 63.6%; intervention: 57.1%
Matthews 2018
Methods Setting: USA, LGBT health centres
Recruitment: from the community
Participants 345 participants, 20.3% to 22.8% female, average age: 38.6-39.4, average cigs/day: 12.
1 to 13.8
Therapists: a professional and a lay counsellor who identified as lesbian, gay, bisexual or
transgender facilitated each group
Interventions Pharmacotherapy: NRT; nicotine patches for 8 weeks (dose regimen dependent on the
number of cigarettes)
Intervention: 6 weekly culturally tailored smoking cessation therapy sessions commenc-
ing two weeks before the quit date
Control: 6 weekly standard smoking cessation therapy sessions commencing two weeks
before the quit date
Outcomes Abstinence: 7-day point prevalence at 1, 3, 6, and 12 months
Validation: carbon monoxide at 1 and 3-month follow-up
Source of Funding/CoI Funding: National Institute on Drug Abuse, National Ceneter for Advancing Transla-
tional Sciences, National Institutes of Health, and National Cancer Institute
Declarations of interest: one of the authors consulted with the Respiratory Health As-
sociation and served on a Health Advisory Board for Pfizer Inc
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The study statistician conducts the per-
muted-block randomization using a soft-
ware program developed by programmers
at UIC.”
Allocation concealment (selection bias) Low risk “The study statistician place the results of
the assignments in sealed, solid envelopes.
All study participants are blinded and retain
no knowledge of CTQor CTQ-CT group”
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Matthews 2018 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition between groups: interven-
tion: 33.7%; control: 34.1%
McCarthy 2008
Methods Setting: clinic, USA
Recruitment: community volunteers
Participants 463 smokers; 50% F, av age 36 to 41 across arms, av cpd 22
Therapists: trained college-aged or bachelor’s level staff, supervised by experienced coun-
sellor
Interventions Factorial trial of bupropion or placebo pharmacotherapy and counselling versus support
1. Bupropion & counselling; 13 office visits, 8 included additional 10-min counselling,
2 prequit, TQD, 5 over 4 weeks (classified as > 300 mins contact)
2. Bupropion & psychoeducation about medication, support & encouragement. 13
office visits, 80 mins less contact time than 1. (classified as 91 to 300 mins contact)
3. Placebo & counselling. Not included in this review
4. Placebo & psychoeducation. Not included in this review
Outcomes 7-day PP abstinence at 12 months (prolonged abstinence reported but not verified so
PP used in MA)
Validation: CO ≤ 10 ppm
Source of Funding/CoI National Institute on Drug Abuse & National Cancer Institute. GlaxoSmithKline pro-
vided complimentary active and placebo medication used in this study. “GlaxoSmithK-
line was not involved in the design, data collection, analysis, or reporting of this study.”
Authors declared potential conflicts of interest
Notes 1 vs 2 used as test of adjunct behavioural support
Also contributed to Cochrane reviews of combined interventions (1 vs 4) (Stead 2016)
, antidepressants (collapsing behavioural conditions) (Hughes 2014) and individual be-
havioural counselling (collapsing pharmacotherapy) (Lancaster 2017)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Staff who screened and enrolled partici-
pants were unaware of the experimental
condition to be assigned
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McCarthy 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 63% reached at 12 m, but attrition rates
did not differ by condition at any point
NCT00879177
Methods Setting: University of Connecticut Health Center, USA
Recruitment: smokers with self-reported desire to stop smoking
Participants 203 smokers
Therapists: no details given
Interventions Pharmacotherapy: NRT; varenicline 1 tablet 0.5 mg once a day for three days followed
by 1 tablet 0.5 mg twice a day for four days and then 1 tablet 1 mg twice a day for 11
weeks
1. Brief smoking cessation counselling weekly for five weeks
2. Brief smoking cessation counselling weekly for five weeks + behavioural therapy for
weeks 2 to 5; ≥ 9 sessions in total
Outcomes Abstinence at 12 months
Validation: carbon monoxide and cotinine levels
Source of Funding/CoI Unpublished study
Notes New for 2019 update
Contacted Professor White (Co-principal investigator) by email who informed us that
the results were comparable for the two groups with quit rates about 50% in each group
at 6 months. The results have not yet been published so we were only able to report this
study narratively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unpublished study
Allocation concealment (selection bias) Unclear risk Unpublished study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
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NCT00879177 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unpublished study
O’Cleirigh 2018
Methods Setting: HIV primary care clinics, USA
Recruitment: providers told potentially eligible patients about the study and offered
them study coordinator’s contact details. Selected for motivation to quit
Participants 53 smokers; 15.1% female; average age 49.7-51.2; average number of cigarettes smoked
per day 14.4
Therapists: intervention was provided by doctoral level clinical psychology interns and
postdoctoral fellows supervised by the first author. The control group sessions were
conducted by the study coordinator or research associate
Interventions Pharmacotherapy: transdermal nicotine replacement therapy provided on the quit day
1. Psychoeducation session before randomisation (60 minutes) + face-to-face hybrid
treatment that targeted smoking cessation, anxiety and depression simultaneously (60
minutes x 9 sessions)
2. Psychoeducation session before randomisation (60 minutes) + post-quit sessions in
person (10 minutes x 4 sessions)
Outcomes 7-day point prevalence abstinence at 1, 2, 4, 6 months
Validation: carbon monoxide level ≤ 4 ppm
Source of Funding/CoI National Institute on Drug Abuse. Authors declared potential conflicts of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation in blocks of 4 con-
ducted by the study coordinator
Allocation concealment (selection bias) Low risk “Before the study’s start, a randomisation
chart was created, corresponding to each
study identification number. The chart was
secured on a password-protected document
accessible only by the study coordinator
and the principal investigator. Assignment
to study condition was concealed from par-
ticipants and study clinicians until the end
of session 1”
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O’Cleirigh 2018 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Lost to follow-up rate: intervention group
50.0%; control group 22.2%
Ockene 1991
Methods Setting: primary care clinics, USA
Recruitment: clinic attenders, not selected for interest in quitting
Participants 380 smokers in relevant arms (excluded deaths and some who did not receive interven-
tion); of 1223 smokers in study; 57% F, av age 35, av cpd 23
Interventions Pharmacotherapy: nicotine gum; offer of free gum
2 x 3 factorial design, physician intervention ± follow-up
1. Physician counselling (initial session and 1 follow-up) and offer of NRT. Follow-up
telephone counselling by psychologist or health educator, 3 calls (1, 2, 3 months) approx
10 mins, behavioural recommendations. Letters
2. Physician counselling as 1. No additional follow-up
Outcomes Abstinence at 6 m (7-day); (3 m sustained abstinence rates not given by condition)
Validation: none
Source of Funding/CoI
Notes Marginal to include since relatively low use of pharmacotherapy; in intervention condi-
tion; of those reached, 33% refused use and 18% tried for 2 days or less
12 m abstinence rates reported in Ockene 1994 but not given by follow-up condition.
Also contributed to review of combined interventions (Stead 2016)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk Allocated prior to physician encounter
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential support
between arms
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19% lost to follow-up, higher in telephone
follow-up group. All included as smokers
in analysis
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Okuyemi 2013
Methods Setting: homeless shelters, Minnesota, USA community
Recruitment: homeless adults willing to use nicotine patch
Participants 430 smokers (≥ 1 cpd for last 7 days)
25.3% female, av age 44.4, av cpd 19.3
Therapists: trained counsellors
Interventions Pharmacotherapy: NRT; 21 mg patch for 8 weeks
1. Single session 10 to 15-min brief advice
2. Motivational interviewing, 6 x 15 to 20-min sessions, baseline, 1, 2, 4. 6 & 8 weeks
Focus on encouraging cessation and NRT adherence
Outcomes Abstinence at 26 weeks (7-day PP)
Validation: CO < 5 ppm
Source of Funding/CoI National Heart Lung and Blood Institute. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “At the baseline visit, pre-assigned ran-
domization numbers prepared by the study
statistician determined which study arm
the participant would be enrolled.”
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall 25% lost to follow-up, not signifi-
cantly different across groups
Otero 2006
Methods Setting: Brazil
Recruitment: community volunteers
Participants 1199 smokers (included 254 non-attenders); 63% F, av age 42, 46% smoked > 20 cpd
Therapists: trained doctors, nurses or psychologists
84Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Otero 2006 (Continued)
Interventions Factorial design with NRT (21 mg or 14 mg patch for 8 weeks including tapering) or
no NRT and 5 levels of behavioural support collapsed into 3 for analysis. Arms without
NRT did not contribute to this review.
1. Single 20-min session - classified as brief intervention control in meta-analysis
2. Cognitive behavioural, 1 or 2 weekly x 1 hour sessions
3. As 2, with 3 or 4 weekly sessions.
Maintenance or recycling sessions provided to all groups at 3, 6, 12 months
Outcomes Abstinence at 12 months (7-day PP)
Validation: none
Source of Funding/CoI
Notes 3 vs 1 in patch conditiononly in primary analysis. Also contributed to reviewof combined
interventions (Stead 2016)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, stratified by age & sex, by in-
dependent specialist
Allocation concealment (selection bias) Low risk Trial administrators blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential levels of
support between arms
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not provided.
Non-participants and losses to follow-up
included as smokers
Patten 2017
Methods Setting: USA, YMCA and worksite fitness centres
Recruitment: by provider referrals and flyers posted in the clinics, and radio and news-
paper advertisements. Willing to quit
Participants 30 participants, 100% female, average age: control: 38.0 ± 11.0; intervention: 37.0 ±
10.0, average cigs/day: ≥ 10
Therapists: certified wellness coaches with a master’s degree in clinical psychology or
bachelor’s degree in health education
Interventions Pharmacotherapy: 4-week supply of nicotine patches at weeks 2 and 6
Intervention: exercise counselling deliveredwhile the participant was engaged in exercise.
The individual-based counselling included social cognitive theory-based assessment and
problem-solving of exercise barriers, reinforcement (shaping) of exercise, andmethods to
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Patten 2017 (Continued)
enhance exercise self-efficacy, using a motivational interviewing counselling style. Total
contact time: 36 X 30- to 40-minute sessions = 1080 minutes
Control: health education. Individual-based sessions, lectures, handouts, films, and dis-
cussions covered various women’s health and lifestyle issues. Total contact time: 36 X
30- to 40-minute sessions = 1080 minutes
Outcomes Abstinence: 7-day point prevalence at 12 weeks and 6 months
Validation: saliva cotinine (abstinent if < 10 ng/mL)
Source of Funding/CoI Funding:National Center for AdvancingTranslational Sciences of theNational Institutes
of Health
No declarations of interest
Notes New for 2019 update
A small number of participants attended all 36 sessions (n = 3 for intervention and n =
1 for control)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details reported
Allocation concealment (selection bias) Unclear risk “[A]llocation to treatment conditions was
unknown to the study staff or investigators
prior to assignment and participants com-
pleted baseline assessments prior to being
informed of their allocation to treatment
condition. A study coordinator blinded
to allocation group conducted all follow-
ups in-person”. However, no description of
how allocation was concealed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition in each group: 15.6%
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Prapavessis 2016
Methods Setting: Exercise and Health Psychology Laboratory, Canada
Recruitment: from local businesses, hospitals, academic institutions and organisations
and through advertisements placed in newspapers, radio stations and city buses in Lon-
don, Ontario. Motivated to quit
Participants 409 participants, 100% female, average age: exercise plus smoking maintenance: 41.
96 (± 12.70); exercise plus contact control 43.47 (± 14.02); smoking maintenance plus
contact control: 43.45 (± 12.22); contact control: 40.36 (± 11.92)
Average cigs/day: exercise plus smoking maintenance: 17.04 (± 6.79); exercise plus con-
tact control 16.71 (± 6.96); smoking maintenance plus contact control: 16.88 (± 5.16);
contact control: 16.41 (± 6.78)
Therapists: trained facilitator
Interventions Pharmacotherapy: transdermal NRT after 4 weeks of exercising (10 week programme:
21 mg once daily for weeks 4 to 9, followed by 14 mg once daily for weeks 10 to 11 and
7 mg once daily during weeks 12 to 13)
Exercise maintenance + smoking cessation maintenance
- 14-week exercise-aided smoking cessation programme (33 x 45-minute sessions)
- Weeks 8 to 14: five 25-minute weekly cognitive behavioural therapy group sessions,
for long-term exercise adherence
- Received a set of Brandon’s “Forever Free” booklets after first 14 weeks
- After week 14: seven 15-minute telephone counselling sessions biweekly for the first
months +monthly for the next twomonths + bimonthly for the last 8months tomaintain
exercise behaviour
- Total contact: 64 sessions, 1985 minutes
Exercise maintenance + contact control
- 14-week exercise-aided smoking cessation programme (33 x 45-minute sessions)
- Weeks 8 to 14: five 25-minute weekly cognitive behavioural therapy group sessions,
for long-term exercise adherence
- After week 14: seven 15-minute telephone counselling sessions biweekly for the first
months + monthly for the next two months + bimonthly for the last 8 months - to
maintain exercise behaviour
- Total contact: 64 sessions, 1985 minutes
Smoking cessation maintenance + contact control
- 14-week exercise programme (33 x 45-minute sessions) and 10 weeks NRT (starting
from week 4)
- Weeks 8 to 14: received messages reinforcing women’s health issues
- Received a set of Brandon’s ’Forever Free’ booklets after first 14 weeks
- After week 14: seven 15-minute telephone counselling sessions biweekly for the first
months +monthly for the next two months + bimonthly for the last 8 months - messages
reinforcing the Forever Free booklets and/or women’s health issues (e.g. vitaminD intake,
oral hygiene, sleep disorders)
- Total contact: 59 sessions, 1860 minutes
Contact control
- 14-week exercise programme (33 x 45-minute sessions) and 10 weeks NRT (starting
from week 4)
- Weeks 8 to 14: received messages reinforcing women’s health issues
- After week 14: seven 15-minute telephone counselling sessions biweekly for the first
months +monthly for the next two months + bimonthly for the last 8 months - messages
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Prapavessis 2016 (Continued)
reinforcing the Forever Free booklets and/or women’s health issues (e.g. vitaminD intake,
oral hygiene, sleep disorders)
- Total contact: 59 sessions, 1860 minutes
Outcomes Abstinence: continuous abstinence at 14, 26, and 56 weeks
Validation: CO < 6 ppm considered abstinent
Source of Funding/CoI Funding: Canadian Cancer Society
No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk The project manager for trial used num-
bered containers to implement the ran-
dom allocation sequence, and the sequence
was concealed until interventions were as-
signed. However, the method of conceal-
ment was not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 54.8%of participants lost to follow-up, but
attrition similar between groups
Reid 1999
Methods Setting: community, Canada
Recruitment: volunteers
Participants 396 smokers interested in quitting within 30 days, smoking ≥ 15 cpd; 48% F, av age
38, av cpd 23 to 24
Interventions Pharmacotherapy: NRT; patch (15 mg x 8 wks, 10 mg x 2 weeks, 5 mg x 2 weeks) free
1. Physician advice (3 x 15-min, 2 weeks before, 4 weeks, 12 weeks after quit date)
2. As 1, plus telephone calls from nurse counsellors, x 3 at 2, 6, 13 weeks
Outcomes Abstinence at 12 m (PP)
Validation: CO, but self-reported rates reported. Only 1 disconfirmation
88Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reid 1999 (Continued)
Source of Funding/CoI National Cancer Institute of Canada with funds from the Canadian Cancer Society
Nicotine replacement therapy was provided at no cost by McNeil Consumer Products.
“The University of Ottawa Heart Institute Research Corporation has a contract with
Johnson & Johnson-Merck Consumer Pharmaceuticals to manage the ’Stop Smoking
Now!’ telephone counselling service offered to users of Nicotrol NRT. The authors
received a grant from Johnson & Johnson-Merck to conduct a pilot study before the
clinical trial; no payment was received from the company for the clinical trial or its
analysis and write-up.”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised using table of random num-
bers, stratified by sex and nicotine depen-
dence
Allocation concealment (selection bias) Unclear risk Concealment unclear but physician blind
to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84% intervention, 86% control, followed
up at 12 m
Rohsenow 2014
Methods Setting: residential substance abuse treatment programme, USA
Recruitment: research therapist assessed patients for eligibility
Participants 165 alcoholic smokers (≥ 10 cpd for 6 m), 60% M, av age 34, av cpd 21
Therapists: research therapists
Interventions Pharmacotherapy: NRT; patch preferred, mostly used for 2-3 months
1. Brief advice ~15 mins, assessed smoking rate and interest in quitting, ± 2 x 5 to 15-
min boosters at 7 & 30 days
2. Motivational interviewing, 45 min, ± 2 x 5 to 15-min boosters at 7 & 30 days
Outcomes Abstinence at 12 months (7-day PP)
Validation: CO < 10 ppm
Source of Funding/CoI National Institute of Alcohol Abuse and Alcoholism, United States Department of Vet-
erans Affairs. No declarations of interest
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Rohsenow 2014 (Continued)
Notes Booster and no-booster conditions combined in analyses. Only 51% used NRT during
the first month, 34% during the subsequent 2 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Low risk Assignment in sealed envelope opened just
before the first treatment session
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall 32% lost to follow-up; MI 35%,
(28/80 including 1 death), BA 29% (25/
85 including 3 deaths)
Rovina 2009
Methods Setting: smoking cessation clinic, Greece
Recruitment: clinic attenders invited to participate
Participants 205 smokers
Interventions Pharmacotherapy: bupropion 300 mg/day for 19 weeks
1. Control: 15 mins physician counselling
2. Nonspecific group therapy (NSGT), 1-hour weekly for 1 month, then every 3 weeks
until 19 weeks
3. Cognitive behavioral group therapy (CBGT), same schedule
4. CBGT without bupropion - not used in review
Outcomes Abstinence at 12 months after end of treatment (continuous)
Validation: CO ≤ 10 ppm
Source of Funding/CoI No source of funding reported. Authors declared no conflicts of interest
Notes 2 & 3 vs 1 in primary analysis, same intensity
Risk of bias
Bias Authors’ judgement Support for judgement
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Rovina 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, method not stated, 3:1:1:1
ratio
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 90% followed up at 12 months
Schlam 2016
Methods Setting: USA, primary care clinics
Recruitment: from primary care clinics, participants willing to quit
Participants 544 participants, 59% female, average age: 46.2 ± 12.8, average cigs/day: 18.6 ± 8.8
Therapists: bachelor’s level study staff supervised a licensed clinical psychologist
Interventions Pharmacotherapy: 8 weeks OR 26 weeks of nicotine patch plus nicotine gum (factorial
design)
Intervention: 4 sessions of face-to-face counselling plus 8 sessions of telephone coun-
selling
Control: 4 sessions of face-to-face counselling
Outcomes Abstinence: 7-day point prevalence abstinence at 6 and 12 months
Validation: none
Source of Funding/CoI National Cancer Institute, Wisconsin Partnership Program, andDepartment of Veterans
Affairs. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Staff could not view the allocation se-
quence. The database did not reveal par-
ticipants’ treatment condition to staff until
participants’ eligibility was confirmed. Par-
ticipants did not know treatment allocation
until they provided consent
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Schlam 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “The percentage of participants
missing abstinence outcome data was 20.
4% at Week 26 and 30.0% at Week 52,
with no differences observed inmissingness
across the two levels (on vs. off ) of any of
the factors.” No further details provided
Schmitz 2007a
Methods Setting: outpatient treatment research clinic, Department of Psychiatry and Behavioral
Sciences Substance Abuse Research Center, USA
Recruitment: by local radio, television and print adverts. Motivated to quit
Participants 154 participants (78 in 2 groups receiving pharmacotherapy), 100% female, average age:
47.8 ± 9.3, average cigs/day: 21.4 ± 9.1
Therapists: a therapist and co-therapist pair; four female, master’s level therapists were
trained on each therapy manual and supervised weekly by a doctoral-level clinical psy-
chologist
Interventions Pharmacotherapy: 6 weeks of sustained-release bupropion (300 mg/day; 150 mg/day for
3 days, followed by 150 mg twice daily)
Intervention: 7 x 60-minute sessions of cognitive behavioural therapy (CBT)
Control: 7 x 60-minute sessions of standard therapy (ST)
Outcomes Abstinence: 7-day point prevalence at 3, 6, 9, and 12 months
Validation: CO (abstinent if≤ 10 ppm) and salivary cotinine (abstinent if≤ 15 ng/mL)
Source of Funding/CoI Funded byNational Institute onDrugAbuse. GlaxoSmithKline provided the bupropion.
No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified
Allocation concealment (selection bias) Low risk Quote: “Investigators and research staff
were blind to the randomization codes,
which were kept by a faculty member in-
dependent of the research and treatment
team.”
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Schmitz 2007a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was high, but similar between
study arms. Control: 56.8%; intervention:
53.7%
Simon 2003
Methods Setting: hospital for military veterans, USA
Recruitment: inpatients (all diagnoses) invited to participate
Participants 223 smokers, ≥ 20 cigs in week before admission, contemplation or action stage of
change, able to use NRT, av age 55, av cpd 23
Interventions Pharmacotherapy: NRT; patches (tailored dose) in hospital and for 8 weeks post-dis-
charge
1. Intervention: nurse or health educator counselling; 30 to 60 mins initial session. 5
calls at 1, 3 weeks, 1 month, 2 months, 3 months, < 30 min/call & S-H materials
2. Control: brief counselling (10 mins) + S-H only
Outcomes Abstinence: 7-day PP at 12 months
Validation: saliva cotinine < 15 ng/mL (alternative analysis allowed spousal corrobora-
tion)
Source of Funding/CoI California Tobacco-Related Disease Research Program. No declarations of interest
Notes Relative effect similar if spousal corroboration allowed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using computer algorithm
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Losses to follow-up (3 intervention, 4 con-
trol) included as smokers. Deaths (5 inter-
vention, 9 control) excluded from denom-
inator
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Smith 2001
Methods Setting: clinic, USA
Recruitment: community volunteers
Participants 677 smokers (> 10/day) attempted to quit for 1 week; 57% F, av age 42; av cpd 25
Interventions Pharmacotherapy: NRT, patches for 8 wks. All participants had attended 3 brief (5 to
10-min) individual counselling sessions pre-quit, quit day and 8 days post-TQD&NCI
booklet ’Clearing The Air’.
1. Cognitive behavioural skills training, x 6 from 1 week post-TQD, incl managing
negative affect, homework, manual
2. Motivational interviewing, supportive group counselling, x 6 from 1 week post-TQD.
No homework or manual
3. No further intervention
Outcomes Abstinence at 12 months (7-day PP)
Validation: CO < 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. Lederle Laboratories supplied the nicotine patches.
No declarations of interest
Notes Marginal to include as the counselling was intended for relapse prevention
1 vs 3 in primary analysis. Including 2 did not alter findings; 17.6% quit in 1, 18.8%
in 2. No evidence found for hypothesised differences in relative efficacy for smokers at
high or low risk of relapse. High-risk smokers expected to do better with motivational
intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised 1 wk after TQD, stratified
by ± any smoking post-TQD. Method not
stated
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number lost to follow-up not reported, all
missing included as smokers
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Smith 2013a
Methods Setting: quitline, USA
Recruitment: adult smokers willing to quit who called theWisconsin Tobacco Quit Line
Participants 987 participants, 57.6% female, average age: 41.9 ± 13, average cigs/day: 20.7 ± 9.6
Therapists: trained cessation counsellors
Interventions Pharmacotherapy: 2 or 6 weeks of NRT (nicotine patch only vs patch plus nicotine gum)
(factorial design)
Intervention: 4 telephone counselling sessions including medication adherence coun-
selling
Control: 4 telephone counselling sessions
Outcomes Abstinence: 7-day point prevalence at 2, 6, and 12 weeks, and at 6 months
Validation: none
Source of Funding/CoI National Cancer Institute. Authors declared potential conflicts of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation computer-randomised
Allocation concealment (selection bias) Unclear risk No detail reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Self-report only but similar amounts of
contact between groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition low and similar between groups.
Intervention: 24.9%, control: 21.6%
Smith 2014
Methods Setting: Menominee Tribal Clinic (primary care centre), USA
Recruitment: all participants were receiving health care at the Menominee Tribal Clinic
and were motivated to quit smoking
Participants 103 participants, 62.1% female, average age: 39.8 (SD 13.1), average cigs/day: 14.4 (SD
7.9)
Therapists: a study coordinator who was an enrolled member of the Menominee Tribe
and trained as a counsellor
Interventions Pharmacotherapy: 12 weeks of varenicline
Intervention: 5 x face-to-face culturally tailored counselling sessions, duration not re-
ported
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Smith 2014 (Continued)
Control: 5 x face-to-face standard counselling sessions, duration not reported
Outcomes Abstinence: 7-day point prevalence abstinence at weeks 1, 3, and 7, and at 3 and 6
months
Validation: CO < 10 ppm
Source of Funding/CoI Wisconsin Partnership Program, the Spirit of Eagles Community Network Program,
the University of Wisconsin Carbone Cancer Center, and the University of Wisconsin
Center for Tobacco Research and Intervention. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate high and differed between
study arms: intervention: 47.2%; control:
66.0%
Solomon 2000
Methods Setting: community, USA
Recruitment: volunteers for free nicotine patch trial
Participants 214 female smokers, > 4 cpd, intending to quit in next 2 weeks; av age 33, av cpd 24
Interventions Pharmacotherapy: NRT; free nicotine patch (dose based on smoking level) for up to 10
weeks, after 1 m contingent on abstinence
1. Access to Nicoderm support line
2. As 1. and proactive telephone counselling from female ex-smoker, 7 hours training.
Up to 12 calls for up to 3 months, starting pre-quit, quit day, day 4, average 7
Outcomes Abstinence at 6 months (multiple PP; 7 days at 3 months & 6 months)
Validation: CO ≤ 8 ppm. 7% to 12% disconfirmation rate. Participants who did not
provide samples remained classified as quitters
Source of Funding/CoI Vermont Department of Health (part). SmithKline Beecham provided nicotine patches.
No declarations of interest
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Solomon 2000 (Continued)
Notes Intervention participants received on average 7 calls of 9 mins. Classified in 4 to 8
subgroup analysis. 95% received at least 1 call. Participants could call Nicoderm support
line, 21% of control vs 8% of intervention did so
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Approximately 73% followed up in each
group
Solomon 2005
Methods Setting: community, USA
Recruitment: volunteers for free nicotine patch trial
Participants 330 female smokers > 4 cpd, intending to quit in next 2 weeks; av age 34, av cpd 24
Interventions Pharmacotherapy: NRT; free nicotine patch (dose based on smoking level) for up to 10
weeks, 2nd & 3rd prescriptions dependent on reporting abstinence
1. No additional support
2. Proactive telephone counselling from female ex-smoker, 8 hrs training. Calls for up
to 4 months, starting pre-quit, quit day, day 4
Outcomes Abstinence at 6 m (30 days at 3 months & 6 months)
Validation: none
Source of Funding/CoI Vermont Department of Health. SmithKline Beecham provided nicotine patches. No
declarations of interest
Notes Similar to Solomon 2000 with more extended telephone contact
Average number of calls 8.2, average duration 10 min. Classified in 4 to 8 subgroup
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Solomon 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, method not described
Allocation concealment (selection bias) Unclear risk No details given
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential amounts
of contact between groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk 87% response in both conditions at 6 m
Stanton 2015
Methods Setting: immunology clinics, USA
Recruitment: adult smokers who have been diagnosed with HIV and identified them-
selves as Latino/Hispanic. Not selected for motivation to quit
Participants 302 participants, 36% female, average age: 45, average cigs/day: not reported but stated
50% of the participants were heavy (> 10 cigarettes per day) smokers
Therapists: 10 health educators who were at least Masters level professionals or had
equivalent years of clinical research experience
Interventions Pharmacotherapy: 8 weeks of nicotine patches
Intervention: self-help and culturally sensitive print materials and videos, tailored be-
havioural counselling, two in-person sessions, two additional in-person sessions focused
on tailored relapse prevention, one phone call on the quit date, two 10-minute booster
phone calls, option to bring a social support buddy to attend all sessions
Control: self-help print materials, two in-person sessions, one phone call on the quit
date
Outcomes Abstinence: 7-day point prevalence at 3, 6 and 12 months
Validation: exhaled carbon monoxide level < 10 ppm
Source of Funding/CoI National Institute on Drug Abuse, National Cancer Institute, National Institute of Al-
lergy and Infectious Diseases, Lifespan/Tufts/Brown Center for AIDS Research, Clini-
cal Core of the Center for AIDS Research at the Albert Einstein College of Medicine
and Montefiore Medical Center funded by the National Institutes of Health. Authors
declared no conflicts of interest
Notes New for 2019 update
Not included in analysis 1.3 because durations of sessions were not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Stanton 2015 (Continued)
Random sequence generation (selection
bias)
Unclear risk No details provided
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar follow-up rates (control 67%; in-
tervention 60%)
Stein 2006
Methods Setting: 5 methadone maintenance treatment programme centres, USA
Recruitment: smokers routinely attending maintenance clinic. Willingness to quit not
required
Participants 383 methadone-maintained adult smokers. 53% M, av age 40, av cpd 27
Interventions Pharmacotherapy: NRT; all participants willing to make quit attempt offered patches (8
to 12 weeks, dose and duration tailored to smoking rate)
1. Motivational interview-based tailored intervention: up to 3 visits from study coun-
sellor, i.e. 1 x 30-min + 15 to 30-min quit-date session, + follow-up relapse prevention
session. Those not ready to quit only received 2 sessions.
2. Control: Brief advice using NCI’s 4As model (< 3 mins), + S-H materials. Up to 2
visits, i.e. baseline and quit date (if set)
Outcomes Abstinence at 6 months (PP)
Validation: CO < 8 ppm
Source of Funding/CoI National Cancer Institute. GlaxoSmithKline provided nicotine patches. No declarations
of interest
Notes Included since most participants in both conditions did make quit attempts and received
NRT; 81% intervention and 80% control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, methods not stated
Allocation concealment (selection bias) Unclear risk No details reported
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Stein 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Approx 82% followed up in both groups at
6 months
Strong 2009
Methods Setting: USA
Recruitment: via newspaper, radio, and television advertisements
Participants 524 participants, 47.5% female, average age: 44.27 ± 10.38, average cigs/day: 24.6 ± 10
Therapists: doctoral level therapist
Interventions Pharmacotherapy: 12weeks of bupropion, initiated during the secondweek of treatment,
2 weeks prior to quit day
Intervention: 12 x 120-minute sessions of standard cessation group counselling with
CBT for depression
Control: 12 x 120-minute sessions of standard cessation group counselling
Outcomes Abstinence: 7-day point prevalence abstinence at 2, 6, and 12 months
Validation: CO (abstinent if≤ 10 ppm) and salivary cotinine (abstinent if≤ 15 ng/mL)
Source of Funding/CoI Funding: National Institutes of Health
Declarations of interest: one of the authors served on the Pfizer Speakers Bureau and a
Pfizer Scientific Advisory Board
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study reported “8 smokers did not provide
any follow-updata”.However, thiswas only
for the 12-week follow-up
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Swan 2003
Methods Setting: HMO, USA
Recruitment: volunteers from Group Health Co-op membership
Participants 1524 smokers ≥ 10 cpd; 57% F, av age 45, av cpd 23, 44% history of depression
Interventions Pharmacotherapy: randomised to bupropion 300 mg/day or 150 mg/day
1. Free & Clear proactive telephone counselling (4 brief calls), access to quitline and S-
H materials
2. Zyban Advantage Program (ZAP); tailored S-H materials, single telephone call after
TQD, access to Zyban support line
Outcomes Abstinence at 12 m (7-day PP)
Validation: none
Source of Funding/CoI National Cancer Institute. “The authors have no relevant financial interest in this article,
and received no financial support or medication from GlaxoSmithKline”
Notes Prescription was mailed. No face-to-face contact during enrolment or prescription. Es-
timated as 31 to 90 minutes contact
No dose/behavioural treatment interaction at 12 m, bupropion arms collapsed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Open-label randomized trial...The com-
puter code for the procedure calculated
probabilities of group assignment that were
dynamically modified based on the num-
ber of members in each group so that fi-
nal group sizes were equal. No restrictions
such as stratification or blocking were used
as part of the randomization process.”
Allocation concealment (selection bias) Low risk Procedure built into study database
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential levels of
support
Incomplete outcome data (attrition bias)
All outcomes
Low risk 83% intervention, 88% control followed
up at 12m
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Swan 2010
Methods Setting: HMO (Group Health), Seattle, WA, USA
Recruitment: Group Health members contacted by phone & mail from Free & Clear
Participants 1202 smokers (≥ 10 cpd); 67% F, av age 47, av cpd 22
Interventions Pharmacotherapy: varenicline for 12 weeks (1mg x 2/day, titrated 1st week). All received
5 to 10-min orientation call, printed Quit Guides and access to a free support line for
ad hoc calls.
1. Web-based counselling: access to online programme, including quit plan, online
library, quit calendar, cost calculator, progress tracker, email links to friends and family
and discussion forums
2. Proactive telephone-based counselling: Free & Clear Quit for Life programme. Up to
5 ’brief ’ one-to-one phone sessions initiated by F&C counsellor. Timed for convenience
and at relapse-sensitive stages. Used MI techniques
3. Combination: proactive calls + web access; counsellor could view info entered online.
Participants encouraged to use website for additional info and social support, and to
track cpd. Counsellors could view quit status, last log-in and last use of discussion forum
Outcomes Abstinence at 6 m (PP)
Validation: none
Source of Funding/CoI National Cancer Institute. “Varenicline and nominal support for recruiting participants
was provided by Pf zer, Inc. Neither entity [NCI or Pfizer] had any role in the study
design; the collection, analysis, and interpretation of data; in the writing of the report; or
in the decision to submit the report for publication.” Authors declared potential conflicts
of interest
Notes 3 vs 1 in main analysis, 2 & 3 vs 1 had little effect on result. 60-min contact on average
for 3
64% were no longer taking varenicline at 3 months, but no between-group differences
in non-compliance or reasons for stopping
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Group assignment was randomly allo-
cated using an automated algorithm built
into the study database”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential levels of
support
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants lost to follow-up counted as
smokers in ITT analysis; equal losses be-
tween groups (103 web, 107 phone, 100
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Swan 2010 (Continued)
web + phone)
Tonnesen 2006
Methods Setting: 7 chest clinics, Denmark
Recruitment: outpatient attender
Participants 370 smokers of > 1 cpd with COPD (185 in relevant arms); 52% F, av age 61, av cpd
20
Therapists: 20 nurses with cessation experience, trained to support medication use and
provide standardised counselling
Interventions Pharmacotherapy: NRT; sublingual. Factorial trial included placebo tablets; only active
treatment groups used in this review.
1. High support: 7 x 20 to 30-min clinic visits (0, 2, 4, 8, 12 wks, 6 m, 12 m) & 5 x 10-
min phone calls (1, 6, 10 wks, 4½ m, 9 m), total contact time 4½ hrs
2. Low support: 4 clinic visits (0, 2 wks, 6 m, 12 m) & 6 phone calls (1, 4, 6, 9, 12 wks,
9 m), total time 2½ hrs
Outcomes Sustained abstinence at 12 m (validated at all visits from wk 2, PP also reported)
Validation: CO < 10 ppm
Source of Funding/CoI “The Danish Medical Research Council provided the major grant for this study ($375,
000). Pfizer ConsumerHealthcare, Sweden, supplied the study drugs used in the trial and
provided grant support ($25,000).” First author declared potential conflicts of interest
Notes Also contributed to review of combined therapy review (Stead 2016), using placebo low-
support arm as control. Therapists were not full-time specialist counsellors. Using PP
outcome did not alter effect. Only contacts before 12 wks counted for classification of
intensity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation list at each centre
Allocation concealment (selection bias) Unclear risk Allocation process not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 42/185 (23%) of active NRT participants
not followed up at 12 m and counted as
smokers. Not reported by support condi-
tion. Of those who were followed up at 12
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Tonnesen 2006 (Continued)
m, 52% had withdrawn from study treat-
ment. Authors stated: “One potential bias
may have been the large early dropout of
failures from the study.Consequently, these
patients were not exposed to the possible
effect of more intensive support.”
Van Rossem 2017
Methods Setting: Netherlands, primary care
Recruitment: by practice assistants, GPs, and practice nurses and via a leaflet displayed
in the waiting room
Participants 311 participants, 52.9% female, average age: 48 ± 13.2, average cigs/day: 19 ± 8.1
Therapists: practice nurse or general practitioner
Interventions Pharmacotherapy: 12-week course of varenicline
Intervention: intensive counselling with practice nurse. 3 face-to-face plus 7 telephone
sessions
Control: brief advice with GP
Outcomes Abstinence: prolonged abstinence (maximum of five cigarettes after a grace period of 9
weeks) at weeks 9 and 26, and at 12 months
Validation: CO < 10 ppm
Source of Funding/CoI Eindhoven Corporation of Primary Health Care Centres, Pfizer, and Research School
CPHRI. Authors declared potential conflicts of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation randomised by computer
Allocation concealment (selection bias) Low risk Quote: “The computer disclosed the allo-
cation once during a phone call by a mem-
ber of the research team with the assistants
of the health-care centre, who then con-
tacted the patient to schedule an appoint-
ment with the GP or PN.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
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Van Rossem 2017 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rates similar. Intervention: 18.
6%, control: 25.8%
Vander Weg 2016
Methods Setting: quitline, USA
Recruitment: by mail to rural veteran daily cigarette smokers aged ≥ 18 years. Selected
for motivation to quit
Participants 63 participants
Therapists: doctoral-level social worker with expertise in substance abuse and a masters-
level counsellor
Interventions Pharmacotherapy: free of charge 12-week supply of pharmacotherapy mailed to the par-
ticipants. Medication options included several forms of nicotine replacement therapy
(patch, gum, lozenge), bupropion and varenicline. Combinatoin therapy was also avail-
able, as appropriate
1. Quitline referral
2. Tailored tobacco intervention: 6 weekly sessions over phone each lasting 20 to 30
minutes
Outcomes 7-day point prevalence abstinence at 12 weeks and 6 months after quit-date
Validation: none
Source of Funding/CoI Department of Veterans Affairs Office of Rural Health. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Unclear risk Insufficient details provided
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-report only and differential levels of
support
Incomplete outcome data (attrition bias)
All outcomes
Low risk Tailored tobacco intervention 25.8%; quit-
line referral 12.5%
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Vidrine 2016
Methods Setting: USA
Recruitment: from the Houston metropolitan area via local print media. Motivated to
quit
Participants 412 participants, 54.9% female, average age: 48.7 ± 11.9, average cigs/day: 19.9 ± 10.1
Therapists: two master’s level therapists
Interventions Pharmacotherapy: 6 weeks of NRT patches
Mindfulness-based addiction treatment (MBAT): 8 x 120-minute in-person group coun-
selling sessions
Cognitive behavioural treatment (CBT): 8 x 120-minute in-person group counselling
sessions
Control: 4 x 5- to 10-minute individual counselling sessions
Outcomes Abstinence: 7-day point prevalence abstinence at 4 weeks and 6 months
Validation: CO (abstinent if < 6 ppm) and salivary cotinine (abstinent if < 20 ng/mL)
Source of Funding/CoI National Institute onDrug Abuse, Centers for Disease Control and Prevention, National
Cancer Institute, National Center for Complementary and Integrative Health, and the
Oklahoma Tobacco Settlement Endowment Trust. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rates similar between groups.
Control: 35.9%; MBAT: 33.1%; CBT: 34.
8%
Wagner 2016
Methods Setting: USA, community-based primary health care clinic
Recruitment: word of mouth and flyers
Participants 400 participants, 58.7% female, average age: 45 ± 10.5, average cigs/day: ≥ 3
Therapists: individual sessions by a nurse practitioner or a physician. Group sessions by
a social worker and a nurse practitioner
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Wagner 2016 (Continued)
Interventions Pharmacotherapy: NRT (unclear about duration or type)
Group counselling: could attend up to 12 sessions but frequency and scheduling deter-
mined by clinician according to the standard of care at the healthcare facility
Individual counselling: could attend up to 12 sessions but frequency and scheduling
determined by clinician according to the standard of care at the healthcare facility
Outcomes Abstinence: planned follow-up at 1, 2, 3, 4, 5, 6, and 9 months
Validation: carbon monoxide
Source of Funding/CoI National Institute on Minority Health and Health Disparities, National Institute on
Drug Abuse, and Pfizer Inc. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “In addition, because of the very
low follow-up rates that could be achieved
with this population, in spite of intensive
efforts, the data was censored at the end
of the 12th week, i.e., at the end of the
intervention.”
Warner 2016
Methods Setting: Mayo Clinic Hospitals, USA
Recruitment: recruited from Mayo Clinic Hospitals
Participants 600 participants
Sex: control: 49% female; intervention: 48% female, average age: control: 46.0 (± 14.7)
; intervention: 46.7 (± 14.9), average cigs/day: control: 14.2 (± 9.6); intervention: 14.6
(± 9.0)
Therapists: study personnel
Interventions Pharmacotherapy:NRTwhile hospitalised and a free 2-week supply ofNRTat discharge,
with instructions to purchase over-the-counter patches if desired
Intervention: brief quitline facilitation session designed to overcome cognitive barriers
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Warner 2016 (Continued)
to quitline utilisation. Also given a written brochure and a wallet-sized ’quit-card’. If
amenable, directly referred to a quitline provider (1 x 5-minute session)
Control: brief advice (1 x 5-minute session)
Outcomes Abstinence: 7-day point prevalence abstinence at 7 days, 1 month, and 6 months
Validation: urine continine < 2 ng/mL
Source of Funding/CoI ClearWay Minnesota. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomized using dynamic ran-
domization allocation based on the Mayo
Clinic Study Data Management System, a
proprietary web application for data entry
and management.”
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition rates. Intervention: 30.
3%; control: 26.0%
Webb Hooper 2017
Methods Setting: USA, university-based research clinic
Recruitment: through advertisements on public transportation, community-based or-
ganisations, street outreach, and word-of-mouth. Inclusion criteria included motivation
to quit
Participants 342 participants, intervention: 39% female; control: 48% female; average age: interven-
tion: 49.48 (± 9.44); control: 49.52 (± 8.73); average cigs/day: intervention:18.20 (± 11.
53); control: 17.88 (± 10.03)
Therapists: doctoral and masters or bachelors level co-therapy pairs and supervision by
the principal investigator or a co-investigator
Interventions Pharmacotherapy: 8 weeks of nicotine patches, including 4 weeks at 21 mg, 2 weeks at
14 mg, and 2 weeks at 7 mg (doses adjusted for smoking history)
Intervention: NRT plus culturally-specific CBT (9 x 90- to 120-minute sessions)
Control: NRT plus standard CBT (9 x 90- to 120-minute sessions)
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Webb Hooper 2017 (Continued)
Outcomes Abstinence: 7-day point prevalence abstinence at 3 and 6 months
Validation: saliva cotinine < 7 ng/mL, exhaled CO < 8 ppm
Source of Funding/CoI National Cancer Institute of theNational Institutes of Health.Nodeclarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition rates: culturally-specific
CBT: 15.5%; standard CBT: 19.5%
Wewers 2017
Methods Setting: USA, community
Recruitment: recruited from Ohio Appalachian counties. Inclusion criteria included
willingness to participate in study protocol
Participants 707 participants
Female: Community Health Worker Face-to-Face (CHWF2F): 65.7%; Community
Health Worker Quitline (CHWQL): 69.8%
Age:
• CHWF2F: 18 to 24: 4.5%; 25 to 54: 62.9%; ≥ 55: 32.6%
• CHWQL: 18 to 24: 5.4%; 25 to 54: 65.8%; ≥ 55: 28.8%
Average cigs/day: CHWF2F: 22.3 (SD 11.7); CHWQL: 20.9 (SD 9.2)
Therapists:
• CHWF2F: community health worker and a registered nurse employed in the county
public health department clinic
• CHWQL: community health worker and quitline services provided by trained coun-
sellors from National Jewish Health
Interventions Pharmacotherapy:
• CHWF2F: a new 21 mg nicotine patch at the start of each visit, beginning on quit-
day and lasting for 8 weeks
• CHWQL: up to two mailings of a 4-week supply of free 21 mg nicotine patches. To
receive the second 4-week supply of free NRT, each participant was required to have
completed at least two proactive counselling calls
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Wewers 2017 (Continued)
1. CHWF2F: 7 face-to-face 30-minute sessions with a community health worker
2. CHWQL: 1 face-to-face 30-minute session with a community healthworker, followed
by up to five proactive telephone counselling sessions, and unlimited reactive calls from
the participant, with a quitline
Outcomes Abstinence: prolonged abstinence at 3, 6, and 12 months, after a 2-week post-quit date
grace period
Validation: saliva cotinine level < 15 ng/mL, expired air CO level < 8 ppm
Source of Funding/CoI National Institutes of Health. No declarations of interest
Notes New for 2019 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail given
Allocation concealment (selection bias) Unclear risk No detail given
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition in study groups.
CHWF2F: 14.4%; CHWQL: 14.7%
Wiggers 2006
Methods Setting: cardiovascular outpatient department, Netherlands
Recruitment: patients attending regular consultation; consenting patients referred to
nurse practitioner
Participants 385 smokers (8 deaths excluded from outcomes). 37% F, av age 59, av cpd 21
Therapist: nurse practitioner
Interventions Pharmacotherapy: NRT; patch (8 wks, dose based on smoking rate) for smokers making
a quit attempt. In both groups, participants planning to quit received 8 wks nicotine
patch with instruction from nurse
1. “Minimal Intervention Strategy for cardiology patients” (C-MIS). 15 to 30 mins at
baseline, 1 phone call at 2 wks, additional session on request. Assessment of dependency
& motivation, barriers; TQD set for motivated participants
2. Usual care without motivational counselling
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Wiggers 2006 (Continued)
Outcomes Abstinence at 12 m (7-day PP)
Validation: Urine or saliva nicotine/cotinine/thiocyanate. Self-reported smokers also
tested; validated rates included smokers with negative biochemical results, so self-re-
ported non-smoking used in MA
Source of Funding/CoI Netherlands Heart Foundation. Novartis Consumer Health provided nicotine patches
’for prime cost’
Notes Participants were referred to nurse practitioner for counselling; not part of usual care.
Unclear how many participants used NRT; in a subgroup who responded to a question-
naire (Wiggers Int J Behav Med 2006), 16% did not start patch therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computerized balanced randomization
programme taking prognostic factors (e.g.
clinic attendance, age and gender) into ac-
count.”
Allocation concealment (selection bias) Low risk “While patients completed their baseline
questionnaire (and signed a written in-
formed consent) nurses randomly assigned
...”. Judged low risk as participant data had
to be entered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% intervention and 85% control fol-
lowed up at 12 m. 8 deaths excluded from
final denominators
Williams 2010
Methods Setting: mental health outpatient clinics, USA
Recruitment: patients with schizophrenia or schizoaffective disorder, willing to use NRT
Participants 100 smokers (> 10 cpd) using an atypical antipsychotic; 16% F, av age ~46, av cpd 23
Therapists: trained mental health clinicians provided both conditions
Interventions Pharmacotherapy: nicotine patch (21 mg for 16 wks incl tapering)
1. Treatment of Addiction toNicotine in Schizophrenia (TANS); 24 x 45-min individual
counselling sessions over 26 wks
2. Medical Management (MM); 9 x 20-min over 26 wks
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Williams 2010 (Continued)
Outcomes Continuous abstinence at 12 m
Validation: CO < 10 ppm
Source of Funding/CoI National Institute on Drug Abuse. Authors also reported support from Pfizer but unclear
how it related to this study; “The authors are also supported in part by grants from
the National Institute of Mental Health (JMW); National Institute on Drug Abuse (to
MLS); Pfizer, Inc.; and theNew JerseyDepartment of Health and Senior Services, Office
of the State Epidemiologist, through funds from New Jersey Comprehensive Tobacco
Control Program (JMW, MLS).”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “adaptive urn randomization procedure
that accounts for motivation, gender, eth-
nicity, and heavy versus light smoking sta-
tus”
Allocation concealment (selection bias) Low risk Judged that process for randomisation pre-
vented prior knowledge of condition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 75% followed up at 12m, authors reported
“not different between groups”
Wu 2009
Methods Setting: research unit for Asian health, NYC, USA
Recruitment: via Asian Community Health Coalition member organisations
Participants Chinese smokers (any smoking in previous wk); 12% F, av age 44, av cpd NS, 25%
smoked < 10 cpd, 49% had never attempted to quit
Interventions Pharmacotherapy: NRT. Patch for 8 wks (could start at any time in 6 m period)
1. Culturally-tailored counselling in Chinese, 4 x 60-min & S-H
2. Health education in Chinese: 4 x 60-min, including general health, nutrition, exercise
& tobacco
Outcomes Abstinence at 6 m (PP)
Validation: CO < 6 ppm
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Wu 2009 (Continued)
Source of Funding/CoI National Cancer Institute Community Network Program. Authors declared no conflicts
of interest
Notes Conditions had same contact time, but control did not focus on smoking
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not stated
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% intervention and 14% control lost to
follow-up at 6 m and counted as smokers
in ITT analysis
Yalcin 2014
Methods Setting: general practice smoking cessation clinic, Turkey
Recruitment: smokers motivated to quit within 6 months
Participants 350 smokers
50% M, av age 36.22, cpd not reported
Therapists: smoking cessation clinic specialists
Interventions Pharmacotherapy: NRT (gum or patch), bupropion, or varenicline for 3 m or as long as
necessary
1. Control; 8 visits & 1 call; baseline, day 8, 20, 23, 30, 45, 60, 120, 210, ~150 mins
2. Same as control plus CBT-oriented anger management and stress control programme,
5 x 90-min sessions, in 1st month, ~730 mins total
Outcomes Abstinence at 180 days, continuous abstinence (from quit-day)
Validation: CO ≤ 10 ppm
Source of Funding/CoI No funding. Authors declared no conflicts of interest.
Notes Pharmacotherapy was only used if the participant wanted to.
Risk of bias
Bias Authors’ judgement Support for judgement
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Yalcin 2014 (Continued)
Random sequence generation (selection
bias)
High risk Alternated allocation, based on order that
they were added to the participant list
Allocation concealment (selection bias) High risk Not specified whether this randomisation
order was known to those enrolling
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6.3% lost to follow-up
ACS:AmericanCancerSociety
ACT: acceptance and commitment therapy
av.: average
BCT-S: behavioural couples treatment
CBGT: cogntive behavioural group therapy
CBT: cognitive behavioural therapy
CHWF2F: community health worker face-to-face
CHWQL: community health worker quitline
cigs: cigarettes
C-MIS: “Minimal intervention strategy for cardiology patients”
CO: carbon monoxide
cpd: cigarettes per day
CQ: Committed Quitters programme
F: female
FAP: functional analytic psychotherapy
FC: face-to-face counselling
F&C:Free&Clear
HE: health education
HMO: health maintenance organisation
hr: hour
incl: included
ITT: intention-to-treat
LGBT: lesbian, gay, bisexual, transgender
M: male
m: month
MA: meta-analysis
MBAT: mindfulness-based addiction treatment
MDD: major depressive disorder
MI: motivational interviewing
mins: minutes
NCI: National Cancer Institute
NP: nurse practitioners
NRT: nicotine replacement therapy
NS: not specified
NSGT: non-specific group therapy
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PI: principal investigator
PP: point prevalence abstinence
ppm: parts per million
RP: relapse prevention
SC: smoking cessation
SD: standard deviation
S-H: self help
TANS: treatment of addiction to nicotine in schizophrenia
TC: telephone counselling
TQD: target quit date
UC: usual care
VUMC: Vanderbild University Medical Center
vs: versus
wk(s): week(s)
yr: year
ZAP: Zyban advantage programme
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Asfar 2010 Compared delivery of quitline counselling: counsellor- versus participant-initiated
Bastian 2013 Tested motivational interviewing to promote smoking cessation. Low use of NRT; only 59% of participants
requested nicotine patches. Included in Lindson-Hawley 2015 Cochrane review of motivational interviewing
Batra 2010 Experimental intervention was tailored for at-risk subgroups, and included recommendation to use combi-
nation NRT. Standard treatment control recommended single type of NRT
Bock 2008 Only participants interested in quitting (17% at baseline) were offered NRT. Main intervention was motiva-
tional interviewing
Bonevski 2018 Pharmacotherapy was only offered to the participants in the intervention arm
Borland 2008 Pharmacotherapy was only offered to participants interested in quitting; 24% reported use
Brandon 2017 Only 3 months follow-up
Breland 2014 Intervention delivered by computer, no personal support.
Brown 2007 Factorial trial of bupropion/placebo and mood management CBT or standard cessation CBT. Both be-
havioural interventions were intensive, and experimental treatment was specifically devised for people with
depression
Buchanan 2004 Only 3 months follow-up (42 participants)
Carlin-Menter 2011 Only 3 months follow-up. Compared 2 versus 4 counselling callbacks for smokers calling a quitline who
received up to 6 weeks of free NRT
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Chandrashekar 2015 Only 12 weeks follow-up
Chouinard 2005 Pharmacotherapy was only offered to participants interested in quitting; 24% used
Christenhusz 2007 Pharmacotherapy differed by arm: control arm advised to use pharmacotherapy but had to pay for it; inter-
vention arm provided with bupropion free of charge
Cooney 2007 Both pharmacotherapy and behavioural components varied by trial arm
Cooper 2004 Main study results have not been published.
Costello 2011 Only 5 weeks follow-up. Compared 2 intensities of pharmacist-led behavioural support for participants using
NRT
Cropsey 2017 Only 12 weeks follow-up
Cummins 2016 Control group participants may or may not have received NRT.
Dezee 2013 Only 12 weeks follow-up
Emmons 2013 Compared web-based versus print formats of smoking cessation intervention
Evins 2007 Only 12 weeks follow-up
Fang 2006 Only 3 months follow-up
Garvey 2012a Both behavioural interventions were of similar intensity, differing only in scheduling of sessions
Hall 1996 Both behavioural interventions were of similar intensity.
Hall 2004 Factorial trial crossing extended behavioural support (CBT) withmedicalmanagement only, and nortriptyline
or placebo, for 1 year, as adjuncts to nicotine patch and 5 group counselling sessions. Placebo arms could have
been compared, but no other trials confounded behavioural support with placebo, and the support common
to all conditions was also much more intensive than in other trials
Hall 2011 Similar design to Hall 2004: factorial trial crossing extended behavioural support (CBT) with medical man-
agement only, and bupropion or placebo, as adjunct to nicotine patch and 5 group support sessions over
11 weeks. As with Hall 2004, placebo arms could have been compared, but no other trials confounded
behavioural support with placebo, and the support common to all conditions was also much more intensive
than in other trials
Hegaard 2003 Study population pregnant smokers, not eligible
Ingersoll 2009 Only 3 months follow-up. Test of motivational interviewing as adjunct to nicotine patch therapy for HIV+
smokers
Japuntich 2006 Intervention was access to an internet site; no person-to-person behavioural support
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Joseph 2004 Intervention and control did not differ on use of pharmacotherapy or intensity of behavioural support. Test
of timing in relation to alcohol dependence treatment
Joyce 2008 Test of reimbursement for pharmacotherapy and counselling
Kim 2012 Pilot study of a culturally-tailored intervention for Koreans, with only 30 participants
Kinnunen 2008 Main intervention was exercise, not eligible for this review. Recruitment to the standard care control was
halted early
Klesges 2015 Compared proactive and reactive telephone counselling. Both conditions could get same intensity of coun-
selling
Kotz 2009 Tested a specific behavioural intervention: feedback of biomedical information
Levine 2010 Behavioural interventions were matched for intensity; specifically tested a weight-related intervention
Marshall 1985 Only offer of nicotine gum
McCarthy 2016 Only 10 weeks follow-up
Moadel 2012 Only 3 months follow-up
Mochizuki 2004 Only 3 months follow-up. Small study of pharmacist advice as adjunct to NRT
NCT00781599 Only 3 months follow-up
Nilsson 1996 Only 4 months follow-up. Intervention was offer of group support and free NRT
Nollen 2007 No difference in intensity of behavioural support
Nollen 2011 Only 3 months follow-up. Study of an intervention to increase adherence to varenicline
Okuyemi 2006 All participants received same intensity of motivational interviewing, group sessions and offer of NRT. Tested
different targets for motivational interviewing
Pakhale 2015 Pharmacotherapy not offered in same way to both arms
Peckham 2015 Pharmacotherapy not offered in same way to both arms
Ramon 2013 Not all participants were offered pharmacotherapy.
Reid 2007 Intervention participants did not automatically receive additional behavioural support; intervention consisted
of automated telephone calls to identify participants at risk of relapse. Only this subgroup then received
further counselling
Schnoll 2005 Only 3 months follow-up, behavioural interventions similar in intensity as adjuncts to nicotine patch
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Severson 2015 Participants were smokeless tobacco users not smokers
Shiffman 2000 Only 12 weeks follow-up from start of treatment. Study of computer-tailored materials as adjunct to nicotine
gum
Shiffman 2001 Only 12 weeks follow-up from start of treatment. Study of computer-tailored materials as adjunct to nicotine
patch
Sorensen 2003 Short follow-up (preoperative period)
Strecher 2005 Only 12 weeks follow-up from start of treatment. No personal behavioural support, study of web-based
tailored materials as adjunct to nicotine patch
Velicer 2006 Intervention was automated telephone counselling messages, no personal contact
Vial 2002 Compared intervention from 2 different types of pharmacist, not between different intensities of support
Ward 2001 Compared 2 group-based behavioural interventions similar in intensity as adjuncts to nicotine patch, see
Stead 2017.
Wilson 1988 Use of nicotine gum was substantially different between the relevant arms of the trial, and the intervention
condition was also a test of the impact of training
Wolfenden 2005 Only 3 month follow-up. Test of multifaceted intervention including offer of NRT at preoperative clinics
Yu 2006 Only 12 weeks follow-up from start of treatment
Zwar 2015 Trial of methods of delivery of care rather than of intensity of support
CBT :cognitivebehaviouraltherapy
NRT: nicotine replacement therapy
Characteristics of ongoing studies [ordered by study ID]
ACTRN12614000876695
Trial name or title Improving radiotherapy outcomes in head and neck cancer patients: a preliminary comparison of smoking
cessation intervention ‘Varenicline plus support’ with ‘treatment as usual’
Methods Study design: randomised controlled trial
Setting: New South Wales, Australia
Recruitment: potential participants identified in the month preceding the new patient clinic using treatment
planning software
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ACTRN12614000876695 (Continued)
Participants Target: 40
Interventions Pharmacotherapy: varenicline for 3 months course initially then an offer of an additional 3 months course
depending on the successful completion of the first course
1. Treatment as usual: standard New South Wales Health Tobacco assessment and smoking cessation advice
2.Multicomponent smoking cessation programme including 10 behaviour change sessionswith a psychologist
Outcomes Abstinence at 6 months post-radiotherapy
Validation: not specified
Starting date August 2014
Contact information Benjamin Britton, University of Newcastle
Notes Stopped due to a higher than anticipated number of ineligible patients and time-limited funding
Only the intervention group was offered varenicline.
Asfar 2018
Trial name or title A cluster-randomised pilot trial of a tailored worksite smoking cessation intervention targeting Hispanic/
Latino construction workers: intervention development and research design
Methods Study design: cluster-randomised pilot trial
Setting: South Florida, USA
Recruitment: identification of potential participants through research partnership with local construction
companies
Participants Target: 126 Hispanic/Latino smokers (63 per arm)
Interventions Pharmacotherapy: 8 weeks of free NRT (6 weeks supply provided by the study team and 2 weeks by the
quitline)
1. Enhanced care: single face-to-face behavioural group counselling session delivered at the food truck + two
brief follow-up counselling phone calls + usual care
2. Usual care: fax referral to the Florida quitline (quitline to provide four brief counselling sessions by phone)
+ informative handout about the quitline
Outcomes Abstinence at 6 months
Validation: saliva cotinine < 15 ng/mL
Starting date April 2017
Contact information David Lee, University of Miami
Notes
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Choi 2011
Trial name or title Culturally-tailored smoking cessation for American Indians
Methods Study design: RCT (cluster randomisation)
Setting: American Indian and Alaskan Native smokers in 2 sites (Kansas and Oklahoma)
Participants will form temporal clusters in recruiting order, and then pairs of clusters will be assigned to the
groups using randomised permuted blocks based on computer-generated random numbers
Participants 58 groups totaling 448 participants
Interventions Pharmacotherapy: choice of free pharmacotherapy, including Chantix®, Zyban®, Nicotine Replacement
Therapy (NRT, patches, gum, or lozenges), or a combination of the latter 2
1.Non-native tailored intervention usingAmericanCancer Society guide to educate about the risks of smoking
+ assisting with planning for cessation (included pharmacotherapy)
2. “All Nations Breath of Life” (ANBL) programme (culturally-tailored) = group support sessions, telephone
motivational interviewing, culturally-tailored educational curriculum, pharmacotherapy, and participants’
incentives
Outcomes Abstinence: continuous abstinence
Validation: salivary cotinine analysis for verification
Starting date September 2010
Contact information Won Choi, University of Kansas
Notes Both usual care and intervention received intensive behaviour counselling; however the types of counselling
were different. The study aimed to assess culturally-tailored smoking cessation interventions among American
Indian populations
- study completed in January 2015
Cummins 2012
Trial name or title Nicotine patches and quitline counselling to help hospitalised smokers stay quit: study protocol for a ran-
domised controlled trial
Methods Setting: hospitalised patients recruited from 2 healthcare systems in San Diego county
Recruitment: motivation: respiratory therapists/research recruiters at bedside; interested in quitting, selected
if they were motivated
Participants 1640 participants
Interventions Pharmacotherapy: 6 to 10 cpd = 6 weeks 14 mg + 2 weeks 7 mg; ≥ 11 cpd = 4 weeks 21 mg, 2 weeks 14 mg
& 2 weeks 7 mg nicotine patches
1. Usual care - brief bedside intervention (< 10 minutes), educational materials & state quitline number
provided
2. Just nicotine patches (8 weeks, step-down programme)
3. Proactive telephone counselling provided by the state quitline after discharge
4. Both patch + telephone counselling
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Cummins 2012 (Continued)
Outcomes Abstinence at 6 months - 30-day PP
Validation: cotinine-validated smoking status
Starting date Date of registration: February 1, 2011; date of first participant: August 3, 2011
Contact information Shu-Hong Zhu, University of California San Diego
Notes Analysis will use 4 vs 2
Garvey 2012b
Trial name or title Duration of behavioural counselling treatment needed to optimise smoking abstinence
Methods RCT
Participants 450
Interventions Pharmacotherapy:
1. 3 months of counselling
2. 6 months of counselling
3. 12 months of counselling
Outcomes Abstinence: 1 year
Validation: not specified
Starting date February 2008
Contact information arthur garvey@hms.harvard.edu
Notes There are no study results yet.
Kim 2017
Trial name or title A pilot study of a smoking cessation intervention for women living with HIV: study protocol
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: convenience sampling. To be recruited offline and online across the nation
Participants 50 women diagnosed with HIV and residing in a community
Interventions Pharmacotherapy: eight weeks of nicotine patches
Eight weekly individualised counselling sessions of 30-minute cognitive behavioural therapy via:
1. telephone video call
2. telephone voice call
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Kim 2017 (Continued)
Outcomes Abstinence at 6 months
Validation: salivary cotinine < 10ng/mL
Starting date Protocol published in February 2017
Contact information Sun S Kim, University of Massachusetts Boston
Notes
NCT00851357
Trial name or title Telephone counselling and the distribution of nicotine patches to smokers
Methods Study design: randomised controlled trial (factorial)
Setting: University of California, California Smokers’ Helpline, USA
Recruitment: recruitment of eligible participants through the Helpline
Participants 4200 participants
Interventions Pharmacotherapy: eight weeks of nicotine patch
1. Telephone counselling: pre-quit session + five proactive follow-up calls
2. Self-help materials: reading materials mailed to the participants
Outcomes Abstinence at 6 months
Validation: unspecified in the trials registry
Starting date February 2009
Contact information Shu-Hong Zhu, University of California
Notes
NCT00937235
Trial name or title Treatment of smoking among individuals with PTSD: a phase II, randomised study of varenicline and
cognitive behavioural therapy
Methods RCT
Participants 166
Interventions Pharmacotherapy: varenicline 1 mg tablets, orally, twice daily x 12 weeks
1. Control = 5-min weekly counselling x 12 weeks, focused on medication adherence and smoking cessation
2. Control = 75 to 90-min weekly psychotherapy sessions x 12 weeks, focused on gradually confronting
distressing trauma-related memories and reminders
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NCT00937235 (Continued)
Outcomes Abstinence: 7-day PP at 6 months
Starting date January 2009
Contact information Edna B Foa, University of Pennsylvania
Notes
NCT00984724
Trial name or title Reducing tobacco-related health disparities
Methods Study design: randomised controlled trial
Setting: not known
Recruitment: not known
Participants 639 participants
Interventions Pharmacotherapy: 300 pieces of nicotine gum issued at baseline visit
1. Standard treatment: mailed packet with standard self-help materials delivered four times + referral to
quitline
2. MAPS-6 (standard treatment + six phone counselling sessions over a two-year period)
3. MAPS-12 (standard treatment + 12 phone counselling sessions over a two-year period)
4. Standard treatment + NRT
5. MAPS-6 + NRT
6. MAPS-12 + NRT
Outcomes Abstinence at 24 months
Validation: carbon monoxide < 10 ppm, saliva cotinine < 20 ng/mL
Starting date January 2011
Contact information Larkin Strong, M.D. Anderson Cancer Center
Notes
NCT01063972
Trial name or title Smoking cessation in rural hospitals
Methods Study design: randomised controlled trial
Setting:
Recruitment:
Participants 606 participants (303 in each arm)
123Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01063972 (Continued)
Interventions Pharmacotherapy: not specified in the trials registry
1. In-hospital smoking cessation counselling by phone + four outpatient counselling sessions by phone
2. Counselling as above but with coordination of pharmacotherapy with their insurance coverage and their
health care provider
Outcomes Abstinence at 12 months
Validation: not specified in the trials registry
Starting date March 2010
Contact information Edward Ellerbeck, University of Kansas Medical Center
Notes
NCT01098955
Trial name or title Smoking cessation treatment for head & neck cancer patients: acceptance and commitment therapy
Methods RCT
Participants 108
Interventions Pharmacotherapy: varenicline 2 mg daily for 12 weeks
1. Acceptance and Commitment Therapy (ACT): 6 x 60-min counselling sessions delivered over a 5-week
period
2. Motivational and Behavioral Counselling (MBC): 6 x 60-min counselling sessions delivered over a 5-week
period
Outcomes Abstinence: 14 and 26 weeks
Validation: cotinine verification
Starting date March 2010
Contact information Jan Blalock M. D. Anderson Cancer Center
Notes
NCT01162239
Trial name or title Maintaining nonsmoking
Methods Setting: USA
Participants 271
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NCT01162239 (Continued)
Interventions Pharmacotherapy: varenicline: 12 weeks, 1 mg bid
1. Participants have monthly meetings with medical staff
2. Participants receive monthly counselling with content based on a health education model
3. Participants receive monthly counselling with content based on a relapse prevention model plus access to
ongoing medication treatment with varenicline
4. Participants receive monthly counselling with content based on a relapse prevention model
Outcomes Abstinence at 12, 24, 52, 64, 104 months
Starting date May 2010
Contact information University of California. No PI listed
Notes
NCT01186016
Trial name or title Developing genetic education for smoking cessation
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: not given in the trials registry
Participants 103 participants
Interventions Pharmacotherapy: 6 weeks of transdermal nicotine replacement therapy
1. Two educational sessions about genetics and smoking
2. Two educational sessions about nutrition
Outcomes Abstinence at 6 months
Validation: not given in the trials registry
Starting date April 2012
Contact information Julia F Houfek, University of Nebraska
Notes
NCT01257490
Trial name or title Integrated smoking cessation treatment for low-income community corrections
Methods RCT
Participants 689
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NCT01257490 (Continued)
Interventions Pharmacotherapy: bupropion
1. Brief physician advice to quit plus bupropion
2. 4 sessions of intensive counselling plus bupropion
Outcomes Abstinence: at 3, 6, 9, 12 months
Validation: verified by expired carbon monoxide
Starting date October 2009
Contact information Karen L Cropsey, University of Alabama at Birmingham
Notes
NCT01736085
Trial name or title Providing free Nicotine patches to quitline smokers
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: smokers aged 18 years or older recruited from the quitline
Participants 3710 participants
Interventions Pharmacotherapy: nicotine patches
1. self-help materials only
2. self-help materials + a voucher for 2 weeks’ worth of nicotine patches
3. self-help materials + 2 weeks’ worth of nicotine patches
4. up to 5 sessions of telephone counselling
5. up to 5 sessions of telephone counselling + a voucher for 2 weeks’ worth of nicotine patches
6. up to 5 sessions of telephone counselling + 2 weeks’ worth of nicotine patches
Outcomes 6 months prolonged abstinence
Validation: none specified in the trials registry
Starting date April 2013
Contact information Shu-Hong Zhu, University of California
Notes
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NCT01800019
Trial name or title The Canadian HIV Quit Smoking Trial: tackling the comorbidities of depression and cardiovascular disease
in HIV+ smokers
Methods RCT
Participants 256
Interventions Pharmacotherapy: NRT = 7 mg to 42 mg depending on cpd; varenicline = 0.5 mg/daily for 3 days, 0.5 mg
twice daily for 4 days and 1 mg twice daily for the remainder of the treatment period
1. NRT only
2. NRT + HIV-tailored smoking cessation counselling
3. Varenicline only
4. Varenicline + HIV-tailored smoking cessation counselling
Outcomes Abstinence: 7-day PP at week 48
Validation: expired carbon monoxide levels measured using a piCO+ Smokerlyzer; CO < 10 ppm
Starting date January 2014
Contact information Louise Balfour, Ottawa Research Hospital
Notes
NCT01901848
Trial name or title CPT and smoking cessation
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: US veteran smokers with post-traumatic stress disorder, aged between 18 and 65 years. Selected
for motivation to quit smoking
Participants 69 participants
Interventions Pharmacotherapy: bupropion, nicotine patches and a rescue method (e.g. nicotine gum, lozenge, inhaler)
1. 12 sessions of combined cognitive processing therapy and integrated care for smoking cessation, involvement
in smokefreeVET.gov’s text messaging programme for smoking cessation
2. 12 sessions of integrated care for smoking cessation, involvement in smokefreeVET.gov’s text messaging
programme for smoking cessation
Outcomes Abstinence at 6 months
Validation: exhaled carbon monoxide < 4ppm
Starting date December 2013
Contact information Eric A Dedert, Durham VA Medical Center
Notes
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NCT01965405
Trial name or title Behavioural smoking cessation for people living with HIV/AIDS
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: smokers with HIV or AIDS diagnosis and aged 18 years or older
Participants 400 participants
Interventions Pharmacotherapy: a prescription for bupropion for all groups
1. Brief counselling
2. Brief counselling + brief high-magnitude prize contingency management
3. Continued counselling + monitored support to quit smoking
4. Monitored support to quit smoking + prize contingency management for abstinence
5. Pharmacotherapy only
6. Continued monitoring + low intensity prize contingency management
Outcomes Abstinence at 6 and 12 months
Validation: urinary cotinine, carbon monoxide
Starting date August 2013
Contact information David Ledgerwood, Wayne State University
Notes
NCT02048917
Trial name or title Smoking cessation strategies in community cancer programmes for lung and head and neck cancer patients
Methods Setting: USA
Participants 180
Interventions 1. High-intensity counselling + long-acting NRT + PRN NRT
2. High-intensity counselling + bupropion + PRN NRT
3. High-intensity counselling + varenicline + PRN NRT
4. High-intensity counselling + long-acting NRT
5. High-intensity counselling + bupropion
6. High-intensity counselling + varenicline
7. Low-intensity counselling + long-acting NRT + PRN NRT
8. Low-intensity counselling + bupropion + PRN NRT
9. Low-intensity counselling + varenicline + PRN NRT
10. Low-intensity counselling + long-acting NRT
11. Low-intensity counselling + bupropion
12. Low-intensity counselling + varenicline
Outcomes Abstinence: 7-day PP at 8 weeks
Validation: CO
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NCT02048917 (Continued)
Starting date July 2014
Contact information Joseph Valentino, University of Kentucky
Notes
NCT02164383
Trial name or title A quit smoking study using smartphones
Methods RCT
Participants 30
Interventions Pharmacotherapy: nicotine patch
1.Nicotine patch plus behavioural cessation counselling without access to Mobile Games
2. Nicotine patch plus behavioural cessation counselling with access to Mobile Games
Outcomes Abstinence: change between baseline mean cigarettes smoked per day and mean cigarettes smoked per day
during the first 4 weeks of the quit attempt
Starting date October 2014
Contact information Tanya R. Schlam, University of Wisconsin Center for Tobacco Research and Intervention
Notes
NCT02378714
Trial name or title Behavioural activation and varenicline for smoking cessation in depressed smokers
Methods Study design: randomised controlled trial
Setting: Chicago, USA
Recruitment: smokers with major depressive disorder
Participants 576 participants
Interventions Pharmacotherapy: varenicline or placebo for 12 weeks
1. Standard behavioural cessation treatment (45 minutes x 8 sessions)
2. Behavioural activation integrated with standard behavioural cessation treatment (45 minutes x 8 sessions)
Outcomes Abstinence at 27 weeks
Validation: expired carbon monoxide ≤ 8 ppm
Starting date June 2015
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NCT02378714 (Continued)
Contact information Brian L Hitsman, Northwestern University
Notes
NCT02460900
Trial name or title Optimising smoking cessation for people with HIV/AIDS who smoke
Methods Study design: randomised controlled trial (factorial)
Setting: University of Maryland Medical Center, USA
Recruitment: not specified in the trials registry
Participants 300 participants
Interventions Pharmacotherapy: varenicline
1. Standard care: low intensity, brief counselling
2. Positively Smoke Free (details unspecified in the trials registry)
Outcomes Abstinence at 24 weeks
Validation: not specified in the trials registry
Starting date July 2016
Contact information Seth Himelhoch, University of Maryland
Notes
NCT02767908
Trial name or title Hospital to home, smoker support trial
Methods Study design: randomised controlled trial
Setting: hospital and home
Recruitment: smokers leaving hospital
Participants 404 participants
Interventions Pharmacotherapy: nicotine replacement products
1. Usual care: behavioural support before leaving hospital, referral to NHS Stop Smoking Services after
discharge
2. Home visit as soon as practicable after discharge and typically within 48 hours to deliver a multicomponent
intervention; tailored support package including telephone support, carbon dioxide measurements, home air
quality measurements, signposting to support groups, self-help materials
Outcomes Abstinence at 4 weeks and 12 weeks post-discharge according to the information on the trials registry
Validation: exhaled carbone monoxide < 6 ppm
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NCT02767908 (Continued)
Starting date June 2016
Contact information John Britton, University of Nottingham
Notes
NCT02898597
Trial name or title Smoking cessation intervention for women with HIV/AIDS
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: smokers with diagnosis of HIV infection and aged between 18 and 75 years
Participants 50 participants
Interventions Pharmacotherapy: nicotine replacement therapy (habitrol patch)
1. cognitive behavioural therapy via video-conferencing
2. cognitive behavioural therapy via telephone
Outcomes Abstinence at 6 months
Validation: saliva cotinine
Starting date June 2016
Contact information Sun S Kim, University of Massachusetts
Notes
NCT02905656
Trial name or title Strategies to promote cessation in smokers who are not ready to quit (PACE)
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: smokers aged 18 years or older
Participants 828 participants
Interventions Pharmacotherapy: nicotine gum
1. brief advice + typical smoking cessation resources
2. motivational interviewing
3. rate reduction
4. motivational interviewing + rate reduction
Outcomes Abstinence at 12 months
Validation: not specified in the trials registry
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NCT02905656 (Continued)
Starting date September 2016
Contact information Robert Klesges, University of Virginia
Notes
NCT03072511
Trial name or title Pilot trial of a smoking cessation intervention informed by construal level theory
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: not specified in the trials registry
Participants 23 participants
Interventions Pharmacotherapy: eight weeks of transdermal nicotine patch
1. Standard informational treatment: in-person session, text messaging
2. Spotlight on smoke-free living 1.5 hour intervention session combined with daily text messaging for up to
1 week pre-quit and 4 weeks post-quit
Outcomes Abstinence at 13 weeks
Validation: not specified in the trials registry
Starting date December 2016
Contact information Richard Yi, University of Florida
Notes
NCT03342027
Trial name or title Smoking cessation interventions for people living with HIV in Nairobi, Kenya
Methods Study design: randomised controlled trial (factorial)
Setting: Nairobi, Kenya
Recruitment: smokers livingwithHIV and receiving care in amethadonemaintenance programme inNairobi,
Kenya
Participants 300 participants
Interventions Pharmacotherapy: bupropion
1. Standard care: brief advice to quit provided in a standardised format
2. Positively smoke free: eight sessions of tailored behavioural treatment for smoking cessation
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NCT03342027 (Continued)
Outcomes Abstinence at 36 months
Validation: carbon monoxide level < 7ppm
Starting date January 2019
Contact information Seth Himelhoch, University of Maryland
Notes
NCT03538938
Trial name or title Improving quitline support study: optimising remotely delivered smoking cessation services for low-income
smokers
Methods Study design: four-factor, fully-crossed randomised controlled trial
Setting: USA
Recruitment: smokers aged 18 years or older selected for motivation to quit
Participants 1600 participants
Interventions Pharmacotherapy: 2 weeks of nicotine patches and lozenges
16 conditions of four factors: phone call, SmokefreeTXT, financial incentive, nicotine replacement (patches
+/- lozenges)
Outcomes Abstinence at 6 months
Validation: saliva cotinine < 4ng/mL
Starting date July 2018
Contact information Danielle E McCarthy, University of Wisconsin
Notes
NCT03603496
Trial name or title Post-discharge smoking cessation strategies: helping HAND 4
Methods Study design: randomised controlled trial
Setting: three hospitals in USA
Recruitment: not specified in the trials registry
Participants 1350 participants
Interventions Pharmacotherapy: eight weeks of nicotine replacement therapy
1. Electronic referral to State tobacco quitline
2. Personalised tobacco care management: seven proactive contacts over three months delivered by automated
interactive voice response phone calls, text messaging and/or email + offer of a return call from the hospital-
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NCT03603496 (Continued)
based tobacco coach who offer counselling, medication advice and coordination of care with the patient’s
outpatient health care team
Outcomes Abstinence at 6 months after hospital discharge
Validation: not specified in the trials registry
Starting date August 2018
Contact information Nancy Rigotti, Massachusetts General Hospital
Notes
Ojo-Fati 2015
Trial name or title Integrating smoking cessation and alcohol use treatment in homeless populations
Methods Study design: randomised controlled trial
Setting: homeless shelters
Recruitment: homeless smokers aged 18 years or older
Participants 645 participants
Interventions Pharmacotherapy: 12 weeks of nicotine patch plus nicotine gum or lozenge
1. Integrated intensive smoking plus alcohol intervention using cognitive behavioural therapy
2. Intensive smoking intervention using cognitive behavioural therapy
3. Usual care: brief smoking cessation and brief alcohol counselling
Outcomes Abstinence at 52 weeks
Validation: cotinine-verified 7-day smoking abstinence
Starting date January 2015
Contact information Olamide Ojo-Fati, Universtiy of Minnesota
Notes
Powers 2016
Trial name or title Efficacy of smoking cessation therapy alone or integrated with prolonged exposure therapy for smokers with
PTSD
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: smokers with post-traumatic stress disorder aged between 18 and 64 years selected formotivation
to quit
Participants 80 participants
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Powers 2016 (Continued)
Interventions Pharmacotherapy: nicotine patch
1. Standard smoking cessation treatment: once-weekly 45-minute sessions of cognitive behavioural therapy
over a 12-week period
2. Integrated PTSD and smoking treatment: once-weekly 90-minute sessions over a 12-week period. Incor-
porated standard treatment with therapy for reducing PTSD symptoms and anxiety sensitivity and enhancing
tolerance for nicotine withdrawal sensations
Outcomes Abstinence at 24 weeks
Validation: saliva cotinine < 10ng/mL for stated abstinence of 2 weeks or more, carbon monoxide analysis of
breath samples < 8ppm for stated abstinence of 24 hours to 2 weeks
Starting date October 2013
Contact information Mark B Powers, University of Texas
Notes
Reid 2011
Trial name or title Interactive voice response telephone technology for the treatment of smoking in patients with heart disease
(IVR)
Methods Setting: smokers recently hospitalised with CHD, Canada Health Care
Recruitment: study co-ordinator recruited within 24 hours of admission
Participants N randomised: 100 (but 99 used in calculations). Dropouts: 15 + 1 death
Sex: 67.4% M, Age: 54, av cpd 16-25
Therapists: nurse specialist
Interventions Pharmacotherapy: NRT in hospital before quit date
1. Access to NRT during hospitalisation, brief bedside counselling by nurse, self-help guide
2. Interactive Voice Response system posted questions “concerning current smoking status, confidence in
staying smoke-free, use of pharmacotherapy, and self-help materials”
Outcomes Abstinence at 12 m, 7-day PP
Validation: none
Starting date July 2006
Contact information Robert Reid, University of Ottawa Heart Institute
Notes
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Salgado 2018
Trial name or title Planning a change easily: a randomised controlled trial for smokers who are not ready to quit
Methods Study design: randomised controlled trial
Setting: not specified in the protocol
Recruitment: smokers recruited via flyers, business cards, medical referrals, Facebook, Pandora Radio, and
‘refer-a-friend’ programme
Participants 840 participants
Interventions Pharmacotherapy: 4mg nicotine gum for rate reduction group andmotivational interviewing + rate reduction
group
1. Brief advice
2. Motivational interviewing
3. Rate reduction
4. Motivational interviewing + rate reduction
Outcomes Abstinence at 12 months
Validation: saliva cotinine
Starting date Not specified in the protocol
Contact information Francisco I Salgado Garcia, Universtiy of Tennesse
Notes
Vander Weg 2018
Trial name or title Community-based physical activity as adjunctive smoking cessation treatment: rationale, design, and baseline
data for the Lifestyle Enhancement Program (LEAP) randomised controlled trial
Methods Study design: randomised controlled trial
Setting: community, USA
Recruitment: smokers who are sedentary or minimally active during leisure time, and aged between 18 and
65 years
Participants 392 participants
Interventions Pharmacotherapy: 6 weeks of transdermal nicotine
1. Behavioural counselling + physical activity intervention
2. Behavoural counselling + wellness intervention
Outcomes Abstinence at 12 months
Validation: expired carbon monoxide < 10ppm
Starting date January 2003
Contact information Kenneth D Ward, University of Memphis
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Vander Weg 2018 (Continued)
Notes
Vidrine 2012
Trial name or title Enhancing cancer outreach for low-income adults with innovative smoking cessation. Project ACTION
(Adult smoking Cessation Treatment through Innovative Outreach to Neighborhoods)
Methods Cluster RCT
Setting: community, USA
Participants 756
Interventions 1. Standard care: brief coach advice to quit smoking, nicotine replacement therapy (NRT), and self-help
written materials
2. Enhanced care: As 1. plus a single motivational interviewing counselling session and a cell phone-delivered
text/graphical messaging component
3. Intensive care: As 2. plus a series of 11 cell phone-delivered proactive counselling sessions and a cell phone-
delivered text/graphical messaging component
Outcomes Abstinence at 12 months
Starting date June 2010
Contact information Alex Prokhorov, University of Texas MD Anderson Cancer Center
Notes
Webb 2018
Trial name or title Reducing racial/ethnic tobacco cessation disparities via cognitive behavioural therapy: design of a dual-site
randomised controlled trial
Methods Study design: randomised controlled trial
Setting: USA
Recruitment: African American/black, Hispanic, or white non-Hispanic smokers aged 18 years or older
Participants 354 participants
Interventions Pharmacotherapy: up to 8 weeks of transdermal nicotine patch
1. Group cognitive behavioural therapy
2. General health education
Outcomes Abstinence at 12 months
Validation: not specified in the trials registry
Starting date August 2015
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Webb 2018 (Continued)
Contact information Monica Webb Hooper, Case Western Reserve University School of Medicine
Notes
ACT :Acceptanceandcommitmenttherapy
bid:bisindie(twiceaday)
CHD: cornary heart disease
cpd: cigarettes per day
CPT: cognitive processing therapy
IVR: interactive voice response
NRT: nicotine replacement therapy
PI: prinicipal investigator
PRN: pro re nata (when necessary)
PTSD: post-traumatic stress disorder
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D A T A A N D A N A L Y S E S
Comparison 1. Effect of increasing behavioural support. Abstinence at longest follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subgroups by type of
pharmacotherapy
65 23331 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.08, 1.22]
1.1 NRT 49 16541 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.04, 1.21]
1.2 Bupropion 5 2298 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.10, 1.46]
1.3 Nortriptyline 2 172 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.60, 1.63]
1.4 Varenicline 2 1111 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.87, 1.27]
1.5 NRT & bupropion 3 719 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.00, 1.54]
1.6 Choice of
pharmacotherapy
5 2490 Risk Ratio (M-H, Random, 95% CI) 1.30 [1.00, 1.68]
2 Subgroups by contrast in
number of contacts between
intervention & control
63 21997 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.08, 1.22]
2.1 4 to 8 or > 8 contacts
versus no contact
8 4018 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.02, 1.43]
2.2 More than 8 contacts
versus 1 to 3 contacts
4 1063 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.70, 1.57]
2.3 4 to 8 contacts versus 1 to
3 contacts
18 9579 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.01, 1.19]
2.4 More than 8 contacts
versus 4 to 8 contacts
12 1737 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.98, 1.33]
2.5 Intervention & control in
same contact category
21 5600 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.16, 1.50]
3 Subgroups by duration of
contact in control condition
(not prespecified)
62 21695 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.08, 1.22]
3.1 No contact for control 8 4018 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.02, 1.43]
3.2 ’Brief intervention’ for
control
22 10565 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.99, 1.21]
3.3 ’Dose response’, over 30
minutes contact for control
32 7112 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.08, 1.32]
4 Subgroup by modality of
intervention contact (not
prespecified)
65 23331 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.08, 1.22]
4.1 Intervention delivered by
telephone
8 6670 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.15, 1.37]
4.2 Intervention included
face-to-face contact
57 16661 Risk Ratio (M-H, Random, 95% CI) 1.11 [1.03, 1.19]
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Comparison 2. Effect of increasing behavioural support: Sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Sensitivity analysis including
intermediate intensity
conditions. Adjunct
behavioural support versus
pharmacotherapy alone
65 27425 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.07, 1.20]
1.1 NRT 49 18666 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.03, 1.19]
1.2 Bupropion 5 2298 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.10, 1.46]
1.3 Nortriptyline 2 172 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.60, 1.63]
1.4 Varenicline 2 1513 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.90, 1.26]
1.5 NRT & bupropion 3 719 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.00, 1.54]
1.6 Choice of
pharmacotherapy
5 4057 Risk Ratio (M-H, Random, 95% CI) 1.23 [1.00, 1.51]
2 By outcome definition 65 23389 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.08, 1.22]
2.1 12 months validation PP
outcomes only
21 6036 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.90, 1.17]
2.2 12 months validated
sustained outcomes
11 3604 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.93, 1.30]
2.3 < 12 months, but validated 19 5581 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.12, 1.39]
2.4 No validation at all 13 7933 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.08, 1.30]
2.5 > 12 months validation
PP outcomes only
1 235 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.59, 3.01]
Comparison 3. Studies matched for contact time. Abstinence at longest follow-up point
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Abstinence at longest follow-up 15 4138 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.25]
1.1 Family support
versus usual care telephone
counselling
1 471 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.72, 1.45]
1.2 Face-to-face, tests
attentional training v placebo
training
1 119 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.48, 2.50]
1.3 ACT versus CBT
telephone counselling
1 121 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.74, 2.46]
1.4 Positive psychotherapy
versus usual care (face-to-face)
1 77 Risk Ratio (M-H, Random, 95% CI) 8.78 [0.49, 157.62]
1.5 Couples treatment versus
individual treatment (face-to-
face)
1 49 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.37, 1.43]
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1.6 Behavioural activation
versus standard treatment (face-
to-face)
1 68 Risk Ratio (M-H, Random, 95% CI) 4.72 [0.24, 94.85]
1.7 Culturally tailored versus
standard (face-to-face)
4 929 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.68, 1.92]
1.8 Exercise counselling versus
health education (face-to-face)
1 30 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.23, 1.89]
1.9 Adherence counselling
versus standard care (telephone)
1 987 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.83, 1.15]
1.10 MIndfulness versus CBT
(face-to-face)
1 309 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.48, 1.45]
1.11 Quitline facilitation
session versus brief advice
(telephone)
1 600 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.62, 4.00]
1.12 Motivational
interviewing versus health
education
1 378 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.33, 0.94]
Analysis 1.1. Comparison 1 Effect of increasing behavioural support. Abstinence at longest follow-up,
Outcome 1 Subgroups by type of pharmacotherapy.
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 1 Effect of increasing behavioural support. Abstinence at longest follow-up
Outcome: 1 Subgroups by type of pharmacotherapy
Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 NRT
Aimer 2017 5/19 4/19 0.3 % 1.25 [ 0.40, 3.95 ]
Alterman 2001 26/80 20/80 1.3 % 1.30 [ 0.79, 2.13 ]
Aveyard 2007 30/456 36/469 1.4 % 0.86 [ 0.54, 1.37 ]
Bailey 2013 15/72 5/71 0.4 % 2.96 [ 1.14, 7.71 ]
Baker 2015 13/122 9/113 0.5 % 1.34 [ 0.59, 3.01 ]
Berndt 2014 63/155 92/218 4.4 % 0.96 [ 0.75, 1.23 ]
Bloom 2017 (1) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Bock 2014 48/406 58/440 2.3 % 0.90 [ 0.63, 1.28 ]
Brown 2013 4/27 2/22 0.1 % 1.63 [ 0.33, 8.08 ]
Busch 2017 (2) 11/31 11/33 0.7 % 1.06 [ 0.54, 2.09 ]
0.5 0.7 1 1.5 2
Favours less support Favours more support
(Continued . . . )
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(. . . Continued)
Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bushnell 1997 22/171 17/143 0.9 % 1.08 [ 0.60, 1.96 ]
Calabro 2012 55/278 24/231 1.6 % 1.90 [ 1.22, 2.98 ]
Cook 2016 6/95 14/98 0.4 % 0.44 [ 0.18, 1.10 ]
Cropsey 2015 8/248 17/252 0.5 % 0.48 [ 0.21, 1.09 ]
Ferguson 2012 121/648 108/648 4.7 % 1.12 [ 0.89, 1.42 ]
Fiore 2004 29/274 25/273 1.2 % 1.16 [ 0.70, 1.92 ]
Ginsberg 1992 11/33 14/35 0.8 % 0.83 [ 0.44, 1.57 ]
Hall 1985 18/41 16/43 1.2 % 1.18 [ 0.70, 1.98 ]
Hall 1987 12/35 18/36 1.0 % 0.69 [ 0.39, 1.20 ]
Hall 1994 18/79 16/70 0.9 % 1.00 [ 0.55, 1.80 ]
Hasan 2014 13/40 7/41 0.5 % 1.90 [ 0.85, 4.27 ]
Hollis 2007 153/721 148/868 5.8 % 1.24 [ 1.02, 1.53 ]
Huber 2003 13/55 15/57 0.8 % 0.90 [ 0.47, 1.71 ]
Humfleet 2013 10/69 14/82 0.6 % 0.85 [ 0.40, 1.79 ]
Jorenby 1995 43/167 44/169 2.3 % 0.99 [ 0.69, 1.42 ]
Kim 2015 7/14 3/16 0.3 % 2.67 [ 0.85, 8.39 ]
Lando 1997 21/162 46/347 1.4 % 0.98 [ 0.60, 1.58 ]
Lifrak 1997 12/33 12/36 0.8 % 1.09 [ 0.57, 2.08 ]
Lloyd-Richardson 2009 21/232 21/212 1.0 % 0.91 [ 0.51, 1.62 ]
MacLeod 2003 110/412 82/442 4.2 % 1.44 [ 1.12, 1.85 ]
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Ockene 1991 48/263 18/117 1.3 % 1.19 [ 0.72, 1.95 ]
Okuyemi 2013 20/216 12/214 0.7 % 1.65 [ 0.83, 3.29 ]
Otero 2006 68/204 57/189 3.3 % 1.11 [ 0.83, 1.48 ]
Prapavessis 2016 19/108 12/95 0.7 % 1.39 [ 0.71, 2.72 ]
Reid 1999 46/197 48/199 2.4 % 0.97 [ 0.68, 1.38 ]
Rohsenow 2014 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Schlam 2016 (3) 11/31 12/36 0.7 % 1.06 [ 0.55, 2.06 ]
Simon 2003 16/102 10/107 0.6 % 1.68 [ 0.80, 3.53 ]
Smith 2001 40/226 54/223 2.3 % 0.73 [ 0.51, 1.05 ]
Solomon 2000 21/106 16/108 0.9 % 1.34 [ 0.74, 2.42 ]
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Solomon 2005 49/171 31/159 2.0 % 1.47 [ 0.99, 2.18 ]
Stanton 2015 10/154 10/148 0.5 % 0.96 [ 0.41, 2.24 ]
Stein 2006 10/191 9/192 0.4 % 1.12 [ 0.46, 2.69 ]
Tonnesen 2006 13/90 13/95 0.6 % 1.06 [ 0.52, 2.15 ]
Vidrine 2016 (4) 24/155 6/51 0.5 % 1.32 [ 0.57, 3.04 ]
Vidrine 2016 (5) 20/154 6/52 0.5 % 1.13 [ 0.48, 2.65 ]
Wewers 2017 47/353 38/354 1.9 % 1.24 [ 0.83, 1.85 ]
Wiggers 2006 35/188 27/188 1.5 % 1.30 [ 0.82, 2.05 ]
Williams 2010 6/45 6/42 0.3 % 0.93 [ 0.33, 2.67 ]
Subtotal (95% CI) 8265 8276 63.8 % 1.12 [ 1.04, 1.21 ]
Total events: 1435 (More support), 1291 (Less support)
Heterogeneity: Tau2 = 0.01; Chi2 = 55.03, df = 49 (P = 0.26); I2 =11%
Test for overall effect: Z = 2.94 (P = 0.0032)
2 Bupropion
Gifford 2011 18/130 14/173 0.7 % 1.71 [ 0.88, 3.31 ]
Hall 2002 9/37 9/36 0.5 % 0.97 [ 0.44, 2.17 ]
McCarthy 2008 24/113 24/116 1.3 % 1.03 [ 0.62, 1.70 ]
Rovina 2009 24/75 28/94 1.5 % 1.07 [ 0.68, 1.69 ]
Swan 2003 247/765 187/759 7.9 % 1.31 [ 1.12, 1.54 ]
Subtotal (95% CI) 1120 1178 11.9 % 1.27 [ 1.10, 1.46 ]
Total events: 322 (More support), 262 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
3 Nortriptyline
Hall 1998 16/51 15/48 0.9 % 1.00 [ 0.56, 1.80 ]
Hall 2002 6/35 7/38 0.3 % 0.93 [ 0.35, 2.50 ]
Subtotal (95% CI) 86 86 1.3 % 0.98 [ 0.60, 1.63 ]
Total events: 22 (More support), 22 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
4 Varenicline
Swan 2010 121/399 110/401 5.3 % 1.11 [ 0.89, 1.37 ]
Van Rossem 2017 38/156 42/155 2.1 % 0.90 [ 0.62, 1.31 ]
Subtotal (95% CI) 555 556 7.4 % 1.05 [ 0.87, 1.27 ]
Total events: 159 (More support), 152 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.51 (P = 0.61)
5 NRT % bupropion
Brody 2017 5/15 2/14 0.2 % 2.33 [ 0.54, 10.14 ]
Hall 2009 85/201 66/195 4.2 % 1.25 [ 0.97, 1.61 ]
Killen 2008 37/147 32/147 1.8 % 1.16 [ 0.76, 1.75 ]
Subtotal (95% CI) 363 356 6.1 % 1.24 [ 1.00, 1.54 ]
Total events: 127 (More support), 100 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
6 Choice of pharmacotherapy
Boyle 2007 87/663 82/666 3.5 % 1.07 [ 0.80, 1.41 ]
Ellerbeck 2009 36/244 33/244 1.6 % 1.09 [ 0.70, 1.69 ]
Gariti 2009 17/128 7/132 0.5 % 2.50 [ 1.07, 5.84 ]
Vander Weg 2016 9/31 9/32 0.5 % 1.03 [ 0.47, 2.25 ]
Yalcin 2014 77/175 48/175 3.3 % 1.60 [ 1.20, 2.15 ]
Subtotal (95% CI) 1241 1249 9.5 % 1.30 [ 1.00, 1.68 ]
Total events: 226 (More support), 179 (Less support)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.13, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 1.94 (P = 0.053)
Total (95% CI) 11630 11701 100.0 % 1.15 [ 1.08, 1.22 ]
Total events: 2291 (More support), 2006 (Less support)
Heterogeneity: Tau2 = 0.00; Chi2 = 71.79, df = 66 (P = 0.29); I2 =8%
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.76, df = 5 (P = 0.45), I2 =0.0%
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(1) Intervention includes additional exercise support
(2) complete case only
(3) Combined arms with different lengths of NRT provision; complete case data only
(4) CBT arm, control group split
(5) Mindfulness group, control group split
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Analysis 1.2. Comparison 1 Effect of increasing behavioural support. Abstinence at longest follow-up,
Outcome 2 Subgroups by contrast in number of contacts between intervention & control.
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 1 Effect of increasing behavioural support. Abstinence at longest follow-up
Outcome: 2 Subgroups by contrast in number of contacts between intervention % control
Study or subgroup Less support More support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 4 to 8 or > 8 contacts versus no contact
Cook 2016 6/95 14/98 0.4 % 0.44 [ 0.18, 1.10 ]
Vander Weg 2016 9/31 9/32 0.6 % 1.03 [ 0.47, 2.25 ]
Solomon 2000 21/106 16/108 1.0 % 1.34 [ 0.74, 2.42 ]
Fiore 2004 29/274 25/273 1.4 % 1.16 [ 0.70, 1.92 ]
Ellerbeck 2009 36/244 33/244 1.8 % 1.09 [ 0.70, 1.69 ]
Solomon 2005 49/171 31/159 2.1 % 1.47 [ 0.99, 2.18 ]
Boyle 2007 87/663 82/666 3.6 % 1.07 [ 0.80, 1.41 ]
MacLeod 2003 110/412 82/442 4.3 % 1.44 [ 1.12, 1.85 ]
Subtotal (95% CI) 1996 2022 15.3 % 1.20 [ 1.02, 1.43 ]
Total events: 347 (Less support), 292 (More support)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.71, df = 7 (P = 0.27); I2 =20%
Test for overall effect: Z = 2.16 (P = 0.031)
2 More than 8 contacts versus 1 to 3 contacts
Humfleet 2013 10/69 14/82 0.7 % 0.85 [ 0.40, 1.79 ]
Gifford 2011 (1) 18/130 14/173 0.8 % 1.71 [ 0.88, 3.31 ]
Alterman 2001 26/80 20/80 1.4 % 1.30 [ 0.79, 2.13 ]
Smith 2001 40/226 54/223 2.4 % 0.73 [ 0.51, 1.05 ]
Subtotal (95% CI) 505 558 5.4 % 1.05 [ 0.70, 1.57 ]
Total events: 94 (Less support), 102 (More support)
Heterogeneity: Tau2 = 0.09; Chi2 = 6.62, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.23 (P = 0.82)
3 4 to 8 contacts versus 1 to 3 contacts
Stanton 2015 10/154 10/148 0.5 % 0.96 [ 0.41, 2.24 ]
Cropsey 2015 8/248 17/252 0.6 % 0.48 [ 0.21, 1.09 ]
Simon 2003 16/102 10/107 0.7 % 1.68 [ 0.80, 3.53 ]
Okuyemi 2013 20/216 12/214 0.8 % 1.65 [ 0.83, 3.29 ]
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Study or subgroup Less support More support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ginsberg 1992 11/33 14/35 0.9 % 0.83 [ 0.44, 1.57 ]
Lloyd-Richardson 2009 21/232 21/212 1.1 % 0.91 [ 0.51, 1.62 ]
Ockene 1991 48/263 18/117 1.4 % 1.19 [ 0.72, 1.95 ]
Lando 1997 21/162 46/347 1.5 % 0.98 [ 0.60, 1.58 ]
Rovina 2009 24/75 28/94 1.7 % 1.07 [ 0.68, 1.69 ]
Van Rossem 2017 38/156 42/155 2.3 % 0.90 [ 0.62, 1.31 ]
Jorenby 1995 43/167 44/169 2.5 % 0.99 [ 0.69, 1.42 ]
Bock 2014 48/406 58/440 2.5 % 0.90 [ 0.63, 1.28 ]
Reid 1999 46/197 48/199 2.6 % 0.97 [ 0.68, 1.38 ]
Otero 2006 68/204 57/189 3.5 % 1.11 [ 0.83, 1.48 ]
Berndt 2014 63/155 92/218 4.4 % 0.96 [ 0.75, 1.23 ]
Swan 2010 121/399 110/401 5.2 % 1.11 [ 0.89, 1.37 ]
Hollis 2007 153/721 148/868 5.7 % 1.24 [ 1.02, 1.53 ]
Swan 2003 247/765 187/759 7.3 % 1.31 [ 1.12, 1.54 ]
Subtotal (95% CI) 4655 4924 45.0 % 1.10 [ 1.01, 1.19 ]
Total events: 1006 (Less support), 962 (More support)
Heterogeneity: Tau2 = 0.00; Chi2 = 18.30, df = 17 (P = 0.37); I2 =7%
Test for overall effect: Z = 2.23 (P = 0.026)
4 More than 8 contacts versus 4 to 8 contacts
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Brown 2013 4/27 2/22 0.1 % 1.63 [ 0.33, 8.08 ]
Gariti 2009 17/128 7/132 0.5 % 2.50 [ 1.07, 5.84 ]
Schlam 2016 (2) 11/31 12/36 0.8 % 1.06 [ 0.55, 2.06 ]
Lifrak 1997 12/33 12/36 0.9 % 1.09 [ 0.57, 2.08 ]
Hall 2002 15/72 16/74 0.9 % 0.96 [ 0.52, 1.80 ]
Hall 1994 18/79 16/70 1.0 % 1.00 [ 0.55, 1.80 ]
Hall 1998 16/51 15/48 1.1 % 1.00 [ 0.56, 1.80 ]
Hall 1987 12/35 18/36 1.1 % 0.69 [ 0.39, 1.20 ]
Hall 1985 18/41 16/43 1.3 % 1.18 [ 0.70, 1.98 ]
Killen 2008 37/147 32/147 2.0 % 1.16 [ 0.76, 1.75 ]
Hall 2009 85/201 66/195 4.2 % 1.25 [ 0.97, 1.61 ]
Subtotal (95% CI) 871 866 14.1 % 1.15 [ 0.98, 1.33 ]
Total events: 251 (Less support), 213 (More support)
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Study or subgroup Less support More support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 10.62, df = 11 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.079)
5 Intervention % control in same contact category
Rohsenow 2014 (3) 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Brody 2017 5/15 2/14 0.2 % 2.33 [ 0.54, 10.14 ]
Kim 2015 7/14 3/16 0.3 % 2.67 [ 0.85, 8.39 ]
Bloom 2017 (4) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Williams 2010 (5) 6/45 6/42 0.3 % 0.93 [ 0.33, 2.67 ]
Bailey 2013 15/72 5/71 0.4 % 2.96 [ 1.14, 7.71 ]
Stein 2006 (6) 10/191 9/192 0.5 % 1.12 [ 0.46, 2.69 ]
Vidrine 2016 (7) 20/154 6/52 0.5 % 1.13 [ 0.48, 2.65 ]
Vidrine 2016 (8) 24/155 6/51 0.5 % 1.32 [ 0.57, 3.04 ]
Baker 2015 13/122 9/113 0.6 % 1.34 [ 0.59, 3.01 ]
Hasan 2014 13/40 7/41 0.6 % 1.90 [ 0.85, 4.27 ]
Tonnesen 2006 13/90 13/95 0.7 % 1.06 [ 0.52, 2.15 ]
Busch 2017 (9) 11/31 11/33 0.8 % 1.06 [ 0.54, 2.09 ]
Prapavessis 2016 19/108 12/95 0.8 % 1.39 [ 0.71, 2.72 ]
Huber 2003 (10) 13/55 15/57 0.9 % 0.90 [ 0.47, 1.71 ]
Bushnell 1997 (11) 22/171 17/143 1.0 % 1.08 [ 0.60, 1.96 ]
McCarthy 2008 (12) 24/113 24/116 1.4 % 1.03 [ 0.62, 1.70 ]
Aveyard 2007 (13) 30/456 36/469 1.6 % 0.86 [ 0.54, 1.37 ]
Wiggers 2006 (14) 35/188 27/188 1.6 % 1.30 [ 0.82, 2.05 ]
Calabro 2012 (15) 55/278 24/231 1.7 % 1.90 [ 1.22, 2.98 ]
Wewers 2017 47/353 38/354 2.1 % 1.24 [ 0.83, 1.85 ]
Yalcin 2014 (16) 77/175 48/175 3.4 % 1.60 [ 1.20, 2.15 ]
Subtotal (95% CI) 2936 2664 20.3 % 1.32 [ 1.16, 1.50 ]
Total events: 467 (Less support), 325 (More support)
Heterogeneity: Tau2 = 0.0; Chi2 = 20.18, df = 21 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 4.19 (P = 0.000029)
Total (95% CI) 10963 11034 100.0 % 1.15 [ 1.08, 1.22 ]
Total events: 2165 (Less support), 1894 (More support)
Heterogeneity: Tau2 = 0.01; Chi2 = 71.66, df = 63 (P = 0.21); I2 =12%
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Chi2 = 5.89, df = 4 (P = 0.21), I2 =32%
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(1) counselling = 1 hour of medication instruction group presenting the rationale for bupropion
(2) Combined arms with different lengths of NRT provision; complete case data only
(3) Longer duration category for intervention group
(4) Intervention includes additional exercise support
(5) Longer sessions for intervention
(6) Longer duration category for intervention group
(7) Mindfulness group, control group split
(8) CBT arm, control group split
(9) complete case only
(10) Longer sessions for intervention
(11) 8 sessions vs 4 sessions
(12) Longer duration category for intervention group
(13) Longer duration category for intervention group
(14) Longer duration category for intervention group
(15) Longer duration category for intervention group
(16) 24 vs 9 sessions
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Analysis 1.3. Comparison 1 Effect of increasing behavioural support. Abstinence at longest follow-up,
Outcome 3 Subgroups by duration of contact in control condition (not prespecified).
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 1 Effect of increasing behavioural support. Abstinence at longest follow-up
Outcome: 3 Subgroups by duration of contact in control condition (not prespecified)
Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 No contact for control
Cook 2016 6/95 14/98 0.5 % 0.44 [ 0.18, 1.10 ]
Vander Weg 2016 9/31 9/32 0.6 % 1.03 [ 0.47, 2.25 ]
Solomon 2000 (1) 21/106 16/108 1.0 % 1.34 [ 0.74, 2.42 ]
Fiore 2004 (2) 29/274 25/273 1.4 % 1.16 [ 0.70, 1.92 ]
Ellerbeck 2009 (3) 36/244 33/244 1.8 % 1.09 [ 0.70, 1.69 ]
Solomon 2005 (4) 49/171 31/159 2.1 % 1.47 [ 0.99, 2.18 ]
Boyle 2007 (5) 87/663 82/666 3.6 % 1.07 [ 0.80, 1.41 ]
MacLeod 2003 (6) 110/412 82/442 4.3 % 1.44 [ 1.12, 1.85 ]
Subtotal (95% CI) 1996 2022 15.3 % 1.20 [ 1.02, 1.43 ]
Total events: 347 (More support), 292 (Less support)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.71, df = 7 (P = 0.27); I2 =20%
Test for overall effect: Z = 2.16 (P = 0.031)
2 ’Brief intervention’ for control
Rohsenow 2014 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Stein 2006 10/191 9/192 0.5 % 1.12 [ 0.46, 2.69 ]
Cropsey 2015 8/248 17/252 0.6 % 0.48 [ 0.21, 1.09 ]
Humfleet 2013 10/69 14/82 0.7 % 0.85 [ 0.40, 1.79 ]
Simon 2003 16/102 10/107 0.7 % 1.68 [ 0.80, 3.53 ]
Okuyemi 2013 20/216 12/214 0.8 % 1.65 [ 0.83, 3.29 ]
Ginsberg 1992 11/33 14/35 0.9 % 0.83 [ 0.44, 1.57 ]
Lloyd-Richardson 2009 21/232 21/212 1.1 % 0.91 [ 0.51, 1.62 ]
Ockene 1991 48/263 18/117 1.4 % 1.19 [ 0.72, 1.95 ]
Alterman 2001 26/80 20/80 1.5 % 1.30 [ 0.79, 2.13 ]
Wiggers 2006 35/188 27/188 1.7 % 1.30 [ 0.82, 2.05 ]
Rovina 2009 24/75 28/94 1.7 % 1.07 [ 0.68, 1.69 ]
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Calabro 2012 55/278 24/231 1.7 % 1.90 [ 1.22, 2.98 ]
Van Rossem 2017 38/156 42/155 2.3 % 0.90 [ 0.62, 1.31 ]
Smith 2001 40/226 54/223 2.4 % 0.73 [ 0.51, 1.05 ]
Jorenby 1995 43/167 44/169 2.5 % 0.99 [ 0.69, 1.42 ]
Bock 2014 48/406 58/440 2.5 % 0.90 [ 0.63, 1.28 ]
Otero 2006 68/204 57/189 3.5 % 1.11 [ 0.83, 1.48 ]
Berndt 2014 63/155 92/218 4.4 % 0.96 [ 0.75, 1.23 ]
Swan 2010 121/399 110/401 5.2 % 1.11 [ 0.89, 1.37 ]
Hollis 2007 153/721 148/868 5.6 % 1.24 [ 1.02, 1.53 ]
Swan 2003 247/765 187/759 7.1 % 1.31 [ 1.12, 1.54 ]
Subtotal (95% CI) 5254 5311 48.8 % 1.09 [ 0.99, 1.21 ]
Total events: 1105 (More support), 1009 (Less support)
Heterogeneity: Tau2 = 0.02; Chi2 = 30.99, df = 21 (P = 0.07); I2 =32%
Test for overall effect: Z = 1.72 (P = 0.085)
3 ’Dose response’, over 30 minutes contact for control
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Brown 2013 4/27 2/22 0.2 % 1.63 [ 0.33, 8.08 ]
Brody 2017 5/15 2/14 0.2 % 2.33 [ 0.54, 10.14 ]
Kim 2015 7/14 3/16 0.3 % 2.67 [ 0.85, 8.39 ]
Bloom 2017 (7) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Williams 2010 6/45 6/42 0.4 % 0.93 [ 0.33, 2.67 ]
Bailey 2013 15/72 5/71 0.4 % 2.96 [ 1.14, 7.71 ]
Vidrine 2016 (8) 20/154 6/52 0.5 % 1.13 [ 0.48, 2.65 ]
Gariti 2009 17/128 7/132 0.5 % 2.50 [ 1.07, 5.84 ]
Vidrine 2016 (9) 24/155 6/51 0.5 % 1.32 [ 0.57, 3.04 ]
Baker 2015 13/122 9/113 0.6 % 1.34 [ 0.59, 3.01 ]
Hasan 2014 13/40 7/41 0.6 % 1.90 [ 0.85, 4.27 ]
Tonnesen 2006 13/90 13/95 0.7 % 1.06 [ 0.52, 2.15 ]
Busch 2017 (10) 11/31 11/33 0.8 % 1.06 [ 0.54, 2.09 ]
Prapavessis 2016 19/108 12/95 0.8 % 1.39 [ 0.71, 2.72 ]
Schlam 2016 (11) 11/31 12/36 0.8 % 1.06 [ 0.55, 2.06 ]
Gifford 2011 18/130 14/173 0.9 % 1.71 [ 0.88, 3.31 ]
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lifrak 1997 12/33 12/36 0.9 % 1.09 [ 0.57, 2.08 ]
Huber 2003 13/55 15/57 0.9 % 0.90 [ 0.47, 1.71 ]
Hall 2002 15/72 16/74 0.9 % 0.96 [ 0.52, 1.80 ]
Bushnell 1997 22/171 17/143 1.0 % 1.08 [ 0.60, 1.96 ]
Hall 1994 18/79 16/70 1.0 % 1.00 [ 0.55, 1.80 ]
Hall 1998 16/51 15/48 1.1 % 1.00 [ 0.56, 1.80 ]
Hall 1987 12/35 18/36 1.1 % 0.69 [ 0.39, 1.20 ]
Hall 1985 18/41 16/43 1.3 % 1.18 [ 0.70, 1.98 ]
McCarthy 2008 24/113 24/116 1.4 % 1.03 [ 0.62, 1.70 ]
Lando 1997 21/162 46/347 1.5 % 0.98 [ 0.60, 1.58 ]
Aveyard 2007 30/456 36/469 1.6 % 0.86 [ 0.54, 1.37 ]
Killen 2008 37/147 32/147 2.0 % 1.16 [ 0.76, 1.75 ]
Wewers 2017 47/353 38/354 2.1 % 1.24 [ 0.83, 1.85 ]
Reid 1999 46/197 48/199 2.6 % 0.97 [ 0.68, 1.38 ]
Yalcin 2014 77/175 48/175 3.4 % 1.60 [ 1.20, 2.15 ]
Hall 2009 85/201 66/195 4.2 % 1.25 [ 0.97, 1.61 ]
Subtotal (95% CI) 3559 3553 35.8 % 1.19 [ 1.08, 1.32 ]
Total events: 703 (More support), 583 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 30.24, df = 32 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.58 (P = 0.00034)
Total (95% CI) 10809 10886 100.0 % 1.15 [ 1.08, 1.22 ]
Total events: 2155 (More support), 1884 (Less support)
Heterogeneity: Tau2 = 0.01; Chi2 = 71.48, df = 62 (P = 0.19); I2 =13%
Test for overall effect: Z = 4.34 (P = 0.000015)
Test for subgroup differences: Chi2 = 1.77, df = 2 (P = 0.41), I2 =0.0%
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(1) No contact for control
(2) No advice or counselling for control, but contact with study staff
(3) No contact for control
(4) No contact for control
(5) No contact for control
(6) No contact for control
(7) Intervention includes additional exercise support
(8) Mindfulness group, control group split
(9) CBT arm, control group split
(10) complete case only
(11) Combined arms with different lengths of NRT provision; complete case data only
Analysis 1.4. Comparison 1 Effect of increasing behavioural support. Abstinence at longest follow-up,
Outcome 4 Subgroup by modality of intervention contact (not prespecified).
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 1 Effect of increasing behavioural support. Abstinence at longest follow-up
Outcome: 4 Subgroup by modality of intervention contact (not prespecified)
Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intervention delivered by telephone
Ferguson 2012 121/648 108/648 4.6 % 1.12 [ 0.89, 1.42 ]
Hollis 2007 153/721 148/868 5.7 % 1.24 [ 1.02, 1.53 ]
MacLeod 2003 (1) 110/412 82/442 4.2 % 1.44 [ 1.12, 1.85 ]
Solomon 2000 (2) 21/106 16/108 0.9 % 1.34 [ 0.74, 2.42 ]
Solomon 2005 (3) 49/171 31/159 2.0 % 1.47 [ 0.99, 2.18 ]
Swan 2003 247/765 187/759 7.6 % 1.31 [ 1.12, 1.54 ]
Swan 2010 121/399 110/401 5.2 % 1.11 [ 0.89, 1.37 ]
Vander Weg 2016 9/31 9/32 0.6 % 1.03 [ 0.47, 2.25 ]
0.5 0.7 1 1.5 2
Favours less support Favours more support
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 3253 3417 30.7 % 1.25 [ 1.15, 1.37 ]
Total events: 831 (More support), 691 (Less support)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.50, df = 7 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
2 Intervention included face-to-face contact
Aimer 2017 5/19 4/19 0.3 % 1.25 [ 0.40, 3.95 ]
Alterman 2001 26/80 20/80 1.3 % 1.30 [ 0.79, 2.13 ]
Aveyard 2007 30/456 36/469 1.5 % 0.86 [ 0.54, 1.37 ]
Bailey 2013 15/72 5/71 0.4 % 2.96 [ 1.14, 7.71 ]
Baker 2015 13/122 9/113 0.5 % 1.34 [ 0.59, 3.01 ]
Berndt 2014 63/155 92/218 4.3 % 0.96 [ 0.75, 1.23 ]
Bloom 2017 (4) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Bock 2014 48/406 58/440 2.4 % 0.90 [ 0.63, 1.28 ]
Boyle 2007 (5) 87/663 82/666 3.5 % 1.07 [ 0.80, 1.41 ]
Brody 2017 5/15 2/14 0.2 % 2.33 [ 0.54, 10.14 ]
Brown 2013 4/27 2/22 0.1 % 1.63 [ 0.33, 8.08 ]
Busch 2017 (6) 11/31 11/33 0.7 % 1.06 [ 0.54, 2.09 ]
Bushnell 1997 22/171 17/143 0.9 % 1.08 [ 0.60, 1.96 ]
Calabro 2012 55/278 24/231 1.6 % 1.90 [ 1.22, 2.98 ]
Cook 2016 6/95 14/98 0.4 % 0.44 [ 0.18, 1.10 ]
Cropsey 2015 8/248 17/252 0.5 % 0.48 [ 0.21, 1.09 ]
Ellerbeck 2009 (7) 36/244 33/244 1.6 % 1.09 [ 0.70, 1.69 ]
Fiore 2004 (8) 29/274 25/273 1.3 % 1.16 [ 0.70, 1.92 ]
Gariti 2009 17/128 7/132 0.5 % 2.50 [ 1.07, 5.84 ]
Gifford 2011 18/130 14/173 0.8 % 1.71 [ 0.88, 3.31 ]
Ginsberg 1992 11/33 14/35 0.8 % 0.83 [ 0.44, 1.57 ]
Hall 1985 18/41 16/43 1.2 % 1.18 [ 0.70, 1.98 ]
Hall 1987 12/35 18/36 1.0 % 0.69 [ 0.39, 1.20 ]
Hall 1994 18/79 16/70 0.9 % 1.00 [ 0.55, 1.80 ]
Hall 1998 16/51 15/48 1.0 % 1.00 [ 0.56, 1.80 ]
Hall 2002 15/72 16/74 0.8 % 0.96 [ 0.52, 1.80 ]
Hall 2009 85/201 66/195 4.1 % 1.25 [ 0.97, 1.61 ]
0.5 0.7 1 1.5 2
Favours less support Favours more support
(Continued . . . )
153Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hasan 2014 13/40 7/41 0.5 % 1.90 [ 0.85, 4.27 ]
Huber 2003 13/55 15/57 0.8 % 0.90 [ 0.47, 1.71 ]
Humfleet 2013 10/69 14/82 0.6 % 0.85 [ 0.40, 1.79 ]
Jorenby 1995 43/167 44/169 2.3 % 0.99 [ 0.69, 1.42 ]
Killen 2008 37/147 32/147 1.8 % 1.16 [ 0.76, 1.75 ]
Kim 2015 7/14 3/16 0.3 % 2.67 [ 0.85, 8.39 ]
Lando 1997 21/162 46/347 1.4 % 0.98 [ 0.60, 1.58 ]
Lifrak 1997 12/33 12/36 0.8 % 1.09 [ 0.57, 2.08 ]
Lloyd-Richardson 2009 21/232 21/212 1.0 % 0.91 [ 0.51, 1.62 ]
McCarthy 2008 24/113 24/116 1.3 % 1.03 [ 0.62, 1.70 ]
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Ockene 1991 48/263 18/117 1.3 % 1.19 [ 0.72, 1.95 ]
Okuyemi 2013 20/216 12/214 0.7 % 1.65 [ 0.83, 3.29 ]
Otero 2006 68/204 57/189 3.3 % 1.11 [ 0.83, 1.48 ]
Prapavessis 2016 19/108 12/95 0.7 % 1.39 [ 0.71, 2.72 ]
Reid 1999 46/197 48/199 2.4 % 0.97 [ 0.68, 1.38 ]
Rohsenow 2014 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Rovina 2009 24/75 28/94 1.5 % 1.07 [ 0.68, 1.69 ]
Schlam 2016 (9) 11/31 12/36 0.8 % 1.06 [ 0.55, 2.06 ]
Simon 2003 16/102 10/107 0.6 % 1.68 [ 0.80, 3.53 ]
Smith 2001 40/226 54/223 2.3 % 0.73 [ 0.51, 1.05 ]
Stanton 2015 10/154 10/148 0.5 % 0.96 [ 0.41, 2.24 ]
Stein 2006 10/191 9/192 0.4 % 1.12 [ 0.46, 2.69 ]
Tonnesen 2006 13/90 13/95 0.7 % 1.06 [ 0.52, 2.15 ]
Van Rossem 2017 38/156 42/155 2.1 % 0.90 [ 0.62, 1.31 ]
Vidrine 2016 (10) 24/155 6/51 0.5 % 1.32 [ 0.57, 3.04 ]
Vidrine 2016 (11) 20/154 6/52 0.5 % 1.13 [ 0.48, 2.65 ]
Wewers 2017 47/353 38/354 1.9 % 1.24 [ 0.83, 1.85 ]
Wiggers 2006 35/188 27/188 1.5 % 1.30 [ 0.82, 2.05 ]
Williams 2010 6/45 6/42 0.3 % 0.93 [ 0.33, 2.67 ]
Yalcin 2014 77/175 48/175 3.3 % 1.60 [ 1.20, 2.15 ]
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Study or subgroup More support Less support Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 8377 8284 69.3 % 1.11 [ 1.03, 1.19 ]
Total events: 1460 (More support), 1315 (Less support)
Heterogeneity: Tau2 = 0.01; Chi2 = 62.34, df = 57 (P = 0.29); I2 =9%
Test for overall effect: Z = 2.77 (P = 0.0057)
Total (95% CI) 11630 11701 100.0 % 1.15 [ 1.08, 1.22 ]
Total events: 2291 (More support), 2006 (Less support)
Heterogeneity: Tau2 = 0.01; Chi2 = 71.75, df = 65 (P = 0.26); I2 =9%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.55, df = 1 (P = 0.03), I2 =78%
0.5 0.7 1 1.5 2
Favours less support Favours more support
(1) Control group received pharmacotherapy by mail
(2) Control group received pharmacotherapy by mail
(3) Control group received pharmacotherapy by mail
(4) Intervention includes additional exercise support
(5) Control group had no face to face contact
(6) complete case only
(7) Control group had no face to face contact
(8) Control group had brief contact with study staff
(9) Combined arms with different lengths of NRT provision; complete case data only
(10) CBT arm, control group split
(11) Mindfulness group, control group split
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Analysis 2.1. Comparison 2 Effect of increasing behavioural support: Sensitivity analyses, Outcome 1
Sensitivity analysis including intermediate intensity conditions. Adjunct behavioural support versus
pharmacotherapy alone.
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 2 Effect of increasing behavioural support: Sensitivity analyses
Outcome: 1 Sensitivity analysis including intermediate intensity conditions. Adjunct behavioural support versus pharmacotherapy alone
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 NRT
Aimer 2017 5/19 4/19 0.2 % 1.25 [ 0.40, 3.95 ]
Alterman 2001 35/160 20/80 1.2 % 0.88 [ 0.54, 1.41 ]
Aveyard 2007 30/456 36/469 1.3 % 0.86 [ 0.54, 1.37 ]
Bailey 2013 15/72 5/71 0.3 % 2.96 [ 1.14, 7.71 ]
Baker 2015 13/122 9/113 0.5 % 1.34 [ 0.59, 3.01 ]
Berndt 2014 63/155 92/218 4.0 % 0.96 [ 0.75, 1.23 ]
Bloom 2017 (1) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Bock 2014 48/406 58/440 2.1 % 0.90 [ 0.63, 1.28 ]
Brown 2013 4/27 2/22 0.1 % 1.63 [ 0.33, 8.08 ]
Busch 2017 (2) 11/31 11/33 0.6 % 1.06 [ 0.54, 2.09 ]
Bushnell 1997 22/171 17/143 0.8 % 1.08 [ 0.60, 1.96 ]
Calabro 2012 55/278 24/231 1.4 % 1.90 [ 1.22, 2.98 ]
Cook 2016 26/298 14/98 0.8 % 0.61 [ 0.33, 1.12 ]
Cropsey 2015 8/248 17/252 0.4 % 0.48 [ 0.21, 1.09 ]
Ferguson 2012 121/648 108/648 4.3 % 1.12 [ 0.89, 1.42 ]
Fiore 2004 50/537 25/273 1.4 % 1.02 [ 0.64, 1.61 ]
Ginsberg 1992 11/33 14/35 0.7 % 0.83 [ 0.44, 1.57 ]
Hall 1985 18/41 16/43 1.1 % 1.18 [ 0.70, 1.98 ]
Hall 1987 12/35 18/36 0.9 % 0.69 [ 0.39, 1.20 ]
Hall 1994 18/79 16/70 0.8 % 1.00 [ 0.55, 1.80 ]
Hasan 2014 13/40 7/41 0.5 % 1.90 [ 0.85, 4.27 ]
Hollis 2007 297/1436 148/868 6.4 % 1.21 [ 1.01, 1.45 ]
Huber 2003 13/55 15/57 0.7 % 0.90 [ 0.47, 1.71 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Humfleet 2013 21/127 14/82 0.8 % 0.97 [ 0.52, 1.79 ]
Jorenby 1995 96/335 44/169 2.8 % 1.10 [ 0.81, 1.49 ]
Kim 2015 7/14 3/16 0.2 % 2.67 [ 0.85, 8.39 ]
Lando 1997 21/162 46/347 1.2 % 0.98 [ 0.60, 1.58 ]
Lifrak 1997 12/33 12/36 0.7 % 1.09 [ 0.57, 2.08 ]
Lloyd-Richardson 2009 21/232 21/212 0.9 % 0.91 [ 0.51, 1.62 ]
MacLeod 2003 110/412 82/442 3.8 % 1.44 [ 1.12, 1.85 ]
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Ockene 1991 48/263 18/117 1.2 % 1.19 [ 0.72, 1.95 ]
Okuyemi 2013 20/216 12/214 0.6 % 1.65 [ 0.83, 3.29 ]
Otero 2006 136/408 57/189 3.7 % 1.11 [ 0.86, 1.43 ]
Prapavessis 2016 (3) 46/314 12/95 0.8 % 1.16 [ 0.64, 2.10 ]
Reid 1999 46/197 48/199 2.2 % 0.97 [ 0.68, 1.38 ]
Rohsenow 2014 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Schlam 2016 (4) 11/31 12/36 0.7 % 1.06 [ 0.55, 2.06 ]
Simon 2003 16/102 10/107 0.5 % 1.68 [ 0.80, 3.53 ]
Smith 2001 83/454 54/223 2.8 % 0.75 [ 0.56, 1.02 ]
Solomon 2000 21/106 16/108 0.8 % 1.34 [ 0.74, 2.42 ]
Solomon 2005 49/171 31/159 1.8 % 1.47 [ 0.99, 2.18 ]
Stanton 2015 10/154 10/148 0.4 % 0.96 [ 0.41, 2.24 ]
Stein 2006 10/191 9/192 0.4 % 1.12 [ 0.46, 2.69 ]
Tonnesen 2006 13/90 13/95 0.6 % 1.06 [ 0.52, 2.15 ]
Vidrine 2016 (5) 24/155 6/51 0.4 % 1.32 [ 0.57, 3.04 ]
Vidrine 2016 (6) 20/154 6/52 0.4 % 1.13 [ 0.48, 2.65 ]
Wewers 2017 47/353 38/354 1.7 % 1.24 [ 0.83, 1.85 ]
Wiggers 2006 35/188 27/188 1.4 % 1.30 [ 0.82, 2.05 ]
Williams 2010 6/45 6/42 0.3 % 0.93 [ 0.33, 2.67 ]
Subtotal (95% CI) 10390 8276 62.4 % 1.10 [ 1.03, 1.19 ]
Total events: 1831 (Experimental), 1291 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 55.46, df = 49 (P = 0.24); I2 =12%
Test for overall effect: Z = 2.62 (P = 0.0087)
2 Bupropion
0.2 0.5 1 2 5
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gifford 2011 18/130 14/173 0.7 % 1.71 [ 0.88, 3.31 ]
Hall 2002 9/37 9/36 0.5 % 0.97 [ 0.44, 2.17 ]
McCarthy 2008 24/113 24/116 1.1 % 1.03 [ 0.62, 1.70 ]
Rovina 2009 24/75 28/94 1.4 % 1.07 [ 0.68, 1.69 ]
Swan 2003 247/765 187/759 7.2 % 1.31 [ 1.12, 1.54 ]
Subtotal (95% CI) 1120 1178 10.9 % 1.27 [ 1.10, 1.46 ]
Total events: 322 (Experimental), 262 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
3 Nortriptyline
Hall 1998 16/51 15/48 0.9 % 1.00 [ 0.56, 1.80 ]
Hall 2002 6/35 7/38 0.3 % 0.93 [ 0.35, 2.50 ]
Subtotal (95% CI) 86 86 1.2 % 0.98 [ 0.60, 1.63 ]
Total events: 22 (Experimental), 22 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
4 Varenicline
Swan 2010 244/801 110/401 5.8 % 1.11 [ 0.92, 1.34 ]
Van Rossem 2017 38/156 42/155 1.9 % 0.90 [ 0.62, 1.31 ]
Subtotal (95% CI) 957 556 7.8 % 1.06 [ 0.90, 1.26 ]
Total events: 282 (Experimental), 152 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.47)
5 NRT % bupropion
Brody 2017 5/15 2/14 0.1 % 2.33 [ 0.54, 10.14 ]
Hall 2009 85/201 66/195 3.8 % 1.25 [ 0.97, 1.61 ]
Killen 2008 37/147 32/147 1.6 % 1.16 [ 0.76, 1.75 ]
Subtotal (95% CI) 363 356 5.6 % 1.24 [ 1.00, 1.54 ]
Total events: 127 (Experimental), 100 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
6 Choice of pharmacotherapy
Boyle 2007 87/663 82/666 3.2 % 1.07 [ 0.80, 1.41 ]
Boyle 2007 87/663 82/666 3.2 % 1.07 [ 0.80, 1.41 ]
Ellerbeck 2009 71/482 33/244 1.9 % 1.09 [ 0.74, 1.60 ]
Gariti 2009 17/128 7/132 0.4 % 2.50 [ 1.07, 5.84 ]
Vander Weg 2016 9/31 9/32 0.5 % 1.03 [ 0.47, 2.25 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yalcin 2014 77/175 48/175 3.0 % 1.60 [ 1.20, 2.15 ]
Subtotal (95% CI) 2142 1915 12.2 % 1.23 [ 1.00, 1.51 ]
Total events: 348 (Experimental), 261 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 8.42, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.96 (P = 0.050)
Total (95% CI) 15058 12367 100.0 % 1.13 [ 1.07, 1.20 ]
Total events: 2932 (Experimental), 2088 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 73.31, df = 67 (P = 0.28); I2 =9%
Test for overall effect: Z = 4.46 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.95, df = 5 (P = 0.42), I2 =0.0%
0.2 0.5 1 2 5
Favours control Favours experimental
(1) Intervention includes additional exercise support
(2) complete case only
(3) Intervention combines exercise and smoking cessation conditions
(4) Combined arms with different lengths of NRT provision; complete case data only
(5) CBT arm, control group split
(6) Mindfulness group, control group split
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Analysis 2.2. Comparison 2 Effect of increasing behavioural support: Sensitivity analyses, Outcome 2 By
outcome definition.
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 2 Effect of increasing behavioural support: Sensitivity analyses
Outcome: 2 By outcome definition
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 12 months validation PP outcomes only
Alterman 2001 26/80 20/80 1.3 % 1.30 [ 0.79, 2.13 ]
Bock 2014 48/406 58/440 2.4 % 0.90 [ 0.63, 1.28 ]
Calabro 2012 (1) 55/278 24/231 1.6 % 1.90 [ 1.22, 2.98 ]
Cropsey 2015 (2) 8/248 17/252 0.5 % 0.48 [ 0.21, 1.09 ]
Gifford 2011 18/130 14/173 0.8 % 1.71 [ 0.88, 3.31 ]
Ginsberg 1992 11/33 14/35 0.8 % 0.83 [ 0.44, 1.57 ]
Hall 1985 18/41 16/43 1.2 % 1.18 [ 0.70, 1.98 ]
Hall 1987 12/35 18/36 1.0 % 0.69 [ 0.39, 1.20 ]
Hall 1998 16/51 15/48 1.0 % 1.00 [ 0.56, 1.80 ]
Hall 2002 15/72 16/74 0.9 % 0.96 [ 0.52, 1.80 ]
Huber 2003 13/55 15/57 0.8 % 0.90 [ 0.47, 1.71 ]
Humfleet 2013 21/127 16/82 1.0 % 0.85 [ 0.47, 1.53 ]
Killen 2008 37/147 32/147 1.8 % 1.16 [ 0.76, 1.75 ]
Lando 1997 21/162 46/347 1.4 % 0.98 [ 0.60, 1.58 ]
McCarthy 2008 24/113 24/116 1.3 % 1.03 [ 0.62, 1.70 ]
Reid 1999 46/197 48/199 2.4 % 0.97 [ 0.68, 1.38 ]
Rohsenow 2014 0/80 3/85 0.0 % 0.15 [ 0.01, 2.89 ]
Simon 2003 16/102 10/107 0.6 % 1.68 [ 0.80, 3.53 ]
Smith 2001 40/226 54/223 2.3 % 0.73 [ 0.51, 1.05 ]
Stanton 2015 10/154 10/148 0.5 % 0.96 [ 0.41, 2.24 ]
Wiggers 2006 35/188 27/188 1.5 % 1.30 [ 0.82, 2.05 ]
Subtotal (95% CI) 2925 3111 25.0 % 1.03 [ 0.90, 1.17 ]
Total events: 490 (Experimental), 497 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 25.80, df = 20 (P = 0.17); I2 =22%
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.39 (P = 0.69)
2 12 months validated sustained outcomes
Aveyard 2007 30/456 36/469 1.5 % 0.86 [ 0.54, 1.37 ]
Bloom 2017 (3) 8/30 4/31 0.3 % 2.07 [ 0.69, 6.15 ]
Fiore 2004 29/274 25/273 1.3 % 1.16 [ 0.70, 1.92 ]
Gariti 2009 17/128 7/132 0.5 % 2.50 [ 1.07, 5.84 ]
Hall 1994 18/79 16/70 0.9 % 1.00 [ 0.55, 1.80 ]
Prapavessis 2016 19/108 12/95 0.8 % 1.39 [ 0.71, 2.72 ]
Rovina 2009 24/75 28/94 1.5 % 1.07 [ 0.68, 1.69 ]
Tonnesen 2006 13/90 13/95 0.7 % 1.06 [ 0.52, 2.15 ]
Van Rossem 2017 38/156 42/155 2.1 % 0.90 [ 0.62, 1.31 ]
Wewers 2017 47/353 38/354 1.9 % 1.24 [ 0.83, 1.85 ]
Williams 2010 6/45 6/42 0.3 % 0.93 [ 0.33, 2.67 ]
Subtotal (95% CI) 1794 1810 11.8 % 1.10 [ 0.93, 1.30 ]
Total events: 249 (Experimental), 227 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.21, df = 10 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
3 < 12 months, but validated
Bailey 2013 15/72 5/71 0.4 % 2.96 [ 1.14, 7.71 ]
Brody 2017 5/15 2/14 0.2 % 2.33 [ 0.54, 10.14 ]
Brown 2013 4/27 2/22 0.1 % 1.63 [ 0.33, 8.08 ]
Busch 2017 (4) 11/31 11/33 0.7 % 1.06 [ 0.54, 2.09 ]
Bushnell 1997 22/171 17/143 0.9 % 1.08 [ 0.60, 1.96 ]
Ellerbeck 2009 36/244 33/244 1.6 % 1.09 [ 0.70, 1.69 ]
Ferguson 2012 (5) 121/648 108/648 4.6 % 1.12 [ 0.89, 1.42 ]
Hall 2009 85/201 66/195 4.1 % 1.25 [ 0.97, 1.61 ]
Hasan 2014 13/40 7/41 0.5 % 1.90 [ 0.85, 4.27 ]
Jorenby 1995 43/167 44/169 2.3 % 0.99 [ 0.69, 1.42 ]
Kim 2015 7/14 3/16 0.3 % 2.67 [ 0.85, 8.39 ]
Lifrak 1997 12/33 12/36 0.8 % 1.09 [ 0.57, 2.08 ]
Lloyd-Richardson 2009 21/232 21/212 1.0 % 0.91 [ 0.51, 1.62 ]
O’Cleirigh 2018 6/26 1/27 0.1 % 6.23 [ 0.80, 48.27 ]
Okuyemi 2013 20/216 12/214 0.7 % 1.65 [ 0.83, 3.29 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Solomon 2000 21/106 16/108 0.9 % 1.34 [ 0.74, 2.42 ]
Stein 2006 10/191 9/192 0.4 % 1.12 [ 0.46, 2.69 ]
Vidrine 2016 (6) 24/155 6/51 0.5 % 1.32 [ 0.57, 3.04 ]
Vidrine 2016 (7) 20/154 6/52 0.5 % 1.13 [ 0.48, 2.65 ]
Yalcin 2014 77/175 48/175 3.3 % 1.60 [ 1.20, 2.15 ]
Subtotal (95% CI) 2918 2663 24.0 % 1.25 [ 1.12, 1.39 ]
Total events: 573 (Experimental), 429 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.15, df = 19 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
4 No validation at all
Aimer 2017 5/19 4/19 0.3 % 1.25 [ 0.40, 3.95 ]
Berndt 2014 63/155 92/218 4.3 % 0.96 [ 0.75, 1.23 ]
Boyle 2007 87/663 82/666 3.5 % 1.07 [ 0.80, 1.41 ]
Cook 2016 6/95 14/98 0.4 % 0.44 [ 0.18, 1.10 ]
Hollis 2007 153/721 148/868 5.6 % 1.24 [ 1.02, 1.53 ]
MacLeod 2003 110/412 82/442 4.1 % 1.44 [ 1.12, 1.85 ]
Ockene 1991 48/263 18/117 1.3 % 1.19 [ 0.72, 1.95 ]
Otero 2006 68/204 57/189 3.3 % 1.11 [ 0.83, 1.48 ]
Schlam 2016 (8) 11/31 12/36 0.8 % 1.06 [ 0.55, 2.06 ]
Solomon 2005 49/171 31/159 2.0 % 1.47 [ 0.99, 2.18 ]
Swan 2003 247/765 187/759 7.5 % 1.31 [ 1.12, 1.54 ]
Swan 2010 121/399 110/401 5.1 % 1.11 [ 0.89, 1.37 ]
Vander Weg 2016 9/31 9/32 0.6 % 1.03 [ 0.47, 2.25 ]
Subtotal (95% CI) 3929 4004 38.8 % 1.18 [ 1.08, 1.30 ]
Total events: 977 (Experimental), 846 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.72, df = 12 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.69 (P = 0.00022)
5 > 12 months validation PP outcomes only
Baker 2015 13/122 9/113 0.5 % 1.34 [ 0.59, 3.01 ]
Subtotal (95% CI) 122 113 0.5 % 1.34 [ 0.59, 3.01 ]
Total events: 13 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 11688 11701 100.0 % 1.15 [ 1.08, 1.22 ]
Total events: 2302 (Experimental), 2008 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 72.17, df = 65 (P = 0.25); I2 =10%
0.2 0.5 1 2 5
Favours control Favours experimental
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 4.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.70, df = 4 (P = 0.22), I2 =30%
0.2 0.5 1 2 5
Favours control Favours experimental
(1) Not all of the participants that self reported quitting could be validated due to problems with sample collection
(2) did not specify whether PP or continuous, so assuming PP for this analysis
(3) Intervention includes additional exercise support
(4) complete case only
(5) only subset of participants were validated
(6) CBT arm, control group split
(7) Mindfulness group, control group split
(8) Combined arms with different lengths of NRT provision; complete case data only
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Analysis 3.1. Comparison 3 Studies matched for contact time. Abstinence at longest follow-up point,
Outcome 1 Abstinence at longest follow-up.
Review: Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Comparison: 3 Studies matched for contact time. Abstinence at longest follow-up point
Outcome: 1 Abstinence at longest follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Family support versus usual care telephone counselling
Bastian 2012 51/235 50/236 11.3 % 1.02 [ 0.72, 1.45 ]
Subtotal (95% CI) 235 236 11.3 % 1.02 [ 0.72, 1.45 ]
Total events: 51 (Experimental), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 Face-to-face, tests attentional training v placebo training
Begh 2015 10/60 9/59 4.3 % 1.09 [ 0.48, 2.50 ]
Subtotal (95% CI) 60 59 4.3 % 1.09 [ 0.48, 2.50 ]
Total events: 10 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
3 ACT versus CBT telephone counselling
Bricker 2014 18/59 14/62 6.7 % 1.35 [ 0.74, 2.46 ]
Subtotal (95% CI) 59 62 6.7 % 1.35 [ 0.74, 2.46 ]
Total events: 18 (Experimental), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
4 Positive psychotherapy versus usual care (face-to-face)
Kahler 2015 4/39 0/38 0.5 % 8.78 [ 0.49, 157.62 ]
Subtotal (95% CI) 39 38 0.5 % 8.78 [ 0.49, 157.62 ]
Total events: 4 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
5 Couples treatment versus individual treatment (face-to-face)
LaChance 2015 9/26 11/23 5.7 % 0.72 [ 0.37, 1.43 ]
Subtotal (95% CI) 26 23 5.7 % 0.72 [ 0.37, 1.43 ]
Total events: 9 (Experimental), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
6 Behavioural activation versus standard treatment (face-to-face)
Macpherson 2010a 2/35 0/33 0.4 % 4.72 [ 0.24, 94.85 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 35 33 0.4 % 4.72 [ 0.24, 94.85 ]
Total events: 2 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
7 Culturally tailored versus standard (face-to-face)
Matthews 2018 35/172 42/173 10.2 % 0.84 [ 0.56, 1.25 ]
Smith 2014 7/50 12/53 4.2 % 0.62 [ 0.26, 1.44 ]
Webb Hooper 2017 39/168 34/174 10.0 % 1.19 [ 0.79, 1.79 ]
Wu 2009 40/67 19/72 9.5 % 2.26 [ 1.47, 3.49 ]
Subtotal (95% CI) 457 472 33.8 % 1.14 [ 0.68, 1.92 ]
Total events: 121 (Experimental), 107 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 13.80, df = 3 (P = 0.003); I2 =78%
Test for overall effect: Z = 0.51 (P = 0.61)
8 Exercise counselling versus health education (face-to-face)
Patten 2017 4/15 6/15 3.0 % 0.67 [ 0.23, 1.89 ]
Subtotal (95% CI) 15 15 3.0 % 0.67 [ 0.23, 1.89 ]
Total events: 4 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
9 Adherence counselling versus standard care (telephone)
Smith 2013a 184/502 182/485 15.4 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 502 485 15.4 % 0.98 [ 0.83, 1.15 ]
Total events: 184 (Experimental), 182 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
10 MIndfulness versus CBT (face-to-face)
Vidrine 2016 20/154 24/155 7.4 % 0.84 [ 0.48, 1.45 ]
Subtotal (95% CI) 154 155 7.4 % 0.84 [ 0.48, 1.45 ]
Total events: 20 (Experimental), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
11 Quitline facilitation session versus brief advice (telephone)
Warner 2016 11/300 7/300 3.6 % 1.57 [ 0.62, 4.00 ]
Subtotal (95% CI) 300 300 3.6 % 1.57 [ 0.62, 4.00 ]
Total events: 11 (Experimental), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
12 Motivational interviewing versus health education
Ahluwalia 2006 19/189 34/189 7.8 % 0.56 [ 0.33, 0.94 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 189 189 7.8 % 0.56 [ 0.33, 0.94 ]
Total events: 19 (Experimental), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Total (95% CI) 2071 2067 100.0 % 1.02 [ 0.84, 1.25 ]
Total events: 453 (Experimental), 444 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 28.07, df = 14 (P = 0.01); I2 =50%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 11.81, df = 11 (P = 0.38), I2 =7%
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Summary of control and intervention characteristics
Intervention Control
Study ID Pharma-
cotherapy
Modality
(included
face-to-face/
telephone
only)
Number of
contacts
Total du-
ration (min-
utes)
Number of
contacts
Total du-
ration (min-
utes)
Comments
Ahluwalia
2006
NRT Face-to-face 6 120 6 120
Aimer 2017 NRT Face-to-face 4 Unclear Unclear Unclear
Alterman
2001
NRT Face-to-face 16 4290 1 30 Multiple arms
- highest vs
lowest inten-
sity
Aveyard 2007 NRT Face-to-face 7 140 4 80
Bailey 2013 NRT Face-to-face 19 950 10 500
Baker 2015 NRT Face-to-face 17 1050 17 290
Bastian 2012 NRT Telephone 5 100 5 100
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Table 1. Summary of control and intervention characteristics (Continued)
Begh 2015 NRT Face-to-face 7 112 7 112
Berndt 2014 NRT Face-to-face 7 285 7 105
Bloom 2017 NRT Face-to-face 20 400 20 880 Ex-
ercise sessions/
time excluded
Bock 2014 NRT Face-to-face 3 Unclear 1 Unclear
Boyle 2007 Choice Face-to-face 9 Unclear 0 0
Bricker 2014 NRT Telephone 5 90 5 90
Brody 2017 NRT &
Bupropion
Face-to-face 22 970 12 720
Brown 2013 NRT Face-to-face Unclear Unclear Unclear Unclear
Busch 2017 NRT Face-to-face 6 220 6 87.5
Bushnell 1997 NRT Face-to-face 8 480 4 240
Calabro 2012 NRT Face-to-face 2 120 1 5 Intervention
also had “ac-
cess to 5 web-
based booster
sessions”
Cook 2016 NRT Face-to-face 11 130 0 0 Multifac-
torial - highest
vs lowest in-
tensity
Cropsey 2015 NRT Face-to-face 4 100 1 Unclear
Ellerbeck
2009
Choice Face-to-face 6 Unclear 0 0 Multiple arms
- highest vs
lowest inten-
sity
Ferguson
2012
NRT Telephone 6 Unclear Unclear Unclear
Fiore 2004 NRT Face-to-face 5 Unclear 0 0 Multiple arms
- highest vs
lowest inten-
sity
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Table 1. Summary of control and intervention characteristics (Continued)
Gariti 2009 Choice Face-to-face 10 125 4 30
Gifford 2011 Bupropion Face-to-face 20 Unclear 1 60
Ginsberg
1992
NRT Face-to-face 5 Unclear 2 Unclear
Hall 1985 NRT Face-to-face 14 1050 4 Unclear
Hall 1987 NRT Face-to-face 14 1050 5 300
Hall 1994 NRT Face-to-face 10 1200 5 450
Hall 1998 Nortriptyline Face-to-face 10 1200 5 450
Hall 2002 Bupropion/
Nortriptyline
Face-to-face 5 450 4 30
Hall 2009 NRT &
Bupropion
Face-to-face 11 330 5 Unclear Multifactorial
study design
Hasan 2014 NRT Face-to-face 7 195 6 105
Hollis 2007 NRT Telephone 4 100 1 15 Multiple arms
- highest vs
lowest inten-
sity
Huber 2003 NRT Face-to-face 5 450 5 225
Humfleet
2013
NRT Face-to-face 6 300 1 ’Brief ’ Multiple arms
- highest vs
lowest inten-
sity
Jorenby 1995 NRT Face-to-face 8 480 0 0 Multiple arms
- highest vs
lowest inten-
sity
Kahler 2015 NRT Face-to-face 6 210 6 210
Killen 2008 NRT &
Bupropion
Face-to-face 10 300 10 200
Kim 2015 NRT Face-to-face 8 320 8 80
LaChance
2015
NRT Face-to-face 7 420 7 420
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Table 1. Summary of control and intervention characteristics (Continued)
Lando 1997 NRT Face-to-face 4 48 0 0 Multiple arms
- highest vs
lowest inten-
sity
Lifrak 1997 NRT Face-to-face 20 736.5 4 82.5
Lloyd-
Richardson
2009
NRT Face-to-face 5 Unclear 2 Unclear
MacLeod
2003
NRT Telephone 5 60 0 0
Macpherson
2010a
NRT Face-to-face 8 480 8 480
Matthews
2018
NRT Face-to-face 6 540 6 540
McCarthy
2008
Bupropion Face-to-face 13 Unclear 13 Unclear Control re-
ceived 80min-
utes less con-
tact than in-
tervention
NCT00879177
NRT &
Varenicline
Face-to-face 9 Unclear 5 Unclear
Ockene 1991 NRT Face-to-face 5 45 2 15
O’Cleirigh
2018
NRT Face-to-face 10 600 5 100
Okuyemi
2013
NRT Face-to-face 6 105 1 12.5
Otero 2006 NRT Face-to-face 4 240 1 20 Multiple arms
- highest vs
lowest inten-
sity
Patten 2017 NRT Face-to-face 36 1080 36 1080 Intervention
group: “exer-
cise coun-
selling deliv-
ered while the
partic-
ipant was en-
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Table 1. Summary of control and intervention characteristics (Continued)
gaged in exer-
cise” - have left
this time in
as also coun-
selling
Prapavessis
2016
NRT Face-to-face 64 1985 59 1860 Multiple arms
- highest vs
lowest inten-
sity
Reid 1999 NRT Face-to-face 6 Unclear 3 45
Rohsenow
2014
NRT Face-to-face 3 65 3 35
Rovina 2009 Bupropion Face-to-face 9 540 1 15 Multiple arms
- highest vs
lowest inten-
sity
Schlam 2016 NRT Face-to-face 12 320 4 200 Multifactorial
study design
Schmitz
2007a
Bupropion Face-to-face 7 420 7 420
Simon 2003 NRT Face-to-face 6 195 1 10
Smith 2001 NRT Face-to-face 6 90 0 0 Multiple arms
- highest vs
lowest inten-
sity
Smith 2013a NRT Telephone 4 67 4 60 Exact dura-
tion of contact
not recorded,
but aver-
ages given, in-
tervention:
67.0 (± 25.8)
, control: 60.1
(± 23.9)
Smith 2014 Varenicline Face-to-face 5 Unclear 5 Unclear Compar-
ing culturally-
tailored
with standard
counselling -
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Table 1. Summary of control and intervention characteristics (Continued)
duration
of sessions not
stated
Solomon
2000
NRT Telephone See note See note 0 0 Control = “ac-
cess to quit-
line”; inter-
vention = “up
to 12 calls”
- averaged 7
calls at 9 min-
utes each
Solomon
2005
NRT Telephone 8.2 80 0 0 Inter-
vention num-
bers based on
average num-
ber/duration
of calls
Stanton 2015 NRT Face-to-face 7 Unclear 3 Unclear
Stein 2006 NRT Face-to-face 3 65 2 5 Control
offered “up to
2 visits”, inter-
ven-
tion only of-
fered 3rd visit
if ready to quit
Strong 2009 Bupropion Face-to-face 12 1440 12 1440
Swan 2003 Bupropion Telephone 4 Unclear 1 7.5 Multiple arms
- highest vs
lowest inten-
sity
Swan 2010 Varenicline Telephone 5 67 0 0
Tonnesen
2006
NRT Face-to-face 12 270 10 150
Van Rossem
2017
Varenicline Face-to-face 10 120 1 20 Duration of
sessions
not stipulated,
but maximum
amounts
recorded in
paper. Inter-
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Table 1. Summary of control and intervention characteristics (Continued)
vention: 120,
control: 20
Vander Weg
2016
Choice Telephone 6 150 0 0 In-
tervention ses-
sions listed as
20 to 30 min-
utes - control
was referral to
a quitline, but
there were no
mandated ses-
sions, so con-
tact listed as 0
Vidrine 2016
(CBT)
NRT Face-to-face 8 960 4 40 Vidrine study
intervention 2
(control split)
Vidrine 2016
(MBAT)
NRT Face-to-face 8 960 4 40 Vidrine study
intervention 1
(control split)
Wagner 2016 NRT Face-to-face 12 Unclear 12 Unclear Sessions’ dura-
tion not re-
ported
Warner 2016 NRT Face-to-face 1 5 1 5
Webb Hooper
2017
NRT Face-to-face 9 945 9 945 Exact
duration not
listed, but ap-
proximate
range given
Wewers 2017 NRT Face-to-face 7 210 6 180 Com-
pared 2 inter-
ventions, less
inten-
sive counted as
control
Wiggers 2006 NRT Face-to-face 3 Unclear 1 Unclear
Williams
2010
NRT Face-to-face 24 1080 9 180
Wu 2009 NRT Face-to-face 4 240 4 240
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Table 1. Summary of control and intervention characteristics (Continued)
Yalcin 2014 Choice Face-to-face 14 730 9 150
A P P E N D I C E S
Appendix 1. Register Search
Search used in the Cochrane Register of Studies.
1. NRT:TI,AB,KW
2. (nicotine NEAR (replacement OR patch* OR transdermal OR gum OR lozenge* OR sublingual OR inhaler* OR inhalator*
OR oral OR nasal OR spray)):TI,AB,KW
3. (bupropion OR zyban OR wellbutrin):TI,AB,KW,MH,EMT
4. (varenicline OR champix OR chantix):TI,AB,KW,MH,EMT
5. combined modality therapy:MH,KW
6. ((behavio?r therapy) AND (drug therapy)):KW,MH,EMT,TI,AB
7. ((counsel*) AND (*drug therapy)):KW,MH,EMT,TI,AB
8. #1 OR #2 OR #3 OR #4 OR #5
9. #6 OR #7 OR #8
10. #9 AND INREGISTER
WH A T ’ S N E W
Date Event Description
13 March 2019 New search has been performed Updated with 36 new included studies. Searches run
June 2018
13 March 2019 New citation required but conclusions have not changed New studies and analyses added; now includes contact-
matched studies and meta-regression. Conclusions not
changed
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H I S T O R Y
Protocol first published: Issue 2, 2012
Review first published: Issue 12, 2012
Date Event Description
10 August 2015 New citation required but conclusions have not
changed
New author PK added for update
10 August 2015 New search has been performed Searches updated, 9 new included studies
21 February 2013 Amended Correction to 2 forest plot labels
C O N T R I B U T I O N S O F A U T H O R S
For this version of the review: JLB ran the searches; BH, HW and JHB screened search results; BH, HW, JHB, CM and JLB extracted
data; JLB, JHB and TF conducted analyses; BH, TF, JLB and JHB updated the text; and all authors reviewed and commented on the
text.
For the original and second version of the review, LS developed the search strategy, screened search results and extracted data. For the
original review TL agreed inclusion or exclusion of potentially relevant studies and checked data extraction. For the second version of
the review, PK agreed inclusion or exclusion of potentially relevant studies and extracted data. All authors contributed to the text.
D E C L A R A T I O N S O F I N T E R E S T
JHB: none known
BH: none known
JLB: none known
HW: none known
TRF: none known
S O U R C E S O F S U P P O R T
Internal sources
• Nuffield Department of Primary Care Health Sciences, Oxford University, UK.
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External sources
• NHS National Institute for Health Research, UK.
• Faculty of Medicine Marvin Burke Summer Studentship, Dalhousie University, Canada.
Funding for travel and accommodation
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We added two additional subgroup analyses. We had initially planned to assess risk of bias based on blinding of participants and
personnel, but given the nature of the studies, we provided a narrative discussion of this instead.
In this version of the review, we switched from fixed-effect to random-effects meta-analyses in accordance with revised guidance from
the Cochrane Tobacco Addiction Group. We also introduced a new, exploratory meta-regression based on the number of contacts.
In addition, we included eligible studies where contact was matched between arms (previously excluded). We expanded our inclusion
criteria to include studies in adolescents.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Tobacco Use Cessation Devices; Antidepressive Agents [therapeutic use]; Behavior Therapy [∗methods]; Benzazepines [therapeutic
use]; Bupropion [therapeutic use]; Combined Modality Therapy [methods]; Counseling [methods]; Nicotinic Agonists [therapeutic
use]; Nortriptyline [therapeutic use]; Quinoxalines [therapeutic use]; Randomized Controlled Trials as Topic; Smoking [∗therapy];
Smoking Cessation [∗methods]; Varenicline [therapeutic use]
MeSH check words
Humans
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